<PAGE>
PROSPECTUS
GENESIS HEALTH VENTURES, INC.
Offer to Exchange its 9 1/4% Senior Subordinated Notes due 2006,
which have been registered under the Securities Act
of 1933, as amended, for any and all of its outstanding
9 1/4% Senior Subordinated Notes due 2006
The Exchange Offer will expire at 5:00 p.m., New York City time, on
February 4, 1997, unless extended.
-------------------------------
Genesis Health Ventures, Inc., a Pennsylvania corporation ("Genesis" or the
"Company"), hereby offers (the "Exchange Offer"), upon the terms and conditions
set forth in this Prospectus (the "Prospectus") and the accompanying Letter of
Transmittal (the "Letter of Transmittal"), to exchange $1,000 principal amount
of its 9 1/4% Senior Subordinated Notes due 2006 (the "Exchange Notes"), which
have been registered under the Securities Act of 1933, as amended (the
"Securities Act"), pursuant to a Registration Statement of which this Prospectus
is a part, for each $1,000 principal amount of its outstanding 9 1/4% Senior
Subordinated Notes due 2006 (the "Existing Notes"), of which $125,000,000
principal amount is outstanding. The form and terms of the Exchange Notes are
the same as the form and terms of the Existing Notes (which they replace),
except that as of the date hereof the Exchange Notes have been registered under
the Securities Act and, therefore, will not bear legends restricting their
transfer and will not contain certain provisions included in the terms of the
Existing Notes relating to an increase in the interest rate in certain
circumstances relating to the timing of the Exchange Offer. The Exchange Notes
will evidence the same debt as the Existing Notes (which they replace) and will
be issued under and be entitled to the benefits of the Indenture, dated as of
October 7, 1996 (the "Indenture"), between the Company and First Union National
Bank, as trustee (the "Trustee"), which also governs the Existing Notes. The
Exchange Notes and the Existing Notes are sometimes referred to herein
collectively as the "Notes." See " Exchange Offer" and "Description of Exchange
Notes."
The Company will accept for exchange any and all Existing Notes duly tendered
and not validly withdrawn prior to 5:00 p.m., New York City time, on February 4,
1997, unless extended by the Company in its sole discretion (the "Expiration
Date"). Tenders of Existing Notes may be withdrawn at any time prior to 5:00
p.m. New York City time on the Expiration Date. The Exchange Offer is subject to
certain customary conditions. The Existing Notes were sold by the Company on
October 7, 1996 to the Initial Purchasers (as defined herein) in transactions
not registered under the Securities Act in reliance upon an exemption from
registration under the Securities Act (the "Offering"). The Initial Purchasers
subsequently resold the Existing Notes to qualified institutional buyers in
reliance upon Rule 144A under the Securities Act and to a limited number of
institutional accredited investors that agreed to comply with certain transfer
restrictions and other conditions. Accordingly, the Existing Notes may not be
reoffered, resold or otherwise transferred in the United States unless
registered under the Securities Act or unless an applicable exemption from the
registration requirements of the Securities Act is available. The Exchange Notes
are being offered hereunder in order to satisfy the obligations of the Company
under the Registration Rights Agreement (as defined herein) entered into by the
Company in connection with the Offering. See "Exchange Offer."
Under existing interpretations of the staff of the Securities and Exchange
Commission (the "Commission") contained in several no-action letters to third
parties, the Exchange Notes will in general be freely tradeable after the
Exchange Offer without further registration under the Securities Act. However,
any purchaser of Existing Notes who is an "affiliate" of the Company or who
intends to participate in the Exchange Offer for the purpose of distributing the
Exchange Notes (i) will not be able to rely on such interpretations of the staff
of the Commission, (ii) will not be able to tender its Existing Notes in the
Exchange Offer and (iii) must comply with the registration and prospectus
delivery requirements of the Securities Act in connection with any sale or
transfer of the Existing Notes, unless such sale or transfer is made pursuant to
an exemption from such requirements. See "Exchange Offer" and "--Resale of the
Exchange Notes." Each broker-dealer that receives Exchange Notes for its own
account pursuant to the Exchange Offer (a "Participating Broker-Dealer") must
acknowledge that it will deliver a prospectus in connection with any resale of
such Exchange Notes. The Letter of Transmittal states that by so acknowledging
and by delivering a prospectus, a Participating Broker-Dealer will not be deemed
to admit that it is an "underwriter" within the meaning of the Securities Act.
This Prospectus, as it may be amended or supplemented from time to time, may be
used by a Participating Broker-Dealer in connection with resales of Exchange
Notes received in exchange for Existing Notes where such Existing Notes were
acquired by such Participating Broker-Dealer as a result of market-making
activities or other trading activities.
Holders of Existing Notes not tendered and accepted in the Exchange Offer
will continue to hold such Existing Notes and will be entitled to all the rights
and benefits and will be subject to the limitations applicable thereto under the
Indenture and with respect to transfer under the Securities Act. Holders of
Existing Notes not tendered in the Exchange Offer will not retain any rights
under the Registration Rights Agreement, except in limited circumstances. The
Company will pay all the expenses incurred by it incident to the Exchange Offer.
See "Exchange Offer."
There has not previously been any public market for the Exchange Notes. The
Company does not intend to list the Exchange Notes on any securities exchange or
to seek approval for quotation through any automated quotation system. There can
be no assurance that an active market for the Exchange Notes will develop.
Merrill Lynch, Pierce, Fenner & Smith Incorporated, CS First Boston Corporation,
Donaldson, Lufkin & Jenrette Securities Corporation, Alex. Brown & Sons
Incorporated, BT Securities Corporation, and Montgomery Securities (the "Initial
Purchasers") have informed the Company that they currently intend to make a
market in the Exchange Notes, but are not obligated to do so and any such market
making may be discontinued at any time without notice. The Initial Purchasers
may act as principal or as agent in such transactions. If a market for the
Exchange Notes should develop, the Exchange Notes could trade at a discount from
their principal amount. See "Risk Factors -- Absence of Public Market."
Moreover, to the extent that Existing Notes are tendered and accepted in the
Exchange Offer, the trading market for untendered and tendered but unaccepted
Existing Notes could be adversely affected.
------------------------------
See "Risk Factors" on page 13 herein for a description of certain risks to
be considered by holders who tender their Existing Notes in the Exchange Offer.
------------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSIONER OR ANY STATE SECURITIES COMMISSION PASSED UPON
THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO
THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this Prospectus is December 11, 1996.
<PAGE>
SUMMARY
The following summary information is qualified in its entirety by reference
to, and should be read in conjunction with, the more detailed information and
Consolidated Financial Statements, including the notes thereto, appearing
elsewhere in this Prospectus or incorporated by reference herein. Unless
otherwise indicated, all information in the Prospectus reflects a three for two
stock dividend on the Common Stock effective March 29, 1996. As used herein,
unless the context otherwise requires, "Genesis" or the "Company" refers to
Genesis Health Ventures, Inc. and its subsidiaries.
The Company
Genesis is a leading provider of healthcare and support services to the
elderly. The Company has developed the Genesis ElderCare(SM) delivery model of
integrated healthcare networks to provide cost-effective, outcome-oriented
services to the elderly. Through these integrated healthcare networks, Genesis
provides basic healthcare and specialty medical services to more than 75,000
customers in five regional markets in the Eastern United States in which over
3,000,000 people over the age of 65 reside. The networks include 153 eldercare
centers with approximately 20,120 beds; 18 primary care physician clinics;
approximately 70 physicians, physician assistants and nurse practitioners; 12
institutional pharmacies and six medical supply distribution centers serving
over 52,000 beds; certified rehabilitation agencies providing services through
over 290 contracts; and seven home healthcare agencies. Genesis has concentrated
its eldercare networks in five geographic regions in order to achieve operating
efficiencies, economies of scale and significant market share. The five
geographic markets that Genesis principally serves are:
Massachusetts/Connecticut/New Hampshire; Eastern Pennsylvania/Delaware Valley;
Southern Delaware/Eastern Shore of Maryland; Baltimore, Maryland/Washington,
D.C.; and Central Florida.
Genesis eldercare services focus on the central medical and physical issues
facing the more medically demanding elderly. By integrating the talents of
physicians with case management, comprehensive discharge planning and, where
necessary, home support services, the Company provides cost-effective care
management to achieve superior outcomes and return customers to the community.
The Company believes that its orientation toward achieving improved customer
outcomes through its eldercare networks has resulted in increased utilization of
specialty medical services, high occupancy of available beds, enhanced quality
payor mix and a broader base of repeat customers. Specialty medical services
revenues have increased at a compound annual rate of 37% from the fiscal year
ended September 30, 1990 to the fiscal year ended September 30, 1995 and
comprise 42% of the Company's revenues for the nine month period ended June 30,
1996. Specialty medical services typically generate higher profit margins than
basic healthcare services and are less capital intensive.
The Company's growth strategy is to enhance its existing eldercare networks,
establish new eldercare networks in markets it deems attractive and broaden its
array of high margin specialty medical services through internal development and
selected acquisitions. Consistent with its strategy, the Company has made
selected acquisitions of eldercare centers and rehabilitation, pharmacy,
physician services and home healthcare companies.
The Company's long-term strategy is to provide comprehensive eldercare
services, in collaboration with other providers, on a prepaid basis in a managed
care environment. The Company has undertaken several initiatives to position
itself to compete in a managed care environment. These initiatives include: (i)
establishing a managed care division to pursue and administer contracts with
managed care organizations, develop clinical care protocols and monitor the
delivery and utilization of medical care; (ii) developing a clinical
administration and healthcare management information system to monitor and
measure clinical and
<PAGE>
patient-outcome data; (iii) establishing the Genesis ElderCare(sm) brand name to
increase awareness of the Company's eldercare services in the healthcare market;
(iv) seeking strategic alliances with other healthcare providers to broaden the
Company's continuum of care; and (v) creating an independent eldercare advisory
board to formulate new and innovative approaches in the delivery of care.
Recent Developments
GMC Transaction
In October 1996, the Company and Geriatric & Medical Companies, Inc. ("GMC")
consummated the merger of GMC with a wholly-owned subsidiary of Genesis (the
"GMC Transaction"). The merger added 26 eldercare centers with approximately
3,240 beds to Genesis. GMC also operates businesses which provide a number of
ancillary healthcare services including ambulance services; respiratory therapy,
infusion therapy and enteral therapy; distribution of durable medical equipment
and home medical supplies; pharmacy services; contract management services;
diagnostic and rehabilitative management services; and information management
services. Under the terms of the merger agreement, GMC shareholders received
$5.75 per share in cash for each share of GMC stock. The purchase price of GMC
stock was approximately $93,900,000. Prior to the Merger, GMC had outstanding
approximately $133,100,000 of indebtedness which included approximately
$87,600,000 which the Company loaned to GMC immediately prior to the Merger to
prepay indebtedness. The Company funded the cash portion of the transaction and
paid a portion of the assumed debt through the proceeds of the Offering and its
Credit Facility (as defined herein). See "Management's Discussion and Analysis
of Financial Condition and Results of Operations."
National Health Transaction
In July 1996, the Company acquired the outstanding stock of National Health
Care Affiliates, Inc. and certain related entities (collectively, "National
Health"). Prior to the closing of the stock acquisitions, an affiliate of a
financial institution purchased nine of the National Health eldercare centers
for $67,700,000 and subsequently leased the centers to a subsidiary of Genesis.
The balance of the total consideration paid to National Health was funded with
available cash of $51,800,000 and assumed debt of $7,900,000. The acquisition of
the stock of National Health and lease of the eldercare centers from the
financial institutional affiliate are referred to hereafter collectively as the
National Health Transaction. The National Health Transaction added 16 eldercare
centers in Florida, Virginia and Connecticut with approximately 2,200 beds to
the Company. National Health also provided enteral nutrition and rehabilitation
therapy services to the eldercare centers which it owns and leases. In addition,
National Health manages four eldercare centers in Colorado with 382 beds
pursuant to an agreement which expires in October 1997. See "Management's
Discussion and Analysis of Financial Condition and Results of Operations."
NeighborCare Transaction
In June 1996, the Company acquired the pharmacy healthcare services
businesses of NeighborCare Pharmacies, Inc. and certain related entities
(collectively, "NeighborCare") for total consideration of approximately
$57,250,000, comprised of approximately $47,250,000 in cash and 312,744 shares
of Genesis Common Stock (the "NeighborCare Transaction"). Based in Baltimore,
Maryland, NeighborCare operates institutional and retail pharmacy and infusion
therapy businesses. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations."
-2-
<PAGE>
McKerley Transaction
In November 1995, the Company acquired McKerley Health Care Centers, Inc. and
certain related entities (collectively, "McKerley") for total consideration of
approximately $68,700,000, including approximately $9,100,000 of assumed debt
(the "McKerley Transaction"). McKerley owns or leases 15 eldercare centers in
New Hampshire and Vermont with a total of 1,535 beds and operates a home
healthcare business. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations."
The Offering
Notes............... The Existing Notes were sold by the Company on October 7,
1996 to Merrill Lynch, Pierce, Fenner & Smith
Incorporated, CS First Boston Corporation, Donaldson,
Lufkin & Jenrette Securities Corporation, Alex. Brown &
Sons Incorporated, BT Securities Corporation, and
Montgomery Securities (the "Initial Purchasers") pursuant
to a Purchase Agreement, dated as of October 1, 1996 (the
"Purchase Agreement"). The Initial Purchasers subsequently
resold the Existing Notes to qualified institutional
buyers pursuant to Rule 144A under the Securities Act and
to a limited number of institutional accredited investors
that agreed to comply with certain transfer restrictions
and other conditions.
Registration Rights
Agreement......... Pursuant to the Purchase Agreement, the Company and the
Initial Purchasers entered into a Registration Rights
Agreement, dated October 7, 1996 (the "Registration Rights
Agreement"), which grants the holders of the Existing
Notes certain exchange and registration rights. The
Exchange Offer is being made pursuant to the Registration
Rights Agreement and such exchange rights terminate upon
the consummation of the Exchange Offer.
The Exchange Offer
Securities Offered.. $125,000,000 aggregate principal amount of 9 1/4% Senior
Notes due 2006.
The Exchange Offer.. $1,000 principal amount of the Exchange Notes in exchange
for each $1,000 principal amount of Existing Notes. As of
the date hereof, $125,000,000 aggregate principal amount
of Existing Notes are outstanding. The Company will issue
the Exchange Notes on or promptly after the Expiration
Date.
Under existing interpretations of the staff of the
Commission contained in several no-action letters to third
parties, the Exchange Notes will in general be freely
-3-
<PAGE>
tradeable after the Exchange Offer without further
registration under the Securities Act. However, any
purchaser of Existing Notes who is an "affiliate" of the
Company or who intends to participate in the Exchange
Offer for the purpose of distributing the Exchange Notes
(i) will not be able to rely on such interpretations of
the staff of the Commission, (ii) will not be able to
tender its Existing Notes in the Exchange Offer and (iii)
must comply with the registration and prospectus delivery
requirements of the Securities Act in connection with any
sale or transfer of the Existing Notes, unless such sale
or transfer is made pursuant to an exemption from such
requirements.
Each Participating Broker-Dealer that receives Exchange
Notes for its own account pursuant to the Exchange Offer
must acknowledge that it will deliver a prospectus in
connection with any resale of such Exchange Notes. The
Letter of Transmittal states that by so acknowledging and
by delivering a prospectus, a Participating Broker-Dealer
will not be deemed to admit that it is an "underwriter"
within the meaning of the Securities Act. This Prospectus,
as it may be amended or supplemented from time to time,
may be used by a Participating Broker-Dealer in connection
with resales of Exchange Notes received in exchange for
Existing Notes where such Existing Notes were acquired by
such Participating Broker-Dealer as a result of
market-making activities or other trading activities.
Any holder who tenders in the Exchange Offer with the
intention to participate or for the purpose of
participating in a distribution of the Exchange Notes
cannot rely on the position of the staff of the Commission
enunciated in no-action letters and, in the absence of an
exemption therefrom, must comply with the registration and
prospectus delivery requirements of the Securities Act in
connection with any resale transaction. Failure to comply
with such requirements in such instance may result in such
holder incurring liability under the Securities Act for
which the holder is not indemnified by the Company.
Expiration Date..... 5:00 p.m., New York City time, on February 4, 1997, unless
the Exchange Offer is extended by the Company in its sole
discretion, in which case the term "Expiration Date" means
that latest date and time to which the Exchange Offer is
extended.
-4-
<PAGE>
Accrued Interest on
the Exchange Notes
and Existing Notes. Interest on each Exchange Note will accrue from the latest
date on which interest was paid on the Existing Notes
surrendered in exchange therefor or, if no interest has
been paid on the Existing Notes, from the date of original
issuance of such Note. No interest will be paid on the
Existing Notes accepted for exchange, and holders of
Existing Notes whose Existing Notes are accepted for
exchange will be deemed to have waived the right to
receive any payment in respect of interest on the Existing
Notes accrued up to the date of the issuance of the
Exchange Notes. Holders of Existing Notes that are not
exchanged will receive the accrued interest payable on
April 1, 1997 in accordance with the Indenture. See
"Exchange Offer -- Interest on the Exchange Notes."
Conditions to the
Exchange Offer..... The Exchange Offer is subject to certain customary
conditions, which may be waived by the Company. See
"Exchange Offer-- Conditions."
Procedures for
Tendering Existing
Notes.............. Each holder of Existing Notes wishing to accept the
Exchange Offer must complete, sign and date the
accompanying Letter of Transmittal, or a facsimile
thereof, in accordance with the instructions contained
herein and therein, and mail or otherwise deliver such
Letter of Transmittal, or such facsimile thereof, together
with the Existing Notes to be exchanged and any other
required documentation to the Exchange Agent (as defined
herein) at the address set forth herein or effect a tender
of such Existing Notes pursuant to the procedures for
book- entry transfer as provided herein. By executing the
Letter of Transmittal, each holder will represent to the
Company that, among other things, the Exchange Notes
acquired pursuant to the Exchange Offer are being obtained
in the ordinary course of business of the person receiving
such Exchange Notes, whether or not such person is the
holder, that neither the holder nor any such other person
has any arrangement or understanding with any person to
participate in the distribution of such Exchange Notes and
that neither the holder nor any such other person is an
"affiliate," as defined under Rule 405 of the Securities
Act, of the Company. See "Exchange Offer-- Purpose and
Effect of the Exchange Offer" and "--Procedures for
Tending." Each broker-dealer that receives Exchange Notes
for its own account in exchange for Existing Notes, where
such Existing Notes were acquired by such broker- dealer
as a result of market-making activities or other trading
activities, must acknowledge that it will deliver a
-5-
<PAGE>
prospectus in connection with any resale of such Exchange
Notes. See "Exchange Offer-- Procedures for Tendering" and
"Plan of Distribution."
Untendered Notes.... Following the consummation of the Exchange Offer, holders
of Existing Notes eligible to participate but who do not
tender their Existing Notes will not have any further
registration rights and such Existing Notes will continue
to be subject to certain restrictions on transfer.
Accordingly, the liquidity of the market for such Existing
Notes could be adversely affected.
Consequences of
Failure to
Exchange........... The Existing Notes that are not exchanged pursuant to the
Exchange Offer will remain outstanding and continue to
accrue interest and will also remain restricted
securities. Accordingly, such Existing Notes may be resold
only (i) to the Company, (ii) pursuant to Rule 144A or
Rule 144 under the Securities Act or pursuant to some
other exemption from registration under the Securities
Act, (iii) outside the United States to a foreign person
pursuant to the requirements of Regulation S under the
Securities Act, or (iv) pursuant to an effective
registration statement under the Securities Act. See
"Exchange Offer-- Consequences of Failure to Exchange."
Shelf Registration
Statement.......... In the event that any changes in law or the applicable
interpretations of the Securities Act by the staff of the
Commission do not permit the Company to effect the
Exchange Offer, or if for any other reason the Exchange
Offer is not consummated within 120 days following the
date of the original issue of the Existing Notes, or if
any holder of the Existing Notes (other than the Initial
Purchasers) is not eligible to participate in the Exchange
Offer, or upon the request of any Initial Purchaser under
certain circumstances, the Company will use its best
efforts to cause to become effective by the 120th day
after the original issue of the Existing Notes a shelf
registration statement pursuant to the Securities Act with
respect to the resale of the Notes (the "Shelf
Registration Statement") and to keep the Shelf
Registration Statement effective until three years after
the effective date thereof (or until one year after such
effective date if such Shelf Registration Statement is
filed at the request of the Initial Purchasers under
certain circumstances) or until such shorter period when
all the Notes covered by the Shelf Registration Statement
have been sold pursuant to the Shelf Registration
Statement or are eligible for resale pursuant to Rule 144
under the Securities Act without volume limitations.
-6-
<PAGE>
Special Procedures
for Beneficial
Owners............. Any beneficial owner whose Existing Notes are registered
in the name of a broker, dealer, commercial bank, trust
company or other nominee and who wishes to tender should
contact such registered holder promptly and instruct such
registered holder to tender on such beneficial owner's
behalf. If such beneficial owner wishes to tender on such
owner's own behalf, such owner must, prior to completing
and executing the Letter of Transmittal and delivering its
Existing Notes, either make appropriate arrangements to
register ownership of the Existing Notes in such owner's
name or obtain a properly completed bond power from the
registered holder. The transfer of registered ownership
may take considerable time.
Guaranteed Delivery
Procedures......... Holders of Existing Notes who wish to tender their
Existing Notes and whose Existing Notes are not
immediately available or who cannot deliver their Existing
Notes, the Letter of Transmittal or any other documents
required by the Letter of Transmittal to the Exchange
Agent (or comply with the procedures for book-entry
transfer) prior to the Expiration Date must tender their
Existing Notes according to the guaranteed delivered
procedures set forth in "Exchange Offer-- Guaranteed
Delivery Procedures."
Withdrawal Rights... Tenders may be withdrawn at any time prior to 5:00 p.m.,
New York City time, on the Expiration Date.
Acceptance of Notes
and Delivery of
Exchange Notes..... The Company will accept for exchange any and all Existing
Notes which are duly tendered in the Exchange Offer and
not validly withdrawn prior to 5:00 p.m., New York City
time, on the Expiration Date. The Exchange Notes issued
pursuant to the Exchange Offer will be delivered promptly
following the Expiration Date. See "Exchange Offer--Terms
of the Exchange Offer."
Certain Tax
Consequences....... The exchange pursuant to the Exchange Offer should not be
a taxable event for Federal income tax purposes. See "Tax
Considerations."
Use of Proceeds..... There will be no cash proceeds to the Company from the
exchange pursuant to the Exchange Offer. See "Use of
Proceeds."
Exchange Agent...... First Union National Bank.
-7-
<PAGE>
The Exchange Notes
General............. The form and terms of the Exchange Notes are the same as
the form and terms of the Existing Notes (which they
replace) except that (i) the Exchange Notes have been
registered under the Securities Act and, therefore, will
not bear legends restricting the transfer thereof, (ii)
the Exchange Notes do not include provisions providing for
an increase in the interest rate in certain circumstances
relating to the timing of the Exchange Offer and (iii) the
holders of Exchange Notes will not be entitled to certain
rights under the Registration Rights Agreement, which
rights will terminate when the Exchange Offer is
consummated. The Exchange Notes will evidence the same
debt as the Existing Notes and will be entitled to the
benefits of the Indenture. See "Description of Notes."
Securities Offered.. $125,000,000 principal amount of 9 1/4% Senior
Subordinated Notes due 2006.
Maturity Date....... October 1, 2006.
Interest Payment
Dates.............. April 1 and October 1 of each year, commencing April 1,
1997.
Optional Redemption. The Exchange Notes are redeemable at the option of the
Company, in whole or in part, in cash, at any time on or
after October 1, 2001 at the redemption prices set forth
herein, together with accrued and unpaid interest, if any,
to the date of redemption.
Change of Control... Upon the occurrence of a Change of Control (as defined
herein), each holder of the Exchange Notes may require the
Company to repurchase all or a portion of such holder's
Exchange Notes at a purchase price in cash equal to 101%
of the principal amount thereof, together with accrued and
unpaid interest, if any, to the date of repurchase. The
occurrence of certain events that would constitute a
Change in Control would also constitute a default under
the company's existing $300,000,000 revolving credit
facility and $150,000,000 lease financing facility
(collectively, the "Credit Facility"), which ranks senior
in right of payment to the Notes, and would also require
the Company to offer to redeem the $25,000,000 principal
amount of the company's 9 1/4% First Mortgage Bonds Series
A, which rank senior in right of payment to the Notes, and
$43,904,000 principal amount of the Company's 6%
Convertible Senior Subordinated Debentures due 2003 (the
"Convertible Debentures") and
-8-
<PAGE>
$120,000,000 of the company's 9 3/4% Senior Subordinated
Notes due 2005 (the "9 3/4% Notes"), which rank pari passu
in right of payment to the Notes. The Company's ability to
repurchase the Notes upon a Change in Control would also
be limited by the terms of the Indenture and the Credit
Facility. As a result of such limitation, a holder of a
Note may not be able to require the Company to repurchase
the Notes unless the Company is able to refinance the
Credit Facility. In addition, there can be no assurance
that the Company will have sufficient funds to repurchase
the Notes if they were tendered upon a Change in Control.
See "Description of the Notes -- Change in Control."
Ranking............. The Exchange Notes will be unsecured senior subordinated
obligations of the Company and, as such, will be
subordinated to all existing and future Senior
Indebtedness (as defined herein) of the Company. The
Exchange Notes will also be effectively subordinated in
right of payment to all existing and future liabilities of
the Company's subsidiaries. As of June 30, 1996, on a pro
forma basis after giving effect to the National Health
Transaction and GMC Transaction and the sale of the Notes
and the use of the net proceeds therefrom, the aggregate
amount of Senior Indebtedness would have been
approximately $402,123,000 (which includes approximately
$9,980,000 of indebtedness and approximately $61,000,000
of lease obligations of subsidiaries and approximately
$6,000,000 of indebtedness of other persons, all of which
are guaranteed by the Company, and approximately
$15,900,000 of letters of credit issued under the
Company's Credit Facility primarily related to the
Company's self-insurance programs) and, as of such date,
the aggregate amount of liabilities of the subsidiaries of
the Company, which consist primarily of trade payables and
accrued compensation, that will effectively rank senior to
the Exchange Notes was approximately $64,163,000. As of
June 30, 1996, there were also outstanding $43,904,000
principal amount of the Convertible Debentures and
$120,000,000 principal amount of the 9 3/4% Notes which
will rank pari passu in right of payment to the Exchange
Notes. The Exchange Notes will rank senior to all other
subordinated indebtedness of the Company. The Credit
Facility is secured by the stock and partnership interests
of the Company's subsidiaries and substantially all of the
Company's subsidiaries are co-obligors of the Credit
Facility. See "Description of the Notes -- Subordination."
-9-
<PAGE>
Restrictive
Covenants.......... The Indenture contains certain covenants, including, but
not limited to, covenants with respect to the following
matters: (i) limitation on indebtedness; (ii) limitation
on restricted payments; (iii) limitation on preferred
stock of subsidiaries and subsidiary distributions; (iv)
limitation on transactions with affiliates; (v) limitation
on disposition of proceeds of asset sales; (vi) limitation
on liens securing subordinated indebtedness; (vii)
limitation on other senior subordinated indebtedness;
(viii) limitation on issuance of guarantees of
subordinated indebtedness; (ix) limitation on dividends
and other payment restrictions affecting subsidiaries; and
(x) limitation on merger and sale of assets. See
"Description of the Notes-- Certain Covenants."
Absence of a Public
Market for the
Notes.............. The Exchange Notes will be new securities for which there
currently is no market. Although the Initial Purchasers
have informed the Company that they currently intend to
make a market in the Exchange Notes, they are not
obligated to do so, and any such market making may be
discontinued at any time without notice. Accordingly,
there can be no assurance as to the development of
liquidity of any market for the Exchange Notes. The
Company does not intend to apply for listing of the
Exchange Notes on any securities exchange or for quotation
through the National Association of Securities Dealers
Automated Quotation System.
Risk Factors
See "Risk Factors" beginning on page 13 for a discussion of certain
factors which should be considered by prospective investors in evaluating an
investment in the Notes.
-10-
<PAGE>
SUMMARY CONSOLIDATED FINANCIAL DATA
(In thousands, except per share and operating data)
<TABLE>
<CAPTION>
Year Ended September 30,
---------------------------------------------------------------------------
1991 1992 1993 1994 1995
-------- --------- -------- -------- -----------------------
Pro Forma, As
Actual Adjusted(1)
-------- -------------
<S> <C> <C> <C> <C> <C> <C>
Summary of Operations Data
Net revenues.............................. $171,449 $196,253 $219,809 $388,616 $486,392 $874,594
Income from operations before depreciation,
amortization, lease expense, interest and
debenture conversion expense (EBITDAR) (2) 30,587 35,597 38,129 69,373 93,253 155,605
Depreciation and amortization............. 6,258 7,239 7,157 14,982 18,793 38,175
Lease expense............................. 7,460 7,207 7,026 11,376 13,798 23,205
Interest expense, net..................... 11,072 8,708 5,042 15,305 20,366 37,592
--------- ------- --------- ------- -------- --------
Debenture conversion expense.............. -- -- -- -- -- --
Earnings before extraordinary items and
cumulative effect of change in
accounting principle................... 3,595 7,710 11,909 17,691 25,531 35,825
Net income................................ 3,283 7,433 11,909 17,673 23,608 33,902
Other Financial Data
EBITDAR (3)............................... $ 23,128 $ 28,390 $ 31,103 $ 57,997 $79,455 $132,400
Ratio of EBITDAR to interest expense plus
rent expense........................... 1.65x 2.24x 3.16 2.60x 2.73x 2.56x
Ratio of EBITDA to interest expense....... 2.09x 3.26x 6.17 3.79x 3.90x 3.52x
Ratio of earnings to fixed charges (4).... 1.27x 1.78x 2.60 2.02x 2.15x 1.94x
Capital expenditures...................... $ 3,843 $ 7,288 $ 23,151 $ 18,784 $ 24,718
Operating Data
ElderCare Networks:
Average eldercare center beds in service
Wholly-owned and leased............. 4,432 4,719 4,534 7,530 8,268
Jointly-owned and managed........... 444 769 1,208 4,532 5,158
--------- ------- -------- -------- --------
Total............................... 4,876 5,488 5,742 12,062 13,426
======== ======== ======== ======== ========
Occupancy percentage in wholly-owned
and leased eldercare centers....... 96% 96% 95% 92% 92%
Physicians, physician assistants and
nurse practitioners................. 12 12 18 22 41
Rehabilitation contracts............... 54 100 106 152 232
Institutional pharmacies/medical
supplies beds served................ 9,000 19,038 21,838 27,964 31,344
Payor mix
Private and other...................... 43% 41% 42% 41% 38%
Medicare............................... 9% 12% 14% 16% 21%
Medicaid............................... 48% 47% 44% 43% 41%
Revenue mix
Basic healthcare services.............. 71% 69% 61% 62% 57%
Specialty medical services............. 26% 26% 34% 32% 37%
Management services and other.......... 3% 5% 5% 6% 6%
</TABLE>
<PAGE>
[RESTUBBED FROM TABLE BEFORE]
<TABLE>
<CAPTION>
(Unaudited)
Nine Months Ended
June 30,
-----------------------------------
1995 1996
------- -----------------------
Pro Forma, As
Actual Actual Adjusted (1)
------- ------ -------------
<S> <C> <C> <C>
Summary of Operations Data
Net revenues.............................. $354,465 $460,354 $723,109
Income from operations before depreciation,
amortization, lease expense, interest and
Debenture conversion expense (EBITDAR) (2) 66,345 87,313 131,400
Depreciation and amortization............. 13,987 17,883 30,756
Lease expense............................. 10,388 11,948 19,064
Interest expense, net..................... 14,369 19,104 29,380
------- ------- -------
Debenture conversion expense.............. -- 1,245 1,245
Earnings before extraordinary items and
cumulative effect of change in
accounting principle................... 17,508 23,759 32,466
Net income................................ 15,585 23,759 32,466
Other Financial Data
EBITDAR (3)............................... $ 55,957 $ 75,365 $112,336
Ratio of EBITDAR to interest expense plus
rent expense........................... 2.68x 2.81x 2.71x
Ratio of EBITDA to interest expense....... 3.89x 3.94x 3.82x
Ratio of earnings to fixed charges (4).... 2.10x 2.14x 2.03x
Capital expenditures...................... $ 19,681 $26,151
Operating Data
ElderCare Networks:
Average eldercare center beds in service
Wholly-owned and leased............. 8,268 9,062
Jointly-owned and managed........... 5,158 5,195
------- ------
Total............................... 13,426 14,257
======= ======
Occupancy percentage in wholly-owned
and leased eldercare centers....... 92% 92%
Physicians, physician assistants and
nurse practitioners................. 41 68
Rehabilitation contracts............... 232 297
Institutional pharmacies/medical
supplies beds served................ 31,145 46,139
Payor mix
Private and other...................... 38% 39%
Medicare............................... 21% 23%
Medicaid............................... 41% 38%
Revenue mix
Basic healthcare services.............. 58% 52%
Specialty medical services............. 36% 42%
Management services and other.......... 6% 6%
</TABLE>
<TABLE>
<CAPTION>
(Unaudited)
June 30, 1996
----------------------------------------
Pro Forma,
Actual As Adjusted (5)
-------------------- ---------------
<S> <C> <C>
Balance Sheet Data
Working capital........................................ $227,599 $267,167
Total assets........................................... 878,348 1,272,993
Long-term debt......................................... 295,897 595,365
Shareholders' equity.................................. 500,238 500,238
</TABLE>
-11-
<PAGE>
- ----------------
(1) Gives effect to the McKerley Transaction, NeighborCare Transaction,
National Health Transaction, GMC Transaction and the sale by the
Company of 6,500,000 shares of Common Stock in May 1996 (the "1996
Equity Offering"), as adjusted to reflect the Offering and the
application of the estimated net proceeds therefrom as described under
"Use of Proceeds." See "Pro Forma Condensed Consolidated Financial
Information."
(2) EBITDAR represents earnings before interest expense, income taxes,
depreciation and amortization, extraordinary items, rental expense and
debenture conversion expense. EBITDAR should not be considered an
alternative measure of the Company's net income, operating
performances, cash flow or liquidity. It is included herein to provide
additional information related to the Company's ability to service
debt.
(3) EBITDA represents earnings before interest expense, income taxes,
depreciation and amortization, extraordinary items and debenture
conversion expense. EBITDA should not be considered an alternative
measure of the Company's net income, operating performance, cash flow
or liquidity. It is included herein to provide additional information
related to the Company's ability to service debt. The Indenture
governing the Notes contains certain covenants that utilize a
Consolidated Fixed Charge Coverage Ratio calculation that is based upon
EBITDA. See "Description of the Notes" for a description of such
covenants.
(4) For the purpose of computing the ratio of earnings to fixed charges,
earnings consist of the sum of earnings before income taxes and
extraordinary items plus fixed charges. Fixed charges consist of
interest on all indebtedness, amortization of debt discount and
expenses, and that portion of rental expense that the Company believes
to be representative of the interest factor. Fixed charges related to
approximately $6,000,000 of debt guaranteed by the Company have not
been included in the computation of the ratio. The definition of fixed
charges used in this calculation differs from that used in the Fixed
Charge Coverage Ratio covenants contained in the Indenture.
(5) Gives effect to the National Health Transaction and the GMC
Transaction, as adjusted to reflect the Sale of the Notes and the use
of the proceeds therefrom as described under "Use of Proceeds."
-12-
<PAGE>
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
Certain statements contained in "Management's Discussion and Analysis
of Financial Condition and Results of Operations," such as statements concerning
Medicare and Medicaid programs and the Company's ability to meet its liquidity
needs and control costs; certain statements contained in "Business," such as
statements concerning strategy, government regulation, Medicare and Medicaid
programs and legal proceedings; certain statements in the Pro Forma Condensed
Consolidated Financial Information, such as certain of the Pro Forma
Adjustments; and other statements contained herein regarding matters that are
not historical facts are forward looking statements (as such term is defined in
the Securities Act) and because such statements involve risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward looking statements. Factors that could cause actual results to differ
materially include, but are not limited to, those discussed herein under "Risk
Factors."
RISK FACTORS
In addition to the other information contained in the Prospectus,
prospective investors should carefully consider the following risk factors
before purchasing the Notes offered hereby.
Certain Financial Considerations. The Company has substantial
indebtedness and, as a result, significant debt service obligations. As of June
30, 1996, after giving pro forma effect to the National Health Transaction and
GMC Transaction and the Offering and the use of proceeds therefrom, the Company
would have had approximately $595,365,000 of long-term indebtedness which would
have represented 54% of its total capitalization. See "Capitalization." The
degree to which the Company is leveraged could have important consequences to
holders of the Notes, including the following: (i) the Company's ability to
obtain additional financing in the future for working capital, capital
expenditures, acquisitions or general corporate purposes may be impaired; (ii) a
substantial portion of the Company's cash flow from operations may be dedicated
to the payment of principal and interest on its indebtedness, thereby reducing
the funds available to the Company for its operations; (iii) all of the
indebtedness incurred under the Credit Facility is scheduled to become due, and
the indebtedness under the 9 3/4 % Notes is due, prior to the time any principal
payments are required on the Notes; (iv) certain of the Company's borrowings are
and will continue to be at variable rates of interest, which causes the Company
to be vulnerable to increases in interest rates; and (v) certain of the
Company's indebtedness contains financial and other restrictive covenants,
including those restricting the incurrence of additional indebtedness, the
creation of liens, the payment of dividends, sales of assets and minimum net
worth requirements. Failure by the Company to comply with such covenants may
result in an event of default which, if not cured or waived, could have a
material adverse effect on the Company.
The Company's ability to make scheduled payments or to refinance its
obligations with respect to its indebtedness depends on its financial and
operating performance, which, in turn, is subject to prevailing economic
conditions and to financial, business and other factors beyond its control.
Although the Company's cash flow from its operations has been sufficient to meet
its debt service obligations in the past, there can be no assurance that the
Company's operating results will continue to be sufficient for payment of the
Company's indebtedness. The Company also has significant long-term operating
lease obligations with respect to certain of its eldercare centers.
Ranking. The Existing Notes will be subordinated to all existing and
future Senior Indebtedness of the Company and will rank pari passu in right of
payment with all of the Company's existing and future senior subordinated
indebtedness. The Existing Notes will also be effectively subordinated to the
indebtedness and other liabilities of the Company's subsidiaries. As of June 30,
1996, on a pro forma basis
-13-
<PAGE>
after giving effect to the National Health Transaction and the GMC Transaction
and the Offering and the use of proceeds therefrom, the aggregate amount of
Senior Indebtedness outstanding would have been approximately $401,143,000
(which includes approximately $9,980,000 of indebtedness and approximately
$61,000,000 of lease obligations of subsidiaries and approximately $6,000,000 of
indebtedness of other persons, all of which are guaranteed by the Company, and
approximately $15,900,000 of letters of credit issued under the Credit Facility
primarily related to the Company's self-insurance programs) and, as of such
date, the aggregate amount of liabilities of the subsidiaries of the Company,
which consist primarily of trade payables and accrued compensation, that will
effectively rank senior to the Existing Notes was approximately $64,163,000.
Upon any payment or distribution of assets of the Company in a total or partial
liquidation, dissolution, reorganization or similar proceeding, the holders of
Senior Indebtedness may be entitled to receive payment in full before the
holders of the Notes are entitled to receive any payment. In addition, under
certain circumstances, no payment may be made with respect to the principal of
or interest on the Notes if a payment default or other defaults exist with
respect to certain Senior Indebtedness. See "Description of the Notes --
Subordination."
Risk of Adverse Effect of Healthcare Reform. In addition to extensive
existing government healthcare regulation, there are numerous initiatives on the
federal and state levels for comprehensive reforms affecting the payment for and
availability of healthcare services. It is not clear at this time what
proposals, if any, will be adopted, or what effect such proposals would have on
the Company's business. Aspects of certain of these healthcare proposals, such
as reductions in funding of the Medicare and Medicaid programs, potential
changes in reimbursement regulations by the Health Care Financing Administration
("HCFA"), enhanced pressure to contain healthcare costs by Medicare, Medicaid
and other payors and permitting greater state flexibility in the administration
of Medicaid, could adversely affect the Company. There can be no assurance that
currently proposed or future healthcare legislation or other changes in the
administration or interpretation of governmental healthcare programs or
regulations will not have a material adverse effect on the Company. Concern
about the potential effects of the proposed reform measures has contributed to
the volatility of prices of securities of companies in healthcare and related
industries, including the Company, and may similarly affect the price of the
Company's securities in the future. See "Business --Government Regulation."
Regulation. The federal government and all states in which the Company
operates regulate various aspects of the Company's business. In particular, the
development and operation of eldercare centers and the provision of healthcare
services are subject to federal, state and local laws relating to the delivery
and adequacy of medical care, distribution of pharmaceuticals, equipment,
personnel, operating policies, fire prevention, rate-setting and compliance with
building codes and environmental laws. Eldercare centers are subject to periodic
inspection by governmental and other authorities to assure continued compliance
with various standards, their continued licensing under state law, certification
under the Medicare and Medicaid programs and continued participation in the
Veterans Administration program and the ability to participate in other third
party programs. The Company is also subject to inspection regarding record
keeping and inventory control. The failure to obtain or renew any required
regulatory approvals or licenses could adversely affect the continued expansion
of the Company and could prevent it from offering its existing services.
Many states have adopted Certificate of Need or similar laws which
generally require that the appropriate state agency approve certain acquisitions
and determine that a need exists for certain bed additions, new services and
capital expenditures or other changes prior to beds and/or new services being
added or capital expenditures being undertaken. To the extent that Certificates
of Need or other similar approvals are required for expansion of Company
operations, either through center acquisitions or expansion
-14-
<PAGE>
or provision of new services or other changes, such expansion could be adversely
affected by the failure or inability to obtain the necessary approvals, changes
in the standards applicable to such approvals and possible delays and expenses
associated with obtaining such approvals.
The Company is also subject to federal and state laws which govern
financial and other arrangements between healthcare providers. These laws often
prohibit certain direct and indirect payments or fee-splitting arrangements
between healthcare providers that are designed to induce or encourage the
referral of Patients to, or the recommendation of, a particular provider for
medical products and services. These laws include the federal "Stark
legislations" which prohibit, with limited exceptions, the referral of patients
for certain services, including home health services, physical therapy and
occupational therapy, by a physician to an entity in which the physician has an
ownership interest and the federal "anti-kickback law" which prohibits, among
other things, the offer, payment, solicitation or receipt of any form of
remuneration in return for the referral of Medicare and Medicaid patients or the
purchasing, leasing, ordering or arranging for any goods, facility services or
items for which payment can be made under Medicare and Medicaid. The federal
government, private insurers and various state enforcement agencies have
increased their scrutiny of providers, business practices and claims in an
effort to identify and prosecute fraudulent and abusive practices. In addition,
the federal government has issued recent fraud alerts concerning nursing
services, double billing, home health services and the provision of medical
supplies to nursing facilities; accordingly, these areas may come under closer
scrutiny by the government. See "Business -- Governmental Regulation."
Furthermore, some states restrict certain business relationships between
physicians and other providers of healthcare services. Many states prohibit
business corporations from providing, or holding themselves out as a provider
of, medical care. Possible sanctions for violation of any of these restrictions
or prohibitions include loss of licensure or eligibility to participate in
reimbursement programs and civil and criminal penalties. These laws vary from
state to state, are often vague and have seldom been interpreted by the courts
or regulatory agencies. From time to time, the Company has sought guidance as to
the interpretation of these laws; however, there can be no assurance that such
laws will ultimately be interpreted in a manner consistent with the practices of
the Company.
Payment by Third Party Payors. For the years ended September 30, 1994
and 1995, and the nine months ended June 30, 1996, respectively, the Company
derived approximately 41%, 38% and 39% of its patient service revenue from
private pay sources, 16%, 21% and 23% from Medicare and 43%, 41% and 38% from
various state Medicaid agencies. Both governmental and private third party
payors have employed cost containment measures designed to limit payments made
to healthcare providers such as the Company. Those measures include the adoption
of initial and continuing recipient eligibility criteria which may limit payment
for services, the adoption of coverage and duration criteria which limit the
services which will be reimbursed and the establishment of payment ceilings
which set the maximum reimbursement that a provider may receive for services.
Furthermore, government payment programs are subject to statutory and regulatory
changes, retroactive rate adjustments, administrative rulings and government
funding restrictions, all of which may materially increase or decrease the rate
of program payments to the Company for its services. There can be no assurance
that payments under governmental and private third party payor programs will
remain at levels comparable to present levels or will, in the future, be
sufficient to cover the costs allocable to patients eligible for reimbursement
pursuant to such programs. In addition, there can be no assurance that centers
owned, leased or managed by the Company, or the provision of services and
supplies by the Company, now or in the future will initially meet or continue to
meet the requirements for participation in such programs. The Company could be
adversely affected by the continuing efforts of governmental and private third
party payors to contain the amount of reimbursement for healthcare services. In
an attempt to limit the federal budget deficit, there have been, and the Company
expects that there will continue to be, a number of proposals to limit Medicare
and Medicaid reimbursement for healthcare services. In certain states
-15-
<PAGE>
there have been proposals to eliminate the distinction in Medicaid payment for
skilled versus intermediate care services and to establish a case mix
prospective payment system pursuant to which the payment to a facility for a
patient is based upon the patient's condition and need for services. The Company
cannot at this time predict whether any of these proposals will be adopted or,
if adopted and implemented, what effect, if any, such proposals will have on the
Company. In addition, private payors, including managed care payors,
increasingly are demanding discounted fee structures or the assumption by
healthcare providers of all or a portion of the financial risk through prepaid
capitation arrangements. Efforts to impose reduced allowances, greater discounts
and more stringent cost controls by government and other payors are expected to
continue. See "Business -- Revenue Sources."
Competition. The healthcare industry is highly competitive. The Company
competes with a variety of other companies in providing eldercare services.
Certain competing companies have greater financial and other resources and may
be more established in their respective communities than the Company. Competing
companies may offer newer or different centers or services than the Company and
may thereby attract the Company's customers who are either presently residents
of its eldercare centers or are otherwise receiving its eldercare services. See
"Business -- Competition."
Risks Associated with Acquisition Strategy. The Company has recently
completed several acquisitions of eldercare businesses. The Company also intends
to pursue additional acquisitions in the future. There can be no assurance that
the Company will be able to realize expected operating and economic efficiencies
from its recent acquisitions or from any future acquisitions or that such
acquisitions will not adversely affect the Company's results of operations or
financial condition. In addition, there can be no assurance that the Company
will be able to locate suitable acquisition candidates in the future, consummate
acquisitions on favorable terms or successfully integrate newly acquired
businesses with the Company's operations. The consummation of acquisitions
likely will result in the incurrence or assumption by the Company of additional
indebtedness.
Absence of Public Market. The Existing Notes currently are owned by a
relatively small number of beneficial owners. The Existing Notes have not been
registered under the Securities Act and will be subject to restrictions on
transferability to the extent that they are not exchanged for the Exchange
Notes. The Exchange Notes will constitute a new issue of securities with no
established trading market. Although the Exchange Notes generally will be
permitted to be resold or otherwise transferred by the holders (who are not
affiliates of the Company) without compliance with the registration requirements
under the Securities Act, the Company does not intend to list the Exchange Notes
on any national securities exchange or to seek the admission thereof to trading
in the National Association of Securities Dealers Automated Quotation System.
The Exchange Notes may trade at a discount from their initial offering price,
depending upon prevailing interest rates, the market for similar securities, the
performance of the Company and certain other factors. The Company has been
advised by the Initial Purchasers that they intend to make a market in the
Exchange Notes, as permitted by applicable laws and regulations; however, the
Initial Purchasers are not obligated to do so and any such market making
activities may be discontinued at any time without notice. In addition, such
market-making activity will be subject to the limits imposed by the Securities
Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act") and
may be limited during the Exchange Offer. Accordingly, no assurance can be given
that an active public or other market will develop for the Exchange Notes or as
to the liquidity of the trading market for the Exchange Notes. Pursuant to the
Registration Rights Agreement, the Company is required to consummate the
Exchange Offer for the Existing Notes or file the Shelf Registration Statement
covering resales of the Existing Notes within 120 days following the original
issue of the Existing Notes. Until the Company performs its obligations under
the Registration Rights Agreement, the Existing Notes may only be offered or
sold pursuant to an exemption
-16-
<PAGE>
from the registration requirements of the Securities Act and applicable state
securities laws or pursuant to an effective registration statement under the
Securities Act and applicable state securities laws.
Exchange Offer Procedures. Issuance of Exchange Notes in exchange for
Existing Notes pursuant to the Exchange Offer will be made only after a timely
receipt by the Company of such Existing Notes, a properly completed and duly
executed Letter of Transmittal and all other required documents. Therefore,
holders of the Existing Notes desiring to tender such Existing Notes in exchange
for Exchange Notes should allow sufficient time to ensure timely delivery. The
Company is under no duty to give notification of defects or irregularities with
respect to the tenders of Notes for exchange. Existing Notes that are not
tendered or are tendered but not accepted will, following the consummation of
the Exchange Offer, continue to be subject to the existing restrictions upon
transfer thereof and, upon consummation of the Exchange Offer, the registration
rights under the Registration Rights Agreement will terminate. In addition, any
holder of Existing Notes who tenders in the Exchange Offer for the purpose of
participating in a distribution of the Exchange Notes may be deemed to have
received restricted securities and, if so, will be required to comply with the
registration and prospectus delivery requirements of the Securities Act in
connection with any resale transaction. Each broker-dealer that receives
Exchange Notes for its own account in exchange for Existing Notes, where such
Existing Notes were acquired by such broker-dealer as a result of market-making
activities or other trading activities, must acknowledge that it will deliver a
prospectus in connection with any resale of such Exchange Notes. See "Plan of
Distribution." To the extent that Existing Notes are tendered and accepted in
the Exchange Offer, the trading market for untendered and tendered but
unaccepted Existing Notes could be adversely affected. See "--Consequences of
the Exchange Offer on Non-Tendering Holders of the Existing Notes."
Consequences of the Exchange Offer on Non-Tendering Holders of the
Existing Notes. The Company intends for the Exchange Offer to satisfy its
registration obligations under the Registration Rights Agreement. If the
Exchange Offer is consummated, the Company does not intend to file further
registration statements for the sale or other disposition of Existing Notes.
Consequently, following completion of the Exchange Offer, holders of Existing
Notes seeking liquidity in their investment would have to rely on an exemption
to the registration requirements under applicable securities laws, including the
Securities Act, with respect to any sale or other disposition of the Existing
Notes.
USE OF PROCEEDS
The Company will not receive any cash proceeds from the Exchange Offer.
The net proceeds to the Company from the Offering after deducting offering
expenses and the Initial Purchasers' discount was approximately $121,000,000.
The Company used the net proceeds from the Offering together with borrowings
under its Credit Facility as follows: approximately $93,900,000 was used to pay
the cash portion of the purchase price of the GMC Transaction; approximately
$87,600,000 was used to make a loan to GMC immediately prior to the GMC
Transaction to prepay $82,800,000 of debt which bore interest at a rate of
12 1/4 % per annum and was due in 2002 and to pay related prepayment expenses;
and approximately $2,400,000 was used to prepay debt assumed as a part of the
GMC Transaction which bore interest at a rate of 11 1/4% per annum and was due
in 2001. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations -- Certain Transactions."
-17-
<PAGE>
CAPITALIZATION
The following table sets forth the capitalization of the Company: (i)
as of June 30, 1996; (ii) on a pro forma basis to give effect to the National
Health Transaction and GMC Transaction; and (iii) as adjusted to give effect to
the Offering and the application of the estimated net proceeds therefrom as
described in "Use of Proceeds."
<TABLE>
<CAPTION>
June 30, 1996
----------------------------------------------
Pro Forma,
Actual Pro Forma As Adjusted
------------- ------------ -------------
(in thousands)
<S> <C> <C> <C>
Current installment of long-term debt.............................. $ 2,512 $ 7,332 $ 2,512
============= ============ =============
Long-term debt, less current maturities:
Senior long-term debt ......................................... $ 132,263 $ 422,911 $ 306,731 (1)
9 1/4% Senior Subordinated Notes due 2006...................... -- -- 125,000
9 3/4% Senior Subordinated Notes due 2005 (2).................. 119,730 119,730 119,730
6% Convertible Senior Subordinated Debentures
due 2003..................................................... 43,904 43,904 43,904
------------- ------------ -------------
Total long-term debt...................................... 295,897 586,545 595,365
Shareholders' equity:
Common stock, $.02 par value, 60,000,000 shares
authorized; 31,981,680 shares issued and
31,936,079 shares outstanding................................ 476 476 476
Additional paid-in capital..................................... 411,677 411,677 411,677
Retained earnings.............................................. 88,328 88,328 88,328
Treasury stock, at cost, 45,601 shares......................... (243) (243) (243)
------------- ------------ -------------
Total shareholders' equity................................... 500,238 500,238 500,238
------------- ------------ -------------
Total capitalization...................................... 796,135 1,086,703 1,095,603
============= ============ =============
</TABLE>
- --------------------------
(1) Primarily includes $260,300,000 under the revolving credit facility of
the Credit Facility; $23,700,000 9 1/4 % First Mortgage Bonds Series A
due October 2007; and approximately $9,980,000 of indebtedness of
subsidiaries guaranteed by the Company. The Company has recently
entered into an agreement with the lenders of the Credit Facility which
increases the revolving credit facility and the lease financing
facility to $300,000,000 and $150,000,000, respectively.
(2) Net of remaining original issue discount of $270,000.
-18-
<PAGE>
EXCHANGE OFFER
Purpose and Effect of the Exchange Offer
The Existing Notes were originally sold by the Company on October 7,
1996 to the Initial Purchasers pursuant to the Purchase Agreement. The Initial
Purchasers subsequently resold the Existing Notes to qualified institutional
buyers in reliance on Rule 144A under the Securities Act and to a limited number
of institutional accredited investors that agreed to comply with certain
transfer restrictions and other conditions. As a condition to the closing under
the Purchase Agreement, the Company entered into the Registration Rights
Agreement with the Initial Purchasers, pursuant to which the Company agreed, for
the benefit of the holders of the Existing Notes, at the Company's cost, among
other things, to use its best efforts to (i) file within 30 days, and cause to
become effective within 90 days, of the date of the original issuance of the
Existing Notes, a registration statement on Form S-4 (the "Exchange Offer
Registration Statement") which term shall encompass all amendments, exhibits,
annexes and schedules thereto and of which this Prospectus is a part and (ii)
cause the Exchange Offer to be consummated within 120 days of the original
issuance of the Existing Notes. Promptly after the Exchange Offer Registration
Statement has been declared effective, the Company will offer the Exchange Notes
in exchange for the Existing Notes.
The Company will keep the Exchange Offer open until the Expiration
Date. For each Existing Note validly tendered to the Company pursuant to the
Exchange Offer and not withdrawn by the holder thereof, the holder of such
Existing Note will receive an Exchange Note having a principal amount equal to
that of the tendered Existing Note. Interest on each Exchange Note will accrue
from the last interest payment date on which interest was paid on the tendered
Existing Note in exchange therefor or, if no interest has been paid on such
Existing Note, from the date of the original issuance of the Existing Note.
Under existing interpretations of the staff of the Commission contained
in several no-action letters to third parties and subject to the immediately
following sentence, the Company believes that the Exchange Notes would in
general be freely tradeable after the Exchange Offer without further compliance
with the registration and prospectus delivery requirements of the Securities
Act. However, any purchaser of Existing Notes who is an "affiliate" of the
Company or who intends to participate in the Exchange Offer for the purpose of
distributing the Exchange Notes (i) will not be able to rely on the
interpretation of the staff of the Commission, (ii) will not be able to tender
its Existing Notes in the Exchange Offer and (iii) must comply with the
registration and prospectus delivery requirements of the Securities Act in
connection with any sale or transfer of the Existing Notes unless such sale or
transfer is made pursuant to an exemption from such requirements.
Each holder of the Existing Notes (other than certain specified
holders) who wishes to exchange Existing Notes for Exchange Notes in the
Exchange Offer will be required to represent that (i) it is not an "affiliate"
of the Company, (ii) it is not a broker-dealer tendering Existing Notes acquired
directly from the Company or if it is such a broker-dealer, it will comply with
the registration and prospectus delivery requirements of the Securities Act to
the extent applicable, (iii) any Exchange Notes to be received by it were
acquired in the ordinary course of its business and (iv) at the time of
commencement of the Exchange Offer, it has no arrangement with any person to
participate in the distribution (within the meaning of the Securities Act) of
the Exchange Notes. In addition, in connection with any resales of Exchange
Notes, any broker-dealer who acquired the Existing Notes for its own account as
a result of market-making or other trading activities (a "Participating
Broker-Dealer") must deliver a prospectus meeting the requirements of the
Securities Act. The Commission has taken the position that Participating
Broker-Dealers may fulfill their prospectus delivery requirements with respect
to the Exchange Notes (other than a resale of an unsold allotment from
-19-
<PAGE>
the original sale of the Existing Notes), with the prospectus contained in the
Exchange Offer Registration Statement. Under the Registration Rights Agreement,
the Company is required to allow Participating Broker-Dealers and other persons
subject to similar prospectus delivery requirements, if any, to use the
prospectus contained in the Exchange Offer Registration Statement in connection
with the resale of such Exchange Notes; provided however that the Company is
only required to use its best efforts to maintain the effectiveness of the
Exchange Offer Registration Statement for a period of 120 days following the
closing of the Exchange Offer.
In the event that any changes in law or the applicable interpretations
of the staff of the Commission do not permit the Company to effect the Exchange
Offer, or if for any reason the Exchange Offer is not consummated within 120
days following the date of original issue of the Existing Notes, or if any
holder of the Existing Notes (other than the Initial Purchasers) is not eligible
to participate in the Exchange Offer, or upon the request of any Initial
Purchaser under certain circumstances, the Company will, at its cost, use its
best efforts to (a) as promptly as practicable, file the Shelf Registration
Statement covering resales of the Existing Notes, (b) cause the Shelf
Registration Statement to be declared effective under the Securities Act by the
120th day after the original issue of the Existing Notes and (c) keep effective
the Shelf Registration Statement until three years after its effective date (or
until one year after such effective date if such Shelf Registration Statement is
filed at the request of any Initial Purchaser under certain circumstances) or
until such shorter period when all the Existing Notes covered by the Shelf
Registration Statement have been sold pursuant to the Shelf Registration
Statement or are eligible for resale pursuant to Rule 144 under the Securities
Act without volume limitations. The Company will, in the event of the filing of
a Shelf Registration Statement, provide to each holder of the Existing Notes
copies of the prospectus which is a part of the Shelf Registration Statement,
notify each such holder when the Shelf Registration Statement for the Existing
Notes has become effective and take certain other actions as are required to
permit unrestricted resales of the Existing Notes. A holder of Existing Notes
that sells such Existing Notes pursuant to the Shelf Registration Statement
generally will be required to be named as a selling security holder in the
related prospectus and to deliver a prospectus to purchasers, will be subject to
certain of the civil liability provisions under the Securities Act in connection
with such sales and will be bound by the provisions of the Registration Rights
Agreement which are applicable to such a holder (including certain
indemnification obligations). In addition, each holder of the Existing Notes
will be required to deliver information to be used in connection with the Shelf
Registration Statement and to provide comments on the Shelf Registration
Statement within the time periods set forth in the Registration Rights Agreement
in order to have their Existing Notes included in the Shelf Registration
Statement and to benefit from the provisions regarding liquidated damages set
forth in the following paragraph.
In the event that either (i) the Exchange Offer Registration Statement
is not filed with the Commission on or prior to the 30th calendar day following
the date of original issue of the Existing Notes, (ii) the Exchange Offer
Registration Statement is not declared effective on or prior to the 90th
calendar day following the date of original issue of the Existing Notes or (iii)
the Exchange Offer is not consummated or a Shelf Registration Statement with
respect to the Existing Notes is not declared effective on or prior to the 120th
calendar day following the date of original issue of the Existing Notes, the
interest rate borne by the Existing Notes shall be increased by one-quarter of
one percent per annum following such 30-day period in the case of clause (i)
above, following such 90-day period in the case of clause (ii) above or
following such 120-day period in the case of clause (iii) above, which rate will
be increased by an additional one-quarter of one percent per annum for each
90-day period that any additional interest continues to accrue. The aggregate
amount of such increase from the original interest rate pursuant to those
provisions will in no event exceed one percent. Upon (x) the filing of the
Exchange Offer Registration Statement after the 30-day period described in
clause (i) above, (y) the effectiveness of the Exchange Offer Registration
Statement after the
-20-
<PAGE>
90-day period described in clause (ii) above or (z) the consummation of the
Exchange Offer or the effectiveness of a Shelf Registration Statement, as the
case may be, after the 120-day period described in clause (iii) above, the
interest rate borne by the Existing Notes from the date of such filing, the date
of such effectiveness or the day before the date of consummation, as the case
may be, will be reduced to the original interest rate.
Terms of the Exchange Offer
Upon the terms and subject to the conditions set forth in this
Prospectus and in the Letter of Transmittal, the Company will accept any and all
Existing Notes validly tendered and not withdrawn prior to 5:00 p.m., New York
City time, on the Expiration Date. The Company will issue $1,000 principal
amount of Exchange Notes in exchange for each $1,000 principal amount of
outstanding Existing Notes accepted in the Exchange Offer. Holders may tender
some or all of their Existing Notes pursuant to the Exchange Offer. However,
Existing Notes may be tendered only in integral multiples of $1,000. The Company
has fixed the close of business on November 26, 1996 as the record date for the
Exchange Offer for purposes of determining the persons to whom this Prospectus
and the Letter of Transmittal will be mailed initially.
The form and terms of the Exchange Notes are the same as the form and
terms of the Existing Notes (which they replace), except that as of the date
hereof the Exchange Notes have been registered under the Securities Act and,
therefore, will not bear legends restricting their transfer and will not contain
certain provisions included in the terms of the Existing Notes relating to an
increase in the interest rate in certain circumstances relating to the timing of
the Exchange Offer. The holders of the Exchange Notes will not be entitled to
certain rights under the Registration Rights Agreement, which rights will
terminate when the Exchange Offer is consummated. The Exchange Notes will
evidence the same debt as the Existing Notes and will be entitled to the
benefits to the Indenture.
Holders of the Existing Notes do not have any appraisal or dissenters'
rights under the Business Corporation Law of Pennsylvania or the Indenture in
connection with the Exchange Offer. The Company intends to conduct the Exchange
Offer in accordance with the applicable requirements of the Exchange Act and the
rules and regulations of the Commission thereunder.
The Company shall be deemed to have accepted validly tendered Existing
Notes when, as and if the Company has given written notice thereof to the
Exchange Agent. The Exchange Agent will act as agent for the tendering holders
for the purpose of receiving the Exchange Notes from the Company.
If any tendered Existing Notes are not accepted for exchange because of
an invalid tender, the occurrence of certain other events set forth herein or
otherwise, the certificates for any such unaccepted Existing Notes will be
returned to the tendering holder thereof, at the Company's expense, as promptly
as practicable after the Expiration Date.
Holders who tender Existing Notes in the Exchange Offer will not be
required to pay brokerage commissions or fees or, subject to the instructions in
the Letter of Transmittal, transfer taxes with respect to the exchange of
Existing Notes pursuant to the Exchange Offer. The Company will pay all charges
and expenses, other than transfer taxes in certain circumstances, in connection
with the Exchange Offer. See "--Fees and Expenses."
-21-
<PAGE>
Expiration Date; Extension; Amendments
The term "Expiration Date" shall mean 5:00 p.m., New York City time, on
February 4, 1997, unless the Company in its sole discretion extends the Exchange
Offer, in which case the term "Expiration Date" shall mean the latest date and
time to which the Exchange Offer is extended.
In order to extend the Exchange Offer, the Company will notify the
Exchange Agent of any extension by written notice prior to 9:00 a.m., New York
City time, on the next business day after the previously scheduled Expiration
Date.
The Company reserves the right, in its sole discretion, (i) to delay
accepting any Existing Notes, to extend the Exchange Offer or to terminate the
Exchange Offer if any of the conditions set forth below under "Conditions" shall
not have been satisfied, by giving written notice of such delay, extension or
termination to the Exchange Agent, or (ii) to amend the terms of the Exchange
Offer in any manner. Any such delay in acceptance, extension, termination or
amendment will be followed as promptly as practicable by written notice thereof
to the registered holders.
Interest on the Exchange Notes
Interest on each Exchange Note will accrue from the last date on which
interest was paid on the Existing Note surrendered in exchange therefor or, if
no interest has been paid on the Existing Note, from the date of original
issuance of such Existing Note. No interest will be paid on the Existing Notes
accepted for exchange, and holders of Existing Notes whose Existing Notes are
accepted for exchange will be deemed to have waived the right to receive any
payment in respect of interest on the Existing Notes accrued up to the date of
the issuance of the Exchange Notes. Holders of Existing Notes whose Existing
Notes are not exchanged will receive the accrued interest payable thereon on
April 1, 1997, in accordance with the Indenture.
Interest on the Exchange Notes is payable semi-annually on each April 1
and October 1, commencing on April 1, 1997.
Procedures for Tendering
Only a holder of Existing Notes may tender such Existing Notes in the
Exchange Offer. To tender in the Exchange Offer, a holder must complete, sign
and date the Letter of Transmittal, or facsimile thereof, have the signatures
thereon guaranteed if required by the Letter of Transmittal, and mail or
otherwise deliver such Letter of Transmittal, or such facsimile thereof,
together with the Existing Notes and any other required documents, to the
Exchange Agent prior to 5:00 p.m., New York City time, on the Expiration Date.
To be tendered effectively, the Existing Notes, the Letter of Transmittal and
other required documents must be completed and received by the Exchange Agent at
the address set forth below under "Exchange Agent" prior to 5:00 p.m., New York
City time, on the Expiration Date. Delivery of the Existing Notes may be made by
book-entry transfer in accordance with the procedures described below.
Confirmation of such book-entry transfer must be received by the Exchange Agent
prior to the Expiration Date.
By executing the Letter of Transmittal, each holder will make to the
Company the representations set forth above in the fourth paragraph under
"Purpose and Effect of the Exchange Offer."
-22-
<PAGE>
The tender by a holder and the acceptance thereof by the Company will
constitute an agreement between such holder and the Company in accordance with
the terms and subject to the conditions set forth herein and in the Letter of
Transmittal.
THE METHOD OF DELIVERY OF EXISTING NOTES AND THE LETTER OF TRANSMITTAL
AND ALL OTHER REQUIRED DOCUMENTS TO THE EXCHANGE AGENT IS AT THE ELECTION AND
SOLE RISK OF THE HOLDER. AS AN ALTERNATIVE TO DELIVERY BY MAIL, HOLDERS MAY WISH
TO CONSIDER OVERNIGHT OR HAND DELIVERY SERVICE. IN ALL CASES SUFFICIENT TIME
SHOULD BE ALLOWED TO ASSURE DELIVERY TO THE EXCHANGE AGENT BEFORE THE EXPIRATION
DATE. NO LETTER OF TRANSMITTAL OR EXISTING NOTES SHOULD BE SENT TO THE COMPANY.
HOLDERS MAY REQUEST THEIR RESPECTIVE BROKERS, DEALERS, COMMERCIAL BANKS, TRUST
COMPANIES OR NOMINEES TO EFFECT THE ABOVE TRANSACTIONS FOR SUCH HOLDERS.
Any beneficial owner whose Existing Notes are registered in the name of
a broker, dealer, commercial bank, trust company or other nominee and who wishes
to tender should contact the registered holder promptly and instruct such
registered holder to tender on such beneficial owner's behalf. See "Instruction
to Registered Holder and/or Book-Entry Transfer Facility Participant from Owner"
included with the Letter of Transmittal.
Signatures on the Letter of Transmittal or a notice of withdrawal, as
the case may be, must be guaranteed by a member firm of a registered national
securities exchange or of the National Association of Securities Dealers, Inc.,
a commercial bank or trust company having an office or correspondent in the
United States or any other "eligible guarantor institution" within the meaning
of Rule 17Ad-15 under the Securities Exchange Act of 1934, as amended that is a
participant in the Securities Transfer Agents Medallion Program, the New York
Stock Exchange, Inc. Medallion Program or the Stock Exchange Medallion Program
(an "Eligible Institution"), unless the Existing Notes tendered pursuant thereto
are tendered (i) by a registered holder who has not completed the box entitled
"Special Registration Instructions" or "Special Delivery Instructions" on the
Letter of Transmittal or (ii) for the account of an Eligible Institution. In the
event that signatures on the Letter of Transmittal or the notice of withdrawal,
as the case may be, are required to be guaranteed, such guarantee must be by an
Eligible Institution.
If the Letter of Transmittal is signed by a person other than the
registered holder of any Existing Notes listed therein, such Existing Notes must
be endorsed or accompanied by a properly completed bond power, signed by such
registered holder as such registered holder's name appears on such Existing
Notes with the signature thereon guaranteed by an Eligible Institution.
If the Letter of Transmittal or any Existing Notes or bond powers are
signed by trustees, executors, administrators, guardians, attorneys-in-fact,
officers of corporations or others acting in a fiduciary or representative
capacity, such persons should so indicate when signing, and (except when
Exchange Notes are being issued to replace Existing Notes registered in the same
name) evidence satisfactory to the Company of their authority to so act must be
submitted with the Letter of Transmittal.
The Company understands that the Exchange Agent will make a request
promptly after the date of this Prospectus to establish accounts with respect to
the Existing Notes at the book-entry transfer facility, The Depository Trust
Company (the "Book-Entry Transfer Facility"), for the purpose of facilitating
the Exchange Offer, and subject to the establishment thereof, any financial
institution that is a participant in the Book-Entry Transfer Facility's system
may make book-entry delivery of Existing Notes by causing such
-23-
<PAGE>
Book-Entry Transfer Facility to transfer such Existing Notes into the Exchange
Agent's account with respect to the Existing Notes in accordance with the
Book-Entry Transfer Facility's procedures for such transfer. Although delivery
of the Existing Notes may be effected through book-entry transfer into the
Exchange Agent's account at the Book-Entry Transfer Facility, an appropriate
Letter of Transmittal properly completed and duly executed with any required
signature guarantee and all other required documents must in each case be
transmitted to and received or confirmed by the Exchange Agent at its address
set forth below on or prior to the Expiration Date, or, if the guaranteed
delivery procedures described below are compiled with, within the time period
provided under such procedures. Delivery of documents to the Book-Entry Transfer
Facility does not constitute delivery to the Exchange Agent.
All questions as to the validity, form, eligibility (including time of
receipt), acceptance and withdrawal of tendered Existing Notes will be
determined by the Company in its sole discretion, which determination will be
final and binding. The Company reserves the absolute right to reject any and all
Existing Notes not properly tendered or any Existing Notes the Company's
acceptance of which would, in the opinion of counsel for the Company, be
unlawful. The Company also reserves the right in its sole discretion to waive
any defects, irregularities or conditions of tender as to particular Existing
Notes. The Company's interpretation of the terms and conditions of the Exchange
Offer (including the instructions in the Letter of Transmittal) will be final
and binding on all parties. Unless waived, any defects or irregularities in
connection with tenders of Existing Notes must be cured within such time as the
Company shall determine. Although the Company intends to notify holders of
defects or irregularities with respect to tenders of Existing Notes, neither the
Company, the Exchange Agent nor any other person shall incur any liability for
failure to give such notification. Tenders of Existing Notes will not be deemed
to have been made until such defects or irregularities have been cured or
waived. Any Existing Notes received by the Exchange Agent that are not properly
tendered and as to which the defects or irregularities have not been cured or
waived will be returned by the Exchange Agent to the tendering holders, unless
otherwise provided in the Letter of Transmittal, as soon as practicable
following the Expiration Date.
Guaranteed Delivery Procedures
Holders who wish to tender their Existing Notes and (i) whose Existing
Notes are not immediately available, (ii) who cannot deliver their Existing
Notes, the Letter of Transmittal or any other required documents to the Exchange
Agent or (iii) who cannot complete the procedures for book-entry transfer, prior
to the Expiration Date, may effect a tender if:
(a) the tender is made through an Eligible Institution;
(b) prior to the Expiration Date, the Exchange Agent receives from such
Eligible Institution a properly completed and duly executed Notice of Guaranteed
Delivery (by facsimile transmission, mail or hand delivery) setting forth the
name and address of the holder, the certificate number(s) of such Existing Notes
and principal amount of Existing Notes tendered, stating that the tender is
being made thereby and guaranteeing that, within three New York Stock Exchange
trading days after the Expiration Date, the Letter of Transmittal (or facsimile
thereof) together with the certificate(s) representing the Existing Notes (or a
confirmation of book-entry transfer of such Existing Notes into the Exchange
Agent's account at the Book-Entry Transfer Facility), and any other documents
required by the Letter of Transmittal will be deposited by the Eligible
Institution with the Exchange Agent; and
(c) such properly completed and executed Letter of Transmittal or
facsimile thereof, as well as the certificate(s) representing all tendered
Existing Notes in proper form for transfer (or a confirmation of
-24-
<PAGE>
book-entry transfer of such Existing Notes into the Exchange Agent's account at
the Book-Entry Transfer Facility), and all other documents required by the
Letter of Transmittal are received by the Exchange Agent upon three New York
Stock Exchange trading days after the Expiration Date.
Upon request to the Exchange Agent, a Notice of Guaranteed Delivery
will be sent to holders who wish to tender their Existing Notes according to the
guaranteed delivery procedures set forth above.
Withdrawal of Tenders
Except as otherwise provided herein, tenders of Existing Notes may be
withdrawn at any time prior to 5:00 p.m., New York City time, on the Expiration
Date.
To withdraw a tender of Existing Notes in the Exchange Offer, a
telegram, telex, facsimile transmission or letter must be received by the
Exchange Agent at its address set forth herein prior to 5:00 p.m., New York City
time, on the Expiration Date. Any such notice of withdrawal must (i) specify the
name of the person having deposited the Existing Notes to be withdrawn (the
"Depositor"), (ii) identify the Existing Notes to be withdrawn (including the
certificate number(s) and principal amount of such delivered Existing Notes, or,
in the case of Existing Notes transferred by book-entry transfer, the name and
number of the account at the Book-Entry Transfer Facility to be credited and the
transaction code number), (iii) state that such Depositor is withdrawing its
election to have the Existing Notes exchanged and specify the name in which any
such Existing Notes are to be registered, if different from that of the
Depositor and (iv) be signed by the holder in the same manner as the original
signature on the Letter of Transmittal by which such Existing Notes were
tendered (including any required signature guarantees) or be accompanied by
documents of transfer sufficient to have the Trustee with respect to the
Existing Notes register the transfer of such Existing Notes into the name of the
person withdrawing the tender. All questions as to the validity, form and
eligibility (including time of receipt) of such notices will be determined by
the Company, whose determination shall be final and binding on all parties. Any
Existing Notes so withdrawn will be deemed not to have been validly tendered for
purposes of the Exchange Offer and no Exchange Notes will be issued with respect
thereto unless the Existing Notes so withdrawn are validly retendered. Any
Existing Notes which have been tendered but which are not accepted for exchange
will be returned to the holder thereof without cost to such holder as soon as
practicable after withdrawal, rejection of tender or termination of the Exchange
Offer. Properly withdrawn Existing Notes may be retendered by following one of
the procedures described above under "Procedures for Tendering" at any time
prior to the Expiration Date.
Conditions
Notwithstanding any other term of the Exchange Offer, the Company shall
not be required to accept for exchange, or exchange Exchange Notes for, any
Existing Notes, and may terminate or amend the Exchange Offer as provided herein
before the acceptance of such Existing Notes, if:
(a) the Exchange Offer or the making of any exchange by a holder of
Existing Notes violates applicable law or any applicable interpretation by the
staff of the Commission; or
(b) the tendering of the Existing Notes is not in accordance with the
Exchange Offer;
(c) each holder of Existing Notes to be exchanged in the Exchange Offer
shall not have represented that all Exchange Notes to be received by it shall be
acquired in the ordinary course of business and that at the time of the
consummation of the Exchange Offer it shall have no arrangement of
-25-
<PAGE>
understanding with any person to participate in the distribution (within the
meaning of the Securities Act) of the Exchange Notes and shall have made such
other representations as may be reasonably necessary under applicable Commission
rules, regulations or interpretations to render the use of the Exchange Offer
Registration Statement or other appropriate form under the Securities Act
available; or
(d) any action or proceeding is instituted or threatened in any court
or by or before any governmental agency with respect to the Exchange Offer
which, in the judgment of the Company, would reasonably be expected to impair
the ability of the Company to proceed with the Exchange Offer.
If the Company determines in its sole discretion that any of the
conditions are not satisfied, the Company may (i) refuse to accept any Existing
Notes and return all tendered Existing Notes to the tendering holders, (ii)
extend the Exchange Offer and retain all Existing Notes theretofore tendered in
the Exchange Offer, subject, however, to the rights of holders to withdraw such
Existing Notes (see "Withdrawal of Tenders") or (iii) waive such unsatisfied
conditions with respect to the Exchange Offer and accept all properly tendered
Existing Notes which have not been withdrawn.
Exchange Agent
First Union National Bank has been appointed as Exchange Agent for the
Exchange Offer. Questions and requests for assistance, requests for additional
copies of this Prospectus or of the Letter of Transmittal and requests for
Notice of Guaranteed Delivery should be directed to the Exchange Agent addressed
as follows:
By Registered, Certified or Overnight Mail or Hand:
First Union National Bank
One Rodney Square
920 King Street, 1st Floor
Wilmington, DE 19801
Attention: Corporate Trust Department
By Facsimile: (302) 888-7544
Confirm: (302) 888-7530
Attention: Corporate Trust Department
DELIVERY TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE, OR TRANSMISSION
OF INSTRUCTIONS VIA A FACSIMILE NUMBER OTHER THAN THE ONE SET FORTH ABOVE, WILL
NOT CONSTITUTE A VALID DELIVERY.
-26-
<PAGE>
Fees and Expenses
The expenses of soliciting tenders will be borne by the Company. The
principal solicitation is being made by mail; however, additional solicitation
may be made by telegraph, facsimile, telephone or in person by officers and
regular employees of the Company and its affiliates.
The Company has not retained any dealer-manager in connection with the
Exchange Offer and will not make any payments to brokers, dealers, or others
soliciting acceptances of the Exchange Offer. The Company, however, will pay the
Exchange Agent reasonable and customary fees for its services and will reimburse
it for its reasonable out-of-pocket expenses in connection therewith.
The cash expenses to be incurred in connection with the Exchange Offer
will be paid by the Company. Such expenses include fees and expenses of the
Exchange Agent and Trustee, accounting and legal fees and printing costs, among
others.
Accounting Treatment
The Exchange Notes will be recorded at the same carrying value as the
Existing Notes, which is face value, as reflected in the Company's accounting
records on the date of exchange. Accordingly, no gain or loss for accounting
purposes will be recognized by the Company. The expenses of the Exchange Offer
will be expenses over the term of the Exchange Notes.
Consequences of Failure to Exchange
The Existing Notes that are not exchanged for Exchange Notes pursuant
to the Exchange Offer will remain outstanding and continue to accrue interest
and will also remain restricted securities. Accordingly, such Existing Notes may
be resold only (i) to the Company, (ii) pursuant to a registration statement
which has been declared effective under the Securities Act, (iii) for so long as
the Existing Notes are eligible for resale pursuant to Rule 144A under the
Securities Act, to a person the seller reasonably believes is a "qualified
institutional buyer" within the meaning of Rule 144A that purchases for its own
account or for the account of a qualified institutional buyer and to whom notice
is given that the transfer is being made in reliance on Rule 144A, (iv) pursuant
to offer and sale to non-U.S. persons that occur outside the United States
within the meaning of Regulation S under the Securities Act, (v) to an
institutional "accredited investor" within the meaning of subparagraphs (a)(1),
(a)(2), (a)(3) or (a)(7) of Rule 501 under the Securities Act that is acquiring
the Existing Notes for its own account or for the account of such an
institutional "accredited investor" for investment purposes and not with a view
to, or for offer or sale in connection with, any distribution in violation of
the Securities Act or (vi) pursuant to any other available exemption from the
registration requirements of the Securities Act, in each case in accordance with
any applicable securities laws of any state of the United States and in
accordance with the Indenture. Holders of Existing Notes not tendered in the
Exchange Offer will not retain any rights under the Registration Rights
Agreement, except in limited circumstances.
Resale of the Exchange Notes
With respect to resales of Exchange Notes, based on an interpretation
by the staff of the Commission set forth in no-action letters issued to third
parties, the Company believes that a holder or other person who receives
Exchange Notes, whether or not such person is the holder (other than a person
that is an "affiliate" of the Company within the meaning of Rule 405 under the
Securities Act), who receives Exchange Notes in
-27-
<PAGE>
exchange for Existing Notes in the ordinary course of business and who is not
participating, does not intend to participate, and has no arrangement or
understanding with a person to participate, in the distribution of the Exchange
Notes, will be allowed to resell the Exchange Notes to the public without
further registration under the Securities Act and without delivering to the
purchasers of the Exchange Notes a prospectus that satisfies the requirements of
Section 10 of the Securities Act. However, if any holder acquires Exchange Notes
in the Exchange Offer for the purpose of distributing or participating in a
distribution of the Exchange Notes, such holder cannot rely on the position of
the staff of the Commission enunciated in such no-action letters or any similar
interpretive letters, and must comply with the registration and prospectus
delivery requirements of the Securities Act in connection with any resale
transaction, unless an exemption from registration is otherwise available.
Further, each Participating Broker-Dealer that receives Exchange Notes for its
own account in exchange for Existing Notes, where such Existing Notes were
acquired by such Participating Broker-Dealer as a result of market-making
activities or other trading activities, must acknowledge that it will deliver a
prospectus in connection with any resale of such Exchange Notes.
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
The following discussion is based upon current provisions of the
Internal Revenue Code of 1986, as amended, applicable Treasury regulations,
judicial authority and administrative rulings and practice. There can be no
assurance that the Internal Revenue Service (the "Service") will not take a
contrary view, and no ruling from the Service has been or will be sought.
Legislative, judicial or administrative changes or interpretations may be
forthcoming that could alter or modify the statements and conditions set forth
herein. Any such changes or interpretations may or may not be retroactive and
could affect the tax consequences to holders. Certain holders (including
insurance companies, tax-exempt organizations, financial institutions,
broker-dealers, foreign corporations and persons who are not citizens or
residents of the United States) may be subject to special rules not discussed
below. The Company recommends that each holder consult such holder's own tax
advisor as to the particular tax consequences of exchanging such holder's
Existing Notes for Exchange Notes, including the applicability and effect of any
state, local or foreign tax laws.
The exchange of the Existing Notes for Exchange Notes pursuant to the
Exchange Offer should not be treated as an "exchange" for federal income tax
purposes because the Exchange Notes should not be considered to differ
materially in kind or extent from the Existing Notes. Rather, the Exchange Notes
received by a holder should be treated as a continuation of the Existing Notes
in the hands of such holder. As a result, there should be no federal income tax
consequences to holders exchanging Existing Notes for Exchange Notes pursuant to
the Exchange Offer.
-28-
<PAGE>
SELECTED CONSOLIDATED FINANCIAL DATA
The selected consolidated financial data presented below for each of
the fiscal years in the five-year period ended September 30, 1995 and as of
September 30, 1995 have been derived from the Company's audited Consolidated
Financial Statements, which have been audited by KPMG Peat Marwick LLP,
independent certified public accountants. The selected consolidated financial
data presented below for the nine months ended June 30, 1995 and 1996 and as of
June 30, 1996 have been derived from the unaudited Condensed Consolidated
Financial Statements of the Company and, in the opinion of the Company, reflect
and include all adjustments (consisting only of normal recurring adjustments)
necessary for a fair presentation of the financial position and results of
operations of the Company for such periods. The results of operations for the
nine months ended June 30, 1996 are not necessarily indicative of the results
that may be expected for a full fiscal year. The selected consolidated financial
data set forth below should be read in conjunction with "Management's Discussion
and Analysis of Financial Condition and Results of Operations" and with the
Consolidated Financial Statements of the Company and the related notes thereto
included elsewhere in this Prospectus.
-29-
<PAGE>
<TABLE>
<CAPTION>
Nine Months Ended
Year Ended September 30, June 30,
-------------------------------------------------------- ----------------------
1991 1992 1993 1994 1995 1995 1996
-------- ---------- --------- ---------- --------- --------- ----------
(in thousands, except share and per share data)
<S> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net revenue:
Basic healthcare services.............. $121,854 $134,763 $133,370 $240,264 $278,121 $206,073 $241,107
Specialty medical services............. 43,726 52,254 75,227 125,718 180,327 128,333 193,347
Management services and other, net..... 5,869 9,236 11,212 22,634 27,945 20,059 25,900
-------- -------- -------- -------- -------- -------- --------
Total net revenues.................. 171,449 196,253 219,809 388,616 486,393 354,465 460,354
-------- -------- -------- -------- -------- -------- --------
Income from operations before depreciation,
amortization, lease expense, interest
and Debenture conversion expense....... 30,587 35,597 38,129 69,373 93,253 66,345 87,313
Depreciation and amortization............. 6,258 7,239 7,157 14,982 18,793 13,987 17,883
Lease expense............................. 7,460 7,207 7,026 11,376 13,798 10,388 11,948
Interest expense, net..................... 11,072 8,708 5,042 15,305 20,366 14,369 19,104
Debenture conversion expense.............. -- -- -- -- -- -- 1,245
-------- -------- -------- -------- -------- -------- --------
Earnings before extraordinary items and
cumulative effect of change in accounting
principle.............................. 3,595 7,710 11,909 17,691 25,531 17,508 23,759
Net income................................ 3,283 7,433 11,909 17,673 23,608 15,585 23,759
Preferred stock dividend.................. 441 -- -- -- -- -- --
-------- -------- -------- -------- -------- -------- --------
Net income available to common
shareholders........................... $ 2,842 $ 7,433 $ 11,909 $ 17,673 $ 23,608 $ 15,585 $ 23,759
======== ======== ======== ======== ======== ======== ========
Per common share data (fully diluted) (1)
Earnings before extraordinary items,
cumulative effect of change in accounting
principle and Debenture conversion expense $ 0.39 $ 0.53 $0.67 $0.84(2) $ 1.03(2) $ 0.72(2) $ 0.91(2)
Debenture conversion expense.............. -- -- -- -- -- -- (0.03)(3)
Extraordinary item, net of tax............ -- -- -- -- -- (0.06) --
Net income................................ $ 0.35 $ 0.51 $0.67 $0.84(2) $ 0.97(2) $ 0.66(2) $ 0.88(2)
Weighted average share of common stock
and equivalents........................ 9,233,902 14,494,575 17,928,522 24,819,711 28,452,436 28,284,792 29,358,861
Ratio of earnings to fixed charges (4).... 1.27x 1.78x 2.60x 2.02x 2.15x 2.10x 2.14x
</TABLE>
<TABLE>
<CAPTION>
September 30,
----------------------------------------------------------- June 30,
1991 1992 1993 1994 1995 1996
---------- --------- ---------- --------- --------- ----------
(in thousands)
<S> <C> <C> <C> <C> <C> <C>
Balance Sheet Data:
Working Capital................................... $ 14,689 $ 31,986 $ 50,081 $ 66,854 $ 134,114 $227,599
Total assets...................................... 173,220 188,677 236,978 511,698 600,389 878,348
Long-term debt ................................... 89,777 80,170 83,842 250,807 308,052 295,897
Shareholders' equity.............................. 52,340 82,703 125,348 195,466 221,548 500,238
</TABLE>
- -----------------------------
(1) Reflects a three for two stock dividend on the Common Stock effective
March 29, 1996.
(2) Includes the assumed conversion of all of the Convertible Debentures which
were issued on November 30, 1993.
(3) In connection with an early conversion of a portion of the Convertible
Debentures, the Company paid approximately $1,245,000 ($784,000 after tax)
representing the prepayment of interest to converting Convertible
Debenture holders.
(4) For the purpose of computing the ratio of earnings to fixed charges,
earnings consist of the sum of earnings before income taxes and
extraordinary items plus fixed charges. Fixed charges consist of interest
on all indebtedness, amortization of debt discount and expenses, and that
portion of rental expense that the Company believes to be representative
of the interest factor. Fixed charges related to approximately $6,000,000
of debt guaranteed by the Company have not been included in the
computation of the ratio. The definition of fixed charges used in this
calculation differs from that used in the Fixed Charge Coverage Ratio
covenants contained in the Indenture.
-30-
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
General
Since the Company began operations in July 1985, it has focused its
efforts on providing an expanding array of specialty medical services to elderly
customers. The delivery of these services was originally concentrated in the
eldercare centers owned and leased by the Company, but now also includes managed
eldercare centers, independent healthcare facilities, outpatient clinics and
home healthcare.
The Company generates revenues from three sources: basic healthcare
services, specialty medical services and management services and other. The
Company includes in basic healthcare services revenues all room and board
charges for its eldercare customers at its owned and leased eldercare centers.
Specialty medical services include all revenues from providing rehabilitation
therapies, institutional pharmacy and medical supply services, subacute care
programs, home healthcare, physician services, and other specialized services.
Management services and other include fees earned for management of eldercare
centers.
Genesis delivers its services through three divisions. The largest, in
terms of revenues, is Genesis Eldercare Centers, which at August 31, 1996
included 87 owned and leased eldercare centers. The second, Genesis Eldercare
Services, provides specialty medical services to all centers owned, leased or
managed by Genesis as well as to over 600 independent healthcare providers. The
third, Genesis Eldercare Network Services, manages 40 eldercare centers.
Certain Transactions
In October 1996, the Company and GMC consummated the merger of GMC with
a wholly-owned subsidiary of Genesis. Under the terms of the merger agreement,
GMC shareholders received $5.75 per share in cash for each GMC share. The total
consideration paid to stockholders of GMC to acquire their shares (including
shares which may have been issued upon exercise of outstanding warrants, options
and long-term incentive plans) was approximately $93,900,000. Prior to the
Merger, GMC had outstanding approximately $133,100,000 of indebtedness which
included approximately $87,600,000 which the Company loaned to GMC immediately
prior to consummation of the Merger to repay $82,800,000 principal amount of
indebtedness and to pay related prepayment expenses. The cash portion of the
purchase price and the loan to GMC were provided through the sale by the Company
of the Notes and borrowing under its Credit Facility. GMC owns and operates 18
long-term care facilities and six assisted living facilities with approximately
3,000 licensed beds. GMC also operates an ambulance transportation business, a
medical supply business, a pharmacy business, a contract management service
business, a diagnostic and rehabilitative management services business and a
financial services and information systems business. In addition, GMC currently
is developing two long-term care facilities with approximately 240 beds.
In July 1996, the Company acquired the outstanding stock of National
Health. Prior to the closing of the stock acquisitions, an affiliate of a
financial institution purchased nine of the National Health eldercare centers
for $67,700,000 and subsequently leased the centers to a subsidiary of Genesis.
The balance of the total consideration paid to National Health was funded with
available cash of $51,800,000 and assumed debt of $7,900,000. National Health
added 16 eldercare centers in Florida, Virginia and Connecticut with
approximately 2,200 beds to Genesis. National Health also provided enteral
nutrition and rehabilitation therapy services to the eldercare centers which it
owns and leases. In addition, National Health manages four eldercare centers in
Colorado with 382 beds pursuant to an agreement which expires in October 1997.
-31-
<PAGE>
In June 1996, the Company acquired the pharmacy healthcare services
businesses of NeighborCare for total consideration of approximately $57,250,000,
comprised of approximately $47,250,000 in cash and 312,744 shares of Genesis
Common Stock. Based in Baltimore, Maryland, NeighborCare operates institutional
and retail pharmacy and infusion therapy businesses.
In March 1996, the Company acquired for total consideration of
approximately $31,900,000, including the payment of assumed debt, the remaining
approximately 71% joint venture interests of four eldercare centers in Maryland
and the remaining 50% joint venture interest of an eldercare center in Florida
(the "Partnership Interest Purchase") which had been acquired as part of the
Meridian Transaction described below.
In March 1996, the Company entered into a strategic alliance with
Doctors Community Hospital, a 250-bed acute care hospital in Maryland, pursuant
to which the Company sold to an affiliate of the hospital a 51% interest in
Magnolia Gardens Center, a 104-bed eldercare center for approximately
$2,900,000. As part of this transaction, the Company entered into a long-term
agreement to manage the center.
In March 1996, the Company sold four eldercare centers and a pharmacy
in Indiana for approximately $22,250,000 (the "Indiana Transaction"). The
properties were acquired as part of the Meridian Transaction described below.
In January 1996, the Company acquired the speech therapy, occupational
therapy and physical therapy services businesses of Medical and Rehab Support
Services, Inc., Professional Rehabilitation Network, Inc. and Healthcare Rehab
Services, Inc. (collectively, "Therapy Companies") for approximately $9,300,000.
The Therapy Companies provide these services in the Company's Baltimore,
Maryland/Washington, D.C. market. The acquisition was financed with borrowings
under the Company's Credit Facility.
Prior to January 1, 1996, the Company provided management, development
and marketing services to life care communities operated by Adult Community
Total Services, Inc. ("ACTS"), a Pennsylvania non-profit corporation, pursuant
to a management agreement which was to expire in April 1998. Effective January
1, 1996, Genesis restructured its relationship with ACTS. Under the revised
arrangement, Genesis was paid a $2,000,000 restructuring fee and will no longer
manage the ACTS life care communities. Genesis will continue to provide
development services for a fee in an amount equal to five percent of the total
cost of developing and completing facilities developed by ACTS. The development
portion of the contract has been extended to December 2002 and Genesis is
guaranteed a minimum annual development fee of approximately $1,500,000 per
year. Genesis also continues to provide certain ancillary services to the ACTS
communities.
In December 1995, the Company acquired substantially all of the assets
of Franklin Nursing Home, Inc. ("Franklin") for approximately $3,600,000.
Franklin operated a 250-bed long-term care facility located in Greenfield,
Massachusetts. The acquisition was financed with borrowings under the Company's
Credit Facility.
In November 1995, the Company acquired McKerley for total consideration
of approximately $68,700,000, including assumed debt of approximately
$9,100,000. The transaction also provides for up to an additional $6,000,000 of
contingent consideration payable upon the achievement of certain financial
objectives through October 1997. McKerley owns or leases 15 eldercare centers in
New Hampshire and Vermont with a total of 1,535 beds and operates a home
healthcare business. The acquisition was financed with borrowings under the
Company's Credit Facility.
-32-
<PAGE>
In September 1995, the Company sold, and simultaneously entered into a
three-year contract to manage, five eldercare centers totaling 606 beds to the
AGE Institute of Massachusetts ("AIMASS") for $19,570,000 (the "AIMASS
Transaction").
In August 1995, the Company entered into a software license agreement
for a clinical operating system with Health Data Systems, Inc. The total
commitment under the license agreement is $12,000,000. The Company has estimated
the cost to install the system and related hardware, not including amounts paid
for the software license, to be approximately $18,000,000.
In June 1995, the Company acquired Eastern Medical Supplies, Inc. and
its affiliate Eastern Rehab Services, Inc. (collectively, "Eastern Medical") for
approximately $2,000,000. Eastern Medical sells and leases home medical
equipment, respiratory products and services and rehabilitation equipment to
patients at home throughout Maryland. The purchase was financed with borrowings
under the Company's Credit Facility.
In April 1995, the Company acquired TherapyCare Systems, L.P.
("TherapyCare") for approximately $7,000,000. TherapyCare provides physical
therapy, occupational therapy and speech therapy to 73 long-term care centers
throughout Pennsylvania. The purchase was financed with borrowings under the
Company's Credit Facility.
In March 1995, a joint venture in which the Company is a 55% partner
acquired Delta Drug, Inc. ("Delta Drug") for approximately $1,700,000. Delta
Drug, an institutional pharmacy company located in Providence, Rhode Island,
serves over 2,000 long-term care beds. The Company's portion of the purchase
price was financed with borrowings under the Company's Credit Facility.
In November 1993, Genesis completed its acquisition of substantially
all of the assets of Meridian, Inc., Meridian Healthcare, Inc. and their
affiliated entities (collectively, "Meridian"). As a result of the transaction
(the "Meridian Transaction"), Genesis owned, leased or managed an additional 36
eldercare centers. Of these 36 centers, 15 were wholly-owned, six were
jointly-owned, seven were leased and eight were managed. Genesis also acquired
certain of the other Meridian businesses, including the institutional pharmacy,
qualified group purchasing business and rehabilitation therapy business and
manages one additional retirement community. As part of the Meridian
Transaction, Genesis entered into agreements to lease and operate, for ten years
with a five year renewal option, seven eldercare centers that continue to be
owned by certain shareholders of Meridian (the "Leased Centers") and obtained
the option (the "Option") to purchase the Leased Centers after the expiration of
the lease. The assets acquired in the Meridian Transaction are located primarily
within four of the Company's five geographic markets.
Nine Months Ended June 30, 1996 Compared to Nine Months Ended June 30, 1995.
The Company's total net revenues for the nine months ended June 30,
1996 were $460,354,000 compared to $354,465,000 for the nine months ended June
30, 1995, an increase of $105,889,000 or 30%. Basic healthcare services
increased $35,034,000 or 17%, which is primarily due to the McKerley Transaction
and the Partnership Interest Purchase in March 1996 (which was partially offset
by the sale of five eldercare centers in the AIMASS Transaction in September
1995, and the Indiana Transaction in March 1996), along with a shift in payor
mix from Medicaid to Medicare and rate increases. Specialty medical service
revenue increased $65,014,000 or 51%, of which approximately $30,005,000 is due
to acquisitions, with the remainder due to other volume growth in the
institutional pharmacy, medical supply and contract therapy divisions. Specialty
medical service revenue per patient day in the health centers division increased
21% to $29.38 in the nine months ended June 30, 1996 as compared to $24.31 for
the same period in the prior year
-33-
<PAGE>
due primarily to treatment of higher acuity patients. Management services and
other income increased $5,841,000 or 29% primarily due to an increase in service
related business revenues (group purchasing and staff replacement services) of
approximately $1,700,000 and an increase in transactional gains of approximately
$3,700,000. Transactional and other activity in the nine months ended June 30,
1996 included gains recognized in connection with the sale of an investment, the
Indiana Transaction and the sale of a majority interest in one eldercare center
in Maryland.
The Company's operating expenses before debenture conversion expense,
depreciation, amortization and lease expense were $373,041,000 compared to
$288,120,000 in the comparable prior period, an increase of $84,921 or 29%,
which was due to the McKerley Transaction, the NeighborCare Transaction, an
increase in cost of goods sold related to increased specialty medical service
revenues, and inflationary wage and benefit increases.
In the nine months ended June 30, 1996 the Company converted
approximately $42,300,000 of its Convertible Debentures. In connection with the
early conversion of a portion of the Convertible Debentures, the Company paid
approximately $1,245,000 representing the prepayment of interest to converting
debenture holders. The non-recurring cash payment is presented as debenture
conversion expense in the results of operations for the nine months ended June
30, 1996.
Interest expense increased $4,735,000 or 33%. This increase reflects
increased debt levels used to fund acquisitions and a higher average prevailing
interest rate due to the issuance of $120,000,000 of 9 3/4% Notes partially
offset by the repayment of approximately $115,480,000 of indebtedness in June
1996 from a part of the net proceeds of the Company's 1996 Equity Offering and
interest income generated from investment of the remaining net proceeds.
Fiscal 1995 Compared to Fiscal 1994
The Company's total net revenues for the fiscal year ended September
30, 1995 ("Fiscal 1995") were $486,393,000 compared to $388,616,000 for the
fiscal year ended September 30, 1994 ("Fiscal 1994"), an increase of $97,777,000
or 25%. Basic healthcare services increased $37,857,000 or 16% of which
approximately $20,500,000 is due to the Meridian Transaction included in the
entire period in Fiscal 1995 as compared to ten months in Fiscal 1994,
approximately $3,400,000 is due to two centers which were leased in Fiscal 1995
that were managed for a part of Fiscal 1994 and the remaining increase is due to
providing care to higher acuity customers and to rate increases. Specialty
medical services revenue increased $54,609,000 or 43% of which approximately
$6,000,000 is due to the Meridian Transaction, approximately $13,000,000 is due
to acquisitions during Fiscal 1995 and the remainder is due to other volume
growth in the institutional pharmacy, medical supply and contract therapy
divisions and increased acuity in the eldercare centers division. Specialty
medical service revenue per patient day in the health centers division increased
41% to $25.06 in Fiscal 1995 compared to $17.80 in Fiscal 1994 primarily due to
treatment of higher acuity patients. Management services and other income
increased $5,311,000 or 23%. This increase is primarily due to the management
contracts and other unrelated businesses acquired in the Meridian Transaction as
well as inflationary rate increases. The number of eldercare centers under
management contracts increased from 31 at September 30, 1994 to 35 at September
30, 1995.
The Company's operating expenses before depreciation, amortization,
lease expense and interest expense were $393,139,000 for Fiscal 1995 compared to
$319,243,000 for Fiscal 1994, an increase of $73,896,000 or 23%. Salaries, wages
and benefits increased $45,076,000 or 23% of which approximately $14,500,000
relates to the Meridian Transaction, approximately $3,100,000 related to two
centers leased in
-34-
<PAGE>
Fiscal 1995 that were managed for a part of Fiscal 1994 and the remainder is due
to the impact of acquisitions and growth in the institutional pharmacy, medical
supply and contract therapy divisions.
Other operating expenses increased $28,885,000 or 26% of which
approximately $8,500,000 is due to the Meridian Transaction and the remainder is
due to increased sales in the pharmacy and medical supply divisions.
Interest expense increased $5,061,000 or 33%. This increase in interest
expense was due to increased debt used to finance the Meridian Transaction
outstanding for the entire period of Fiscal 1995 compared to ten months in the
prior year, borrowings under the revolving credit agreement and a higher average
interest rate due to the issuance of the Notes in June 1995.
Depreciation and amortization expense increased from $14,982,000 in
Fiscal 1994 to $18,793,000 in Fiscal 1995 primarily due to the Meridian
Transaction.
Lease expense increased from $11,376,000 in Fiscal 1994 to $13,798,000
in Fiscal 1995 of which $1,000,000 is related to the Meridian Transaction,
$500,000 is due to two centers that were leased in Fiscal 1995 that were managed
for a part of Fiscal 1994 and the remainder is due to new leases as a result of
growth of the eldercare services division and inflationary rate increases.
In connection with the early repayment of debt and the restructuring
and amendment of its bank credit facility, the Company recorded an extraordinary
loss of approximately $1,923,000 to write off unamortized, deferred financing
fees.
Fiscal 1994 Compared to Fiscal 1993
The Company's total net revenues for Fiscal 1994 were $388,616,000
compared to $219,809,000 for the fiscal year ended September 30, 1993 ("Fiscal
1993"), an increase of $168,807,000 or 76.8%. Basic healthcare services
increased $106,894,000 or 80.1% of which approximately $97,600,000 was due to
the Meridian Transaction and the remainder was due to providing care to higher
acuity customers and to rate increases. Specialty medical service revenue
increased $50,491,000 or 67.1%. Of this increase, approximately $32,000,000
related to the Meridian Transaction, $13,200,000 related to increased sales to
independent customers and a full year of operations for a medical supply company
acquired in Fiscal 1993, and $5,300,000 related to intensity and rate increases.
Management services and other income increased $11,422,000 or 101.9%. This
increase is primarily attributable to management services contracts acquired in
connection with the Meridian Transaction which accounted for approximately
$4,100,000, approximately $2,700,000 of revenue associated with a qualified
group purchasing business and other unrelated operations acquired in the
Meridian Transaction, and the remainder is attributable to rate increases and a
full year of revenue related to management contracts entered into in Fiscal
1993. The number of eldercare centers under management contracts increased from
24 at September 30, 1993 to 31 at September 30, 1994.
The Company's operating expenses before depreciation, amortization,
lease expense and interest expense were $319,243,000 for Fiscal 1994 compared to
$181,680,000 for Fiscal 1993, an increase of $137,563,000 or 75.7%. Salaries,
wages and benefits increased $80,241,000 or 71.5% of which approximately
$66,400,000 was due to the Meridian Transaction and the remainder is related to
other additional full-time equivalent personnel and increases in wages,
incentive compensation accruals, workers' compensation and other payroll related
benefits.
-35-
<PAGE>
Other operating expenses increased $47,268,000 or 76.5% of which
approximately $42,000,000 was related to the Meridian Transaction and $5,200,000
was due to an increase in cost of goods sold related to increased sales of
specialty medical services.
Interest expense increased $10,263,000 due to additional indebtedness
of approximately $205,000,000 incurred in connection with the Meridian
Transaction. This increase was partially offset by the June 1994 equity offering
of 3,219,000 shares of Common Stock resulting in net proceeds of approximately
$51,700,000 which was used to repay debt incurred in the Meridian Transaction.
Depreciation and amortization expense increased $7,825,000 which
consists of approximately $4,700,000 related to the additional depreciation
expense associated with the assets acquired in the Meridian Transaction,
$1,800,000 of goodwill amortization and approximately $500,000 of amortization
from deferred financing fees.
Lease expense increased from $7,026,000 in Fiscal 1993 to $11,376,000
in Fiscal 1994 due primarily to the lease agreements entered into in connection
with the Meridian Transaction.
Liquidity and Capital Resources
Working capital increased to $227,599,000 at June 30, 1996 from
$134,114,000 at September 30, 1995 due primarily to cash raised in the 1996
Equity Offering which was not used to repay indebtedness. Accounts receivable
increased to $144,036,000 at June 30, 1996 from $101,124,000 at September 30,
1995. Approximately $14,300,000 of this increase relates to accounts receivables
purchased as a part of the NeighborCare Transaction, approximately $4,800,000 of
this increase relates to accounts receivables purchased as part of the McKerley
Transaction, approximately $3,000,000 relates to accounts receivables purchased
as part of the acquisition of the Therapy Companies in January 1996,
approximately $3,800,000 relates to the Partnership Interest Purchase, and the
remaining $17,012,000 relates primarily to the continuing shift in business mix
to specialty medical services including the specialty medical businesses
acquired during Fiscal 1995. Days of revenue in accounts receivable increased to
75 from 72 during this period.
In October 1996, the Company amended and restructured its Credit
Facility to provide for a $150,000,000 lease financing facility which bears
interest at a floating rate equal, at the Company's option, to prime rate or
LIBOR plus 1.09% and a $300,000,000 revolving credit facility which bears
interest at a floating rate equal, at the Company's option, to prime rate or
LIBOR plus 1.25%. Amounts outstanding under the revolving credit facility in
September 1998 convert to a four year term loan that provides for equal annual
amortization payments payable quarterly. At June 30, 1996, $86,800,000 was
outstanding under the revolving credit facility and there were no amounts
outstanding under the acquisition credit facility. The Company used the
borrowings under the Credit Facility to fund the McKerley Transaction, the
Partnership Interest Purchase, the acquisition of the Therapy Companies and a
portion of the GMC Transaction. The revolving Credit Facility is secured by the
stock and partnership interests of the Company's subsidiaries.
In May 1996, the Company completed its 1996 Equity Offering of
6,500,000 shares of Common Stock at $32.50 per share, resulting in net proceeds
of $202,280,000. The Company used the net proceeds from the offering to repay a
portion of amounts outstanding under its Credit Facility and for working capital
purposes.
In March 1996, the Company sold four eldercare centers and a pharmacy
in Indiana for approximately $22,250,000. The Company used the net proceeds from
the sale to repay a portion of its Credit Facility.
-36-
<PAGE>
In November 1995, the Company received in cash approximately
$18,000,000 in connection with the September 1995 sale of five facilities in
Massachusetts. The Company used the proceeds from the sale to repay a portion of
its Credit Facility.
The Company's cash flow from operations for the nine months ended June
30, 1996 was $14,228,000 compared to $7,191,000 for the nine months ended June
30, 1995.
In June 1995, the Company completed an offering of $120,000,000 of 9
3/4% Notes. The Company used $100,000,000 of the net proceeds of the 9 3/4 %
Notes offering to repay in full the term loan component of its Credit Facility
and the remaining proceeds to repay a part of the revolving portion of the
Credit Facility.
In June 1994, the Company completed an offering of 3,264,457 shares of
Common Stock at $17.00 per share, of which 3,219,457 were offered by the
Company. The net proceeds to the Company of approximately $51,700,000 were used
to repay a portion of the indebtedness incurred in the Meridian Transaction.
Certain of the Company's outstanding loans contain covenants which,
without the prior consent of the lenders, limit certain activities of the
Company. Such covenants contain limitations relating to the merger or
consolidation of the Company and the Company's ability to secure indebtedness,
make guarantees, grant security interests and declare dividends. In addition,
the Company must maintain certain minimum levels of tangible net worth, interest
coverage and debt service coverage, and must maintain certain liabilities to net
worth and working capital ratios. Under these loans, the Company is restricted
from paying cash dividends on the Common Stock, unless certain conditions are
met. The Company has not declared or paid any cash dividends on its Common Stock
since its inception.
Legislative and regulatory action has resulted in continuing change in
the Medicare and Medicaid reimbursement programs which has adversely impacted
the Company. The changes have limited, and are expected to continue to limit,
payment increases under these programs. Also, the timing of payments made under
the Medicare and Medicaid programs is subject to regulatory action and
governmental budgetary constraints; in recent years, the time period between
submission of claims and payment has increased. Implementation of the Company's
strategy to expand specialty medical services to independent providers should
reduce the impact of changes in the Medicare and Medicaid reimbursement programs
on the Company as a whole. Within the statutory framework of the Medicare and
Medicaid programs, there are substantial areas subject to administrative rulings
and interpretations which may further affect payments made under those programs.
Further, the federal and state governments may reduce the funds available under
those programs in the future or require more stringent utilization and quality
reviews of eldercare centers. See "Risk Factors -- Regulation."
The Company believes that its liquidity needs can be met by expected
operating cash flow and availability of borrowings under its Credit Facility. At
October 24, 1996, $196,250,000 was outstanding under the revolving credit
facility and approximately $69,700,000 was outstanding under the lease financing
facility, and approximately $86,950,000 was available under the revolving credit
facility as a result of $16,800,000 outstanding letters of credit issued under
the Credit Facility.
Seasonality
-37-
<PAGE>
The Company's earnings generally fluctuate from quarter to quarter.
This seasonality is related to a combination of factors which include the timing
of Medicaid rate increases, seasonal census cycles and the number of calendar
days in a given quarter.
Impact of Inflation
The healthcare industry is labor intensive. Wages and other labor costs
are especially sensitive to inflation and marketplace labor shortages. To date,
the Company has offset its increased operating costs by increasing charges for
its services and expanding its services. Genesis has also implemented cost
control measures to limit increases in operating costs and expenses but cannot
predict its ability to control such operating cost increases in the future.
-38-
<PAGE>
BUSINESS
General
Genesis is a leading provider of healthcare and support services to the
elderly. The Company has developed the Genesis ElderCare(sm) delivery model of
integrated healthcare networks to provide cost-effective, outcome-oriented
services to the elderly. Through these integrated healthcare networks, Genesis
provides basic healthcare and specialty medical services to more than 75,000
customers in five regional markets in the Eastern United States in which over
3,000,000 people over the age of 65 reside. The networks include 153 eldercare
centers with approximately 20,120 beds; 18 primary care physician clinics;
approximately 70 physicians, physician assistants and nurse practitioners; 12
institutional pharmacies and six medical supply distribution centers serving
over 52,000 beds; certified rehabilitation agencies providing services through
over 290 contracts; and seven home healthcare agencies. Genesis has concentrated
its eldercare networks in five geographic regions in order to achieve operating
efficiencies, economies of scale and significant market share. The five
geographic markets that Genesis principally serves are:
Massachusetts/Connecticut/New Hampshire; Eastern Pennsylvania/Delaware Valley;
Southern Delaware/Eastern Shore of Maryland; Baltimore, Maryland/Washington,
D.C.; and Central Florida.
Genesis eldercare services focus on the central medical and physical
issues facing the more medically demanding elderly. By integrating the talents
of physicians with case management, comprehensive discharge planning and, where
necessary, home support services, the Company provides cost-effective care
management to achieve superior outcomes and return customers to the community.
The Company believes that its orientation toward achieving improved customer
outcomes through its eldercare networks has resulted in increased utilization of
specialty medical services, high occupancy of available beds, enhanced quality
payor mix and a broader base of repeat customers. Specialty medical services
revenues have increased at a compound annual rate of 37% from the fiscal year
ended September 30, 1990 to the fiscal year ended September 30, 1995 and
comprise 42% of the Company's revenues for the nine month period ended June 30,
1996. Specialty medical services typically generate higher profit margins than
basic healthcare services and are less capital intensive.
The Company's growth strategy is to enhance its existing eldercare
networks, establish new eldercare networks in markets it deems attractive and
broaden its array of high margin specialty medical services through internal
development and selected acquisitions. Consistent with its strategy, the Company
has made selected acquisitions of eldercare centers and rehabilitation,
pharmacy, physician services and home healthcare companies.
The Company's long-term strategy is to provide comprehensive eldercare
services, in collaboration with other providers, on a prepaid basis in a managed
care environment. The Company has undertaken several initiatives to position
itself to compete in a managed care environment. These initiatives include: (i)
establishing a managed care division to pursue and administer contracts with
managed care organizations, develop clinical care protocols and monitor the
delivery and utilization of medical care; (ii) developing a clinical
administration and healthcare management information system to monitor and
measure clinical and patient-outcome data; (iii) establishing the Genesis
ElderCare(SM) brand name to increase awareness of the Company's eldercare
services in the healthcare market; (iv) seeking strategic alliances with other
healthcare providers to broaden the Company's continuum of care; and (v)
creating an independent eldercare advisory board to formulate new and innovative
approaches in the delivery of care.
-39-
<PAGE>
The Company was incorporated in May 1985 as a Pennsylvania corporation.
The Company's principal executive offices are located at 148 West State Street,
Kennett Square, Pennsylvania 19348 and its telephone number at that location is
(610) 444-6350.
Basic Healthcare Services
Genesis operates 153 eldercare centers (76 wholly-owned, three
jointly-owned, 34 leased and 40 managed) located in 13 states. The centers offer
three levels of care for their customers: skilled, intermediate and personal.
Skilled care provides 24-hour per day professional services of a registered
nurse; intermediate care provides less intensive nursing care; and personal care
provides for the needs of customers requiring minimal supervision and
assistance. Each eldercare center is supervised by a licensed healthcare
administrator and employs a Medical Director to supervise the delivery of
healthcare services to residents and a Director of Nursing to supervise the
nursing staff. The Company maintains a corporate quality assurance program to
ensure regulatory compliance and to enhance the standard of care provided in
each center.
In addition to programs to meet the healthcare needs of its customers,
all Genesis eldercare centers offer a variety of quality of life programs. These
include the Intergenerational Learning Program that enables residents to
function both as students and as instructors in programs with community schools,
as well as The Magic Mix Program that provides a supervised setting in which
children of working parents can interact with residents of the centers after
school. These programs have received recognition at both local and national
levels.
In eight of its eldercare centers, the Company operates Genesis
ElderCare Focus programs which are dedicated to meeting the special medical,
emotional and psychological needs of Alzheimer's patients. The Focus programs
were developed in conjunction with the Dementia Research Clinic at the Johns
Hopkins University School of Medicine. These units provide an environment that
is designed or modified to assist those with cognitive loss. Clinical experts
have experienced significant success and produced benefits to customers served
in both Alzheimer's day services and dedicated residential units.
The following table sets forth, for the periods indicated, information
regarding the Company's average number of beds and average occupancy levels at
its eldercare centers.
<TABLE>
<CAPTION>
Nine Months
Year Ended September 30, Ended June 30,
------------------------------------- ----------------------
1993 1994 1995 1995 1996
----------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C>
Average Beds in Service
Wholly-owned and Leased Centers.................... 4,534 7,530 8,268 8,268 9,062
Jointly-owned and Managed Centers.................. 1,208 4,532 5,158 5,158 5,195
Occupancy Based on Average Beds in Service
Wholly-owned and Leased Centers.................... 95% 92% 92% 92% 92%
Jointly-owned and Managed Centers.................. 94% 93% 95% 95% 95%
</TABLE>
-40-
<PAGE>
Specialty Medical Services
The Company emphasizes the delivery of specialty medical services which
typically requires smaller capital investment and generates higher profit
margins than providing basic healthcare services. The Company provides the
specialty medical services described below.
Institutional Pharmacy and Medical Supply Services. The Company
provides pharmacy and other services including infusion therapy and medical
supplies and equipment to eldercare centers it operates, as well as to
independent healthcare providers by contract. The pharmacy services provided in
these settings are tailored to meet the needs of the institutional customer.
These services include highly specialized packaging and dispensing systems,
computerized medical records processing and 24-hour emergency services. The
Company's institutional pharmacy and medical supply services were developed to
provide the products and support services required in the healthcare market.
Institutional pharmacy services are designed to help assure quality of care and
to control costs at the facilities served. Medical supply services are designed
to assure availability and control through maintenance of a comprehensive
inventory, extensive delivery services and special ordering and tracking
systems. The Company also provides pharmacy consulting services to assure proper
and effective drug therapy. The Company provides these services through 12
pharmacies (of which three are jointly-owned) and six distribution centers
located in its various market areas. Approximately 76% of the sales attributable
to pharmacy operations in Fiscal 1995 were generated through external contracts
with independent healthcare providers with the balance attributable to centers
operated by the Company.
Rehabilitation Therapy. The Company provides an extensive range of
rehabilitation therapy services, including speech pathology, physical therapy
and occupational therapy through seven certified rehabilitation agencies in all
five of its market concentrations. These services are provided by over 1,000
licensed rehabilitation therapists and assistants employed by Genesis to
substantially all of the eldercare centers the Company operates, as well as by
contract to healthcare facilities operated by others.
Subacute Care Programs. The Company has established and actively
markets programs for elderly and other customers who require subacute levels of
medical care. These programs include ventilator care, intravenous therapy,
post-surgical recovery, respiratory management, orthopedic or neurological
rehabilitation, terminal care and various forms of coma, pain and wound
management. Private insurance companies and other third party payors, including
certain state Medicaid programs, have recognized that treating customers
requiring subacute medical care in centers such as those operated by Genesis is
a cost-effective alternative to treatment in an acute care hospital. The Company
provides such care at rates that the Company believes are substantially below
the rates typically charged by acute care hospitals for comparable services.
Physician Services. The Company employs or has consulting arrangements
with approximately 70 physicians, physician assistants and nurse practitioners
to provide physician services at certain of its eldercare centers. These
physicians, physician assistants and nurse practitioners provide a range of
services, including direct patient care, the design and administration of
clinical programs, such as the Company's subacute care program, as well as
traditional medical director and utilization review services. The Company
compensates these employees and consultants for services rendered and, where
appropriate, bills directly for such services. The Company believes that the
involvement of these
-41-
<PAGE>
physicians in the Company's eldercare centers provides a significant competitive
advantage. These physicians direct the operations of 18 free-standing physician
clinics, as well as Functional Evaluation and Treatment Units in 16 of its
eldercare centers. The purpose of each of these units is to provide a
comprehensive assessment and treatment plan for all new admissions to the
center. The process is directed by a physician specializing in gerontology and
involves an intensive evaluation in which social service professionals, clinical
staff and the customer and the customer's family participate. The Company
believes that this program reduces average lengths of stay and increases
discharge-to-home rates. The Company also believes the Functional Evaluation and
Treatment Units enhance its reputation for providing quality care and result in
improved occupancy rates, as well as improve its ability to attract subacute and
other high acuity customers.
Home Healthcare Services. The Company provides home healthcare services
to customers in its markets through seven certified home health agencies owned
by the Company. The Company currently provides these services in all of its
geographic markets other than Central Florida and has been granted Certificates
of Need to begin providing services in Central Florida. The services offered
include skilled nursing care, physical, occupational and speech therapy, medical
social services and home health aide services. The Company's focus is on
providing infusion therapy, total parenteral nutrition, ventilator care and
peritoneal dialysis. In June 1994, the Company entered into a joint venture with
six other healthcare providers to purchase the Visiting Nurses Association in
Baltimore ("VNA"), an organization which is one of the largest providers of home
healthcare services in Maryland. Excluding VNA, the Company provided
approximately 47,100 home healthcare visits in the nine months ended June 30,
1996.
Management Services and Other
Management Services. The Company provides management services to 43
eldercare centers (including three jointly-owned centers) pursuant to management
agreements that provide generally for the Company's day-to-day responsibility
for the operation and management of the centers. In turn, Genesis receives
management fees, depending on the agreement, computed as either an overall fixed
fee, a fixed fee per customer, a percentage of net revenues of the center plus
an incentive fee, or a percentage of gross revenues of the center with some
incentive clauses. The various management agreements, including option periods,
terminate between 1996 and 2012.
In March 1996, the Company entered into a strategic alliance with
Doctors Community Hospital, a 250-bed acute hospital in Maryland. As part of
this transaction, the Company entered into a long-term agreement to manage the
hospital's subacute care center.
Prior to January 1, 1996, the Company also provided management,
development and marketing services to 15 life care communities operated by Adult
Community Total Services, Inc. ("ACTS"), a Pennsylvania non-profit corporation
pursuant to a management agreement which was to expire in April 1998. Effective
January 1, 1996, Genesis restructured its relationship with ACTS. Under the
revised arrangement, Genesis was paid a $2,000,000 restructuring fee and will no
longer manage the ACTS life care communities. Genesis will continue to provide
development services for a fee in an amount equal to five percent of the total
cost of developing and completing facilities developed by ACTS. The development
portion of the contract has been extended to December 2002 and Genesis is
guaranteed a minimum annual development fee of $1,500,000 per year. Genesis also
continues to provide certain ancillary services to the ACTS communities.
-42-
<PAGE>
Group Purchasing. The Company's subsidiary, The Tidewater Healthcare
Shared Services Group, Inc. ("Tidewater"), is one of the largest group
purchasing companies in the mid-Atlantic region. Tidewater provides purchasing
and shared service programs specially designed to meet the needs of eldercare
centers and other long-term care facilities. Tidewater's services are contracted
to approximately 1,200 members with over 141,000 beds in 25 states and the
District of Columbia.
Managed Care Initiatives
The Company has undertaken several initiatives to position itself to
compete effectively on a prepaid basis in a managed care environment. In January
1995, the Company established a Managed Care division which currently consists
of 55 employees. The Managed Care division is responsible for pursuing and
administering contracts with managed care organizations, developing clinical
care protocol and monitoring the delivery and utilization of medical care. The
Company has begun to develop a clinical administration and healthcare management
information system to monitor and measure clinical and patient outcome data for
use by healthcare providers and the Company. The Company is also seeking
strategic alliances with selected providers in order to further the continuum of
care, increase market share and customer acceptance and create strategic
affiliations for negotiating with payors in a managed care environment. In
addition to these initiatives, the Company has consolidated its core business
under the Genesis ElderCare(SM) brand name in an effort to increase the
Company's visibility among current and potential customers, payors and other
healthcare providers. The Company has also created an independent eldercare
advisory board composed of individuals with distinguished credentials in
geriatric care to formulate new and innovative approaches in the delivery of
care.
Centers
The following table provides information by state regarding the
eldercare centers owned, leased and managed by the Company as of October 15,
1996.
<TABLE>
<CAPTION>
Wholly-Owned Jointly-Owned Managed
Centers Centers Leased Centers Centers Total
----------------- --------------- ----------------- --------------- ------------------
Centers Beds Centers Beds Centers Beds Centers Beds Centers Beds
--------- ------- -------- ------ --------- ------- -------- ----- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Massachusetts................ 8 1,092 -- -- -- -- 5 606 13 1,698
New Hampshire................ 7 651 -- -- 6 608 -- -- 13 1,259
Connecticut.................. 4 615 -- -- 1 120 -- -- 5 735
Vermont...................... 2 256 -- -- -- -- -- -- 2 256
Pennsylvania ................ 19 2,681 1 73 -- -- 8 1,082 28 3,836
New Jersey................... 14 1,606 -- -- 2 404 3 396 19 2,406
Delaware..................... 4 504 -- -- -- -- 1 99 5 603
Maryland..................... 12 1,958 2 206 9 1,326 4 706 27 4,196
Virginia..................... 2 421 -- -- 4 670 -- -- 6 1,091
Florida...................... 4 598 -- -- 10 1,231 13 1,404 27 3,223
West Virginia................ -- -- -- -- 2 180 -- -- 2 180
North Carolina............... -- -- -- -- -- -- 2 340 2 340
Colorado..................... -- -- -- -- -- -- 4 283 4 283
--------- ------- -------- ------ --------- ------- -------- ----- --------- --------
Total............... 76 10,382 3 279 34 4,539 40 4,916 153 20,116
========= ======= ======== ====== ========= ======= ======== ===== ========= ========
</TABLE>
-43-
<PAGE>
Revenue Sources
The Company derives its basic healthcare and specialty medical revenue
from private pay sources, state Medicaid programs and Medicare. The Company
classifies payments from persons or entities other than the government as
private pay and other revenue. The private pay and other classification also
includes revenues from commercial insurers, health maintenance organizations and
other charge-based payment sources. Blue Cross and Veterans Administration
payments are included in private pay and other revenues and are made pursuant to
renewable contracts negotiated with these payors.
Medicare is a federally funded and administered health insurance
program that consists of Parts A and B. Participation in Part B is voluntary and
is funded in part through the payment of premiums. Benefits under Part A include
inpatient hospital services, skilled nursing in an eldercare center and medical
services such as physical, speech and occupational therapy, certain
pharmaceuticals and medical supplies. Part B provides coverage for physician
services. Part B also reimburses for medical services with the exception of
pharmaceutical services. Medicare benefits are not available for intermediate
and custodial levels of care; however, medical and physician services furnished
to such patients may be reimbursable under Part B. Under the Part A
reimbursement methodology, each eldercare center receives an interim payment
during the year which is adjusted to reflect actual allowable direct and
indirect costs of services based on the submission of a cost report at the end
of each year. For services not billed through each eldercare center, the
Company's specialty medical operations bill Medicare directly for nutritional
support services, infusion therapy, certain medical supplies and equipment,
physician services and certain therapy services as provided. Medicare payments
for these services may be based on reasonable cost charges or a fixed-fee
schedule determined by Medicare.
Medicaid is the state administered reimbursement program that covers
both skilled and intermediate long-term care. Although Medicaid programs vary
from state to state, typically they provide for payment for services including
nursing facility services, physician's services, therapy services and
prescription drugs, up to established ceilings, at rates based upon cost
reimbursement principles. Reimbursement rates are typically determined by the
state from cost reports filed annually by each center, on a prospective or
retrospective basis. In a prospective system, a rate is calculated from
historical data and updated using an inflation index. The resulting prospective
rate is final, but in some cases may be adjusted pursuant to an audit. In this
type of payment system, center cost increases during the rate year do not affect
payment levels in that year. In a retrospective system, final rates are based on
reimbursable costs for that year. An interim rate is calculated from previously
filed cost reports, and may include an inflation factor to account for the time
lag between the final cost report settlement and the rate period. Consequently,
center cost increases during any year may affect revenues in that year. Certain
states are scheduled to convert, or have recently converted, from a
retrospective system, which generally recognizes only two or three levels of
care, to a case mix prospective pricing system, pursuant to which payment to a
center for patient services directly considers the individual patient's
condition and need for services. The effect, if any, of such a payment system on
the Company is unclear. The Company employs specialists in reimbursement at the
corporate level to monitor both Medicaid and Medicare regulatory developments to
comply with all reporting requirements and to insure appropriate payments.
-44-
<PAGE>
The following table reflects the allocation of customer service
revenues among these sources of revenue.
<TABLE>
<CAPTION>
Nine Months
Year Ended September 30, Ended June 30,
--------------------------------------------------- ----------------------
1991 1992 1993 1994 1995 1995 1996
-------- --------- --------- --------- --------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C> <C>
Private pay and other.................. 43% 41% 42% 41% 38% 38% 39%
Medicaid............................... 48 47 44 43 41 41 38
Medicare............................... 9 12 14 16 21 21 23
------ ------ ------ ------- ------- ------- -------
Total......................... 100% 100% 100% 100% 100% 100% 100%
====== ====== ====== ======= ======= ======= =======
</TABLE>
Marketing
Marketing for eldercare centers is focused at the local level and is
conducted primarily by the center administrator and its admissions director who
call on referral sources such as doctors, hospitals, hospital discharge
planners, churches and various community organizations. Besides actively
soliciting admissions from these sources, the Company's marketing objective is
to maintain public awareness of the eldercare center and its capabilities. The
Company takes advantage of its regional concentrations in its marketing efforts,
where appropriate, through consolidated marketing programs which benefit more
than one center.
Genesis markets specialty medical services to its managed eldercare
centers, as well as to independent healthcare providers, in addition to
providing such services to its owned and leased eldercare centers. The Company
markets its rehabilitation therapy and institutional pharmacy and medical supply
services through a direct sales force which primarily calls on eldercare
centers, hospitals, clinics and home health agencies. The corporate business
development department, through regional managers, markets the Company's
subacute program directly to insurance companies, managed care organizations and
other third party payors. In addition, the marketing department supports the
eldercare centers in developing promotional materials and literature focusing on
the Company's philosophy of care, services provided and quality clinical
standards. See "Governmental Regulation" below for a discussion of the federal
and state laws which limit financial and other arrangements between healthcare
providers.
In February 1996, the Company announced a consolidation of its core
business under the name Genesis ElderCare(sm). The Genesis ElderCare logo and
trademark have been featured in a series of print advertisements in publications
serving the regional markets in which the Company operates. The Company's
marketing of Genesis ElderCare is aimed at increasing awareness among decision
makers in key professional and business audiences. The Company is using
advertising to promote its brand name in trade, professional and business
publications and to promote services directly to consumers.
Personnel
At October 15, 1996, Genesis employed over 26,500 people, including
approximately 17,900 full-time and 8,500 part-time employees. Approximately 24%
of these employees are physicians and nursing and professional staff.
-45-
<PAGE>
The Company currently has collective bargaining agreements which relate
to 41 facilities including eight managed eldercare centers. The agreements
expire beginning in December 1996 through August 2000 and cover approximately
2,900 employees. The Company believes that its relationship with its employees
is generally good.
Employee Training and Development
Genesis believes that nursing and professional staff retention and
development has been and continues to be a critical factor in the successful
operation of the Company. In response to this challenge, a compensation program
which provides for annual merit reviews as well as financial and quality of care
incentives has been implemented to promote center staff motivation and
productivity and to reduce turnover rates. Management believes that the
Company's wage rates for professional nursing staff are commensurate with market
rates. The Company also provides employee benefit programs which management
believes, as a package, exceed industry standards. The Company has not
experienced any significant difficulty in attracting or retaining qualified
personnel.
In addition, Genesis has established an internal training and
development program for both nurse assistants and nurses. Employee training is
emphasized by the Company through a variety of in-house programs as well as a
tuition reimbursement program. The Company has established, company-wide, the
Genesis Nursing Assistant Specialist Program. This program is offered on a joint
basis with community colleges. Classes are held on the employees' time, last for
approximately six months and provide advanced instruction in nursing care. The
Company pays the tuition. When all of the requirements for class participation
have been met through attendance, discussion and examinations, the nurse aide
graduates and is awarded the title of Nursing Assistant Specialist and receives
a salary adjustment. The Company has maintained a retention rate of 75% since
1988 of the nurses aide graduates. Over 1,300 nurse aides have graduated from
the Genesis Nursing Assistant Specialist Program and received an increase in
salary. As the nurse aide continues through the career ladder, the Company
continues to provide incentives. At the next level, Senior Nursing Assistant
Specialist, the employee receives another increase in salary and additional
tuition reimbursement of up to $2,250 toward becoming a Licensed Practical Nurse
("LPN") or Registered Nurse ("RN") and at the Senior Nursing Assistant
Specialist Coordinator level, tuition reimbursement increases to a maximum of
$3,000 per year towards a nursing degree.
The Company began a junior level management and leadership training
program in 1990 referred to as the Pilot Light Program. The target audience for
this training is RNs and LPNs occupying charge nurse positions within the
Company's nursing centers as well as junior level managers throughout the
Genesis networks. Over 475 participants have graduated from this program.
In addition, a flexible RN associate degree program has been
established to meet the needs of those employees who cannot attend nursing
school on a full-time basis. The program is conducted jointly with local
community colleges and Regents College in New York. The program combines
self-study, flexible class scheduling, mentoring and tutoring by Genesis
professional nursing staff. This format allows for a self-paced RN degree.
Currently, there are approximately 18 Genesis employees enrolled in this
program, which the Company believes is the first of its kind in the United
States.
Government Regulation
The federal government and all states in which the Company operates
regulate various aspects of the Company's business. The Company's eldercare
centers are subject to certain federal statutes and regulations and to statutory
and regulatory licensing requirements by state and local authorities. All
Genesis
-46-
<PAGE>
eldercare centers are currently so licensed. In addition, eldercare centers are
subject to various local building codes and other ordinances.
All of the Company's eldercare centers and healthcare services, to the
extent required, are licensed under applicable law. All eldercare centers and
healthcare services, or practitioners providing the services therein, are
certified or approved as providers under one or more of the Medicaid, Medicare
or Veterans Administration programs. Licensing, certification and other
applicable standards vary from jurisdiction to jurisdiction and are revised
periodically. State and local agencies survey all eldercare centers on a regular
basis to determine whether such centers are in compliance with governmental
operating and health standards and conditions for participation in government
sponsored third party payor programs. The Company believes that its centers are
in substantial compliance with the various Medicare and Medicaid regulatory
requirements applicable to them. However, in the ordinary course of its
business, the Company receives notices of deficiencies for failure to comply
with various regulatory requirements. Genesis reviews such notices and takes
appropriate corrective action. In most cases, Genesis and the reviewing agency
will agree upon the measures to be taken to bring the center into compliance
with regulatory requirements. In some cases or upon repeat violations, the
reviewing agency may take various adverse actions against a center, including
the imposition of fines, temporary suspension of admission of new patients to
the center, suspension or decertification from participation in the Medicare or
Medicaid programs and, in extreme circumstances, revocation of a center's
license. These actions may adversely affect the eldercare centers' ability to
continue to operate, the ability of the Company to provide certain services, and
eligibility to participate in the Medicare, Medicaid or Veterans Administration
programs or to receive payments from other payors. Additionally, actions taken
against one center may subject other centers under common control or ownership
to adverse measures, including loss of licensure or eligibility to participate
in Medicare and Medicaid programs. Certain of the Company's centers have
received notices in the past from state agencies that, as a result of certain
alleged deficiencies, the agency was taking steps to decertify the centers from
participation in Medicare and Medicaid programs. In all cases, such deficiencies
were remedied before any centers were decertified.
All but four of the Genesis eldercare centers provide skilled nursing
services and are currently certified to receive benefits provided under Medicare
for these services. Additionally, all Genesis eldercare centers are currently
certified to receive benefits under Medicaid. Both initial and continuing
qualifications of an eldercare center to participate in such programs depend
upon many factors including accommodations, equipment, services, patient care,
safety, personnel, physical environment, and adequate policies, procedures and
controls.
Under the various Medicaid programs, the federal government supplements
funds provided by the participating states for medical assistance to "medically
indigent" persons. The programs are administered by the applicable state welfare
or social service agencies. Although Medicaid programs vary from state to state,
traditionally they have provided for the payment of certain expenses, up to
established limits, at rates based generally on cost reimbursement principles.
All states in which Genesis operates have adopted Certificate of Need
or similar laws which generally require that a state agency approve certain
acquisitions and determine that the need for certain bed additions, new
services, and capital expenditures or other changes exists prior to the
acquisition or addition of beds or services, the implementation of other
changes, or the expenditure of capital. State approvals are generally issued for
a specified maximum expenditure and require implementation of the proposal
within a specified period of time. Failure to obtain the necessary state
approval can result in the inability to provide the service, to operate the
centers, to complete the acquisition, addition or other change, and can also
result in the imposition of sanctions or adverse action on the center's license
and adverse reimbursement action.
-47-
<PAGE>
The Company is also subject to federal and state laws which govern
financial and other arrangements between healthcare providers. These laws often
prohibit certain direct and indirect payments or fee-splitting arrangements
between healthcare providers that are designed to induce or encourage the
referral of patients to, or the recommendation of, a particular provider for
medical products and services. These laws include the "anti-kickback" provisions
of the federal Medicare and Medicaid programs, which prohibit, among other
things, knowingly and willfully soliciting, receiving, offering or paying any
remuneration (including any kickback, bribe or rebate) directly or indirectly in
return for or to induce the referral of an individual to a person for the
furnishing or arranging for the furnishing of any item or service for which
payment may be made in whole or in part under Medicare or Medicaid. These laws
also include the "Stark legislations" which prohibit, with limited exceptions,
the referral of patients by physicians for certain services, including home
health services, physical therapy and occupational therapy, to an entity in
which the physician has an ownership interest. In addition, some states restrict
certain business relationships between physicians and other providers of
healthcare services. Many states prohibit business corporations from providing,
or holding themselves out as a provider of medical care. Possible sanctions for
violation of any of these restrictions or prohibitions include loss of licensure
or eligibility to participate in reimbursement programs and civil and criminal
penalties. These laws vary from state to state, are often vague and have seldom
been interpreted by the courts or regulatory agencies. From time to time, the
Company has sought guidance as to the interpretation of these laws; however,
there can be no assurance that such laws will ultimately be interpreted in a
manner consistent with the practices of the Company. Although the Company has
contractual arrangements with some healthcare providers to which the Company
pays fees for services rendered or products provided, the Company believes that
its practices are not in violation of these laws. The Company cannot accurately
predict whether enforcement activities will increase or the effect of any such
increase on its business. There have also been a number of recent federal and
state legislative and regulatory initiatives concerning reimbursement under the
Medicare and Medicaid programs. In particular, the federal government has issued
recent fraud alerts concerning double billing, home health services and the
provisions of medical supplies. Accordingly, it is anticipated that these areas
may come under closer scrutiny by the government. The Company cannot accurately
predict the impact of any such initiatives.
Competition
The Company competes with a variety of other companies in providing
healthcare services. Certain competing companies have greater financial and
other resources and may be more established in their respective communities than
the Company. Competing companies may offer newer or different centers or
services than the Company and may thereby attract the Company's customers who
are either presently residents of its eldercare centers or are otherwise
receiving its healthcare services.
The Company operates eldercare centers in 13 states. In each market,
the Company's eldercare centers may compete for customers with rehabilitation
hospitals, subacute units of hospitals, skilled or intermediate nursing centers
and personal care or residential centers which offer comparable services to
those offered by the Company's centers. Certain of these providers are operated
by not-for-profit organizations and similar businesses which can finance capital
expenditures on a tax-exempt basis or receive charitable contributions
unavailable to the Company. In competing for customers, a center's local
reputation is of paramount importance. Referrals typically come from acute care
hospitals, physicians, religious groups, other community organizations, health
maintenance organizations and the customer's families and friends. Members of a
customer's family generally actively participate in selecting an eldercare
center. Competition for subacute patients is intense among hospitals with
long-term care capability, rehabilitation hospitals and other specialty
providers and is expected to remain so in the future. Important competitive
factors include the reputation in the community, services offered, the
appearance of a center and the cost of services.
-48-
<PAGE>
Genesis competes in providing specialty medical services with a variety
of different companies. Generally, this competition is national, regional and
local in nature. The primary competitive factors in the specialty medical
services business are similar to those in the eldercare center business and
include reputation, the quality of clinical services, responsiveness to patient
needs, and the ability to provide support in other areas such as third party
reimbursement, information management and patient record-keeping.
Insurance
Genesis carries property and general liability insurance, professional
liability insurance, and medical malpractice insurance coverage in amounts
deemed adequate by management. However, there can be no assurance that any
current or future claims will not exceed applicable insurance coverage. Genesis
also requires that physicians practicing at its eldercare centers carry medical
malpractice insurance to cover their individual practices.
Legal Proceedings
On May 10, 1996, the Company's agent for service of process in Maryland
received notice that Orem Medical Home Health Care, Inc. and Orem Medical
Corporation (collectively, "Orem"), which are engaged in the business of
selling, renting and servicing durable medical equipment and supplies, filed
suit in the Circuit Court for Baltimore City on May 2, 1996 against Genesis and
its subsidiary Eastern Medical Supplies, Inc. ("Eastern"). The suit alleges that
Genesis and/or Eastern have interfered with certain contractual obligations and
business relations between Orem and third parties and that Genesis and/or
Eastern have induced such third parties to breach certain contractual
obligations to Orem. The allegations relate to terminated discussions of a
possible acquisition by Genesis of assets of Orem. Orem seeks compensatory and
punitive damages and injunctive relief for such alleged actions. Genesis filed
an answer to the complaint on June 24, 1996, generally denying the allegations
and including a counter-claim for amounts due to its subsidiaries. The Company
believes it has defenses to the claims, intends to vigorously defend such claims
and believes that any amount paid or accrued with respect to this matter will
not have a material adverse effect on the financial position or results of
operations of the Company. However, there can be no assurance as to the outcome
of the suit and that it will not have a material adverse effect on the financial
position or results of operations of the Company.
For a discussion of certain litigation in which GMC is involved see
Note 14 to GMC's financial statements incorporated by reference herein.
-49-
<PAGE>
MANAGEMENT
Executive Officers and Directors
The following table sets forth certain information with respect to the
executive officers and directors of the Company.
<TABLE>
<CAPTION>
Name Age Position
- ------------------------------------------ ------------ ------------------------------------------------------
<S> <C> <C>
Michael R. Walker (1)..................... 48 Chairman and Chief Executive Officer
Richard R. Howard (1)..................... 47 President, Chief Operating Officer and Director
David C. Barr............................. 46 Executive Vice President
John F. DePodesta......................... 52 Senior Vice President, Law and Public Policy
George V. Hager, Jr....................... 40 Senior Vice President and Chief Financial Officer
Edward B. Romanov, Jr..................... 45 Senior Vice President, Development
Louis Swart............................... 57 Senior Vice President, Managed Operations
Maryann Timon............................. 43 Senior Vice President for Managed Care
Marc D. Rubinger.......................... 47 Vice President and Chief Information Officer
Edward J. Boeggeman....................... 49 Vice President and Controller
Allen R. Freedman (2)..................... 56 Director
Samuel H. Howard (2)(3)................... 57 Director
Roger C. Lipitz (2)....................... 54 Director
Stephen E. Luongo (3)..................... 49 Director
Alan B. Miller (3)........................ 59 Director
Fred F. Nazem (1)......................... 55 Director
</TABLE>
- ----------------------
(1) Member of the Executive Committee of the Board of Directors.
(2) Member of the Audit Committee of the Board of Directors.
(3) Member of the Compensation Committee of the Board of Directors.
Michael R. Walker is the founder of the Company and has served as
Chairman and Chief Executive Officer of the Company since its inception. In
1981, Mr. Walker co-founded Health Group Care Centers ("HGCC"). At HGCC, he
served as Chief Financial Officer and, later, as President and Chief Operating
Officer. Prior to its sale in 1985, HGCC operated nursing homes with 4,500
nursing beds in 12 states. From 1978 to 1981, Mr. Walker was the Vice President
and Treasurer of AID Healthcare Centers, Inc. ("AID"). AID, which owned and
operated 20 nursing centers, was co-founded in 1977 by Mr. Walker as the nursing
home division of Hospital Affiliates International. Mr. Walker holds a Master of
Business Administration degree from Temple University and a Bachelor of Arts in
Business Administration from Franklin and Marshall College. Mr. Walker serves on
the Board of Directors of Renal Treatment Centers, Inc. and the Board of
Trustees of Universal Health Realty & Income Trust.
Richard R. Howard has served as a director of the Company since its
inception and as Chief Operating Officer since June 1986. He joined the Company
in September 1985 as Vice President of Development. Mr. Howard's background in
healthcare includes two years as the Chief Financial Officer of HGCC. Mr.
Howard's experience also includes over ten years with Fidelity Bank,
Philadelphia, Pennsylvania
-50-
<PAGE>
and one year with Equibank, Pittsburgh, Pennsylvania. Mr. Howard is a graduate
of the Wharton School, University of Pennsylvania, where he received a Bachelor
of Science degree in Economics in 1971.
David C. Barr has served as Executive Vice President of the Company
since October 1988. Prior to joining Genesis, Mr. Barr was a principal of a
private consulting firm, Kane Maiwurm Barr, Inc., which provided management
consulting for small and medium-sized firms. Prior to forming this firm, he
served as Executive Vice President of Allegheny Beverage Corporation, a service
conglomerate. During 1984 and 1985, Mr. Barr served with Equibank, Pittsburgh,
Pennsylvania, where he held several positions including Executive Vice President
of Corporate Banking. Mr. Barr graduated in 1972 from the University of Miami
with a Bachelor of Science degree in Accounting.
John F. DePodesta joined the Company as Senior Vice President, Law and
Public Policy in January 1996. Mr. DePodesta was previously a partner and
currently is of-counsel in the law firm of Pepper, Hamilton & Scheetz. Mr.
DePodesta received a Bachelor of Arts degree from Harvard College in 1966 and
his Juris Doctor from the University of Pennsylvania Law School in 1969. Pepper,
Hamilton & Scheetz performs outside legal services for the Company.
George V. Hager, Jr. has served the Company as Senior Vice President
and Chief Financial Officer since February 1994. Mr. Hager joined the Company in
July 1992 as Vice President and Chief Financial Officer. Mr. Hager was
previously partner in charge of the healthcare practice for KPMG Peat Marwick
LLP in the Philadelphia office. Mr. Hager began his career at KPMG Peat Marwick
LLP in 1979 and has over 15 years of experience in the healthcare industry. Mr.
Hager received a Bachelor of Arts degree in Economics from Dickinson College in
1978 and a Master of Business Administration degree from Rutgers Graduate School
of Management. He is a certified public accountant and a member of the AICPA and
PICPA.
Edward B. Romanov, Jr. has served as Senior Vice President, Development
since May 1992. From June 1990 through April 1, 1995, Mr. Romanov served as a
financial consultant to the Company pursuant to a Consulting and Services
Agreement between the Company and American Community Environments Corporation of
which he is an employee. Mr. Romanov was founder and President of WesTerra
Construction, WesTerra Capital Company and WesTerra Development, through which
Mr. Romanov developed and financed real estate projects. Mr. Romanov holds both
a Master of Business Administration and a Bachelor of Science degree from Lehigh
University.
Louis Swart joined the Company in 1990 and became Senior Vice
President, Managed Operations in 1994. Prior to joining the Company, Mr. Swart
established and was President of Wedgwood Retirement Inns. After selling
Wedgwood in 1988, he became President and Chief Executive Officer of Retirement
Corporation of America, until it was sold in 1990. Mr. Swart currently serves on
the Board of Directors of Sterling Health Care Corporation, a behavioral
medicine hospital group. Mr. Swart is a graduate of the University of South
Africa and completed his graduate work at Texas Christian University. He is
founder and past director of the California Association of Senior Living
Industries and is a member of the National Association of Senior Living
Industries and American Association of Homes for the Aged.
Maryann Timon has served as Senior Vice President for Managed Care
since May 1996. From January 1995 through May 1996 she served as Corporate Vice
President of the Managed Care Division. Ms. Timon joined the Company in December
1990 to form and serve as President of a wholly-owned subsidiary, Healthcare
Services Network. Ms. Timon was previously President of Mercy Ventures, Inc., a
five-company healthcare specialty group owned by Mercy Medical Center in
Baltimore, Maryland. Ms. Timon has 25 years of experience providing eldercare
healthcare services. Ms. Timon received an Associate Degree in Applied
-51-
<PAGE>
Science in Nursing in 1973 from the State University of New York at Canton, a
Bachelor of Science Degree in Nursing in 1976 from the State University of New
York at Utica/Rome and a Master of Gerontological Nursing Degree in 1978 from
the University of Rochester.
Marc D. Rubinger has served as Vice President and Chief Information
Officer since November 1995. Prior to joining the Company, Mr. Rubinger served
as General Manager-Decision Support Systems of Shared Medical Systems. From 1975
through 1986, Mr. Rubinger was a partner with Ernst & Young in their national
healthcare consulting practice. Mr. Rubinger received a Bachelor of Arts degree
in Bioscience from Binghamton University in 1971 and a Masters of Health
Administration and Planning from The George Washington University in 1973.
Kenneth R. Kuhnle has served as Vice President and Treasurer of the
Company since February 1990. He joined Genesis in October 1988 as Reimbursement
Director, which includes responsibility for monitoring government programs as
well as third party reimbursement planning and maximization. Mr. Kuhnle served
as Reimbursement Manager for Beverly enterprises, owners and operators of
long-term care centers, from January 1986 to October 1988 and as Medicare
Auditor for Aetna Life Insurance Company from November 1982 to December 1985. He
received a Bachelor of Science degree in Business Administration from Temple
University in 1979. Mr. Kuhnle serves as President of the Delaware Healthcare
Facilities Association and President of the Worcester chapter of the
Massachusetts Federation of Nursing Homes.
Edward J. Boeggeman has served as Vice President and Corporate
Controller of the Company since December 1993. He joined Genesis in January 1993
as Controller of Genesis Health Centers. Mr. Boeggeman has over twenty years of
experience in the healthcare industry, including four years with KPMG Peat
Marwick LLP from 1979 to 1983. Prior to joining Genesis, he served in various
accounting positions including Assistant Controller, Controller and Vice
President of Financial Affairs at a teaching hospital, academic medical center
and community hospital, all within the Greater Philadelphia area. Mr. Boeggeman
received a Bachelor of Arts degree in Accounting from Villanova University in
1973 and is a certified public accountant.
Allen R. Freedman has served as a director of the Company since
February 1996. Since 1990, Mr. Freedman has served on the executive board of
Fortis, a multinational financial services organization, which is the operating
entity of Fortis AG, based in Belgium, and Fortis AMEV, based in the
Netherlands. Since 1990, he has been Chairman and Chief Executive Officer of
Fortis, Inc. and Chairman of the Board of its principal insurance and investment
affiliates in the United States. These affiliates include American Security
Group; Fortis Benefits Insurance Company; Time Insurance Company; and United
Family Life Insurance Company. Mr. Freedman served as President of Fortis, Inc.
from 1979 to 1990. Mr. Freedman is also a director of Fortis Advisors, Inc. and
Systems and Computer Technology Corporation.
Samuel H. Howard has served as a director of the Company since March
1988. He is the founder and chairman of Phoenix Healthcare Corporation ("Phoenix
Healthcare") and the founder and President of Phoenix Communications Group, Inc.
("Phoenix Group") and Phoenix Holdings, Inc. all of which are based in
Nashville, Tennessee. Formed in 1993, Phoenix Healthcare provides management
services for managed care organizations, including health maintenance
organizations serving Tennessee's Medicaid population through the innovative
TennCare program which offers a managed care approach to meeting the healthcare
needs of Tennessee's Medicaid and uninsured populations. In April 1990, Phoenix
Group filed a petition under the Federal Bankruptcy laws. Phoenix Group proposed
a plan of reorganization that was approved by the bankruptcy court in August
1991 and became effective in December 1991. Mr. Howard's past corporate and
operations experience in the healthcare industry include having served as the
Senior Vice President of Public Affairs for Hospital Corporation of America from
August 1981 to January 1990, Vice President and
-52-
<PAGE>
Treasurer for Hospital Affiliates International ("HAI"), and Vice President of
Finance and Business for Meharry Medical College. In addition, Mr. Howard was a
financial analyst for General Electric and a White House Fellow with U.S.
Ambassador Arthur Goldberg. Mr. Howard is a member of the Board of Directors of
O'Charley's Inc.
Richard R. Howard and Samuel H. Howard are not related.
Roger Lipitz has served as a director of the Company since March 1994.
From January 1994 until January 1996, Mr. Lipitz served on a consulting basis as
Director of Government Relations of the Company. From 1969 until its acquisition
by the Company in 1993, Mr. Lipitz served as Chairman of the Board of Meridian
Healthcare, Inc., a Maryland based long-term care company which operated over
5,000 beds and related businesses. Mr. Lipitz is a past president of the
American Health Care Association, Health Facilities Association of Maryland and
the National Council of Health Care Services. Since 1994, he has been Chairman
of the Board of Allegis Health Management, Inc. (formerly known as Global Health
Management, Inc.), a privately held Maryland based long-term care company. Mr.
Lipitz is a member of the Board of Directors of Blue Cross and Blue Shield of
Maryland.
Stephen E. Luongo has served as a director of the Company since June
1985. He currently is a partner in the law firm of Blank Rome Comisky &
McCauley. Blank Rome Comisky & McCauley serves as outside legal counsel for the
Company.
Alan B. Miller has served as a director of the Company since October
1993. Since 1978, he has been Chairman of the Board, President and Chief
Executive Officer of Universal Health Services, Inc., a Pennsylvania based
health services company. Prior thereto, Mr. Miller was Chairman of the Board,
President and Chief Executive Officer of American Medicorp, Inc. Mr. Miller is
Chairman of the Board of Trustees of Universal Health Realty Income Trust and a
member of the Board of Directors of CDI Corp., GMIS, Inc., and Penn Mutual Life
Insurance Company.
Fred F. Nazem has served as a director of the Company since January
1989. Since 1981, he has been President of Nazem Inc. and Managing Partner of
the general partner of several Nazem & Company limited partnerships which are
affiliated venture capital funds. Mr. Nazem is a member of the Board of
Directors of Consep, Inc., Tegal Corporation and Oxford Health Plans, Inc. as
well as a number of privately held firms.
-53-
<PAGE>
DESCRIPTION OF THE NOTES
The Exchange Notes will be issued under an Indenture dated as of
October 7, 1996 (the "Indenture") between the Company and First Union National
Bank, as trustee (the "Trustee"). Upon the effectiveness of the Exchange Offer
Registration Statement, the Indenture will be subject to, and governed by, the
Trust Indenture Act of 1939, as amended (the "Trust Indenture Act"). Certain
capitalized terms used below are defined under "Certain Definitions." The
following summary of the material provisions of the Indenture and the Notes does
not purport to be complete and is subject to, and is qualified in its entirety
by reference to, all of the provisions of the Indenture, including the
definitions of certain terms provided therein that are used herein but not
otherwise defined, and to terms made a part of the Indenture by the Trust
Indenture Act. A copy of the Indenture will be made available to holders of the
Notes upon request and is filed as an exhibit to this Exchange Offer
Registration Statement. See "Available Information".
General
The Exchange Notes and any Existing Notes that remain outstanding after
consummation of the Exchange Offer will be treated as a single class of
securities under the Indenture.
The Exchange Notes offered hereby will mature on October 1, 2006, will
be limited to $125,000,000 aggregate principal amount and will be unsecured
obligations of the Company. The Exchange Notes will bear interest at 9 1/4 % per
annum. Each Note will bear interest from October 7, 1996 or from the most recent
interest payment date to which interest has been paid, payable semiannually on
April 1 and October 1 of each year, commencing April 1, 1997 to the Person in
whose name the Note (or any predecessor Note) is registered at the close of
business on the September 15 or March 15 next preceding such interest payment
date. Interest will be computed on the basis of a 360-day year comprised of
twelve 30-day months.
Principal of, premium, if any, and interest on the Notes will be
payable, and the Notes will be exchangeable and transferable, at the office or
agency of the Company in the City of New York maintained for such purposes;
provided, however, that payment of interest may be made at the option of the
Company by check mailed to the Person entitled thereto as shown on the security
register. The Notes will be issued only in fully registered form without
coupons, in denominations of $1,000 and any integral multiple thereof. No
service charge will be made for any registration of transfer, exchange or
redemption of Notes, except in certain circumstances for any documentary, stamp
or similar issue or transfer taxes or other tax or other governmental charge
that may be imposed in connection therewith.
As discussed under "Exchange Offer; Registration Rights," pursuant to
the Registration Rights Agreement, the Company has agreed for the benefit of the
holders of the Notes, at the Company's cost, either (i) to effect a registered
Exchange Offer under the Securities Act to exchange the Notes for Exchange
Notes, which will have terms identical in all material respects to the Notes
(except that the Exchange Notes will not contain terms with respect to transfer
restrictions or interest rate increases) or (ii) in the event that any changes
in law or applicable interpretations of the staff of the Commission do not
permit the Company to effect the Exchange Offer, or if for any other reason the
Exchange Offer is not consummated within 120 days following the date of the
original issue of the Notes, or if any holder of the Notes (other than the
Initial Purchasers) is not eligible to participate in the Exchange Offer, or
upon the request of any Initial Purchaser in certain circumstances, to register
the Notes for resale under the Securities Act through the Shelf Registration
Statement. In the event that either (a) the Exchange Offer Registration
Statement is not filed with the Commission on or prior to the 30th calendar day
following the date of original issue of the Notes, (b) the Exchange Offer
Registration Statement has not been declared effective on or prior to the 90th
calendar day following the date of original issue of the Notes or (c) the
Exchange Offer is not consummated
-54-
<PAGE>
or a Shelf Registration Statement is not declared effective on or prior to the
120th calendar day following the date of original issue of the Notes, the
interest rate borne by the Notes shall be increased by one-quarter of one
percent per annum following such 30-day period in the case of clause (a) above,
following such 90-day period in the case of clause (b) above or following such
120-day period in the case of clause (c) above, which rate will be increased by
an additional one-quarter of one percent per annum for each 90-day period that
any additional interest continues to accrue. The aggregate amount of such
increase from the original interest rate pursuant to these provisions will in no
event exceed one percent. Upon (x) the filing of the Exchange Offer Registration
Statement after the 30-day period described in clause (a) above, (y) the
effectiveness of the Exchange Offer Registration Statement after the 90-day
period described in clause (b) above or (z) the consummation of the Exchange
Offer or the effectiveness of a Shelf Registration Statement, as the case may
be, after the 120-day period described in clause (c) above, the interest rate
borne by the Notes from the date of such filing, the date of such effectiveness
or the day before the date of consummation, as the case may be, will be reduced
to the original interest rate if the Company is otherwise in compliance with
this paragraph. See "Exchange Offer; Registration Rights."
Existing Notes that remain outstanding after the consummation of the
Exchange Offer and Exchange Notes issued in connection with the Exchange Offer
will be treated as a single class of securities under the Indenture.
Optional Redemption
The Notes will be subject to redemption at any time on or after October
1, 2001 at the option of the Company, in whole or in part, on not less than 30
nor more than 60 days' prior notice in amounts of $1,000 or an integral multiple
of $1,000 at the following redemption prices (expressed as a percentage of the
principal amount), if redeemed during the 12-month period beginning on October 1
of each of the years indicated below:
Year Redemption Price
------------------------------------------- ----------------
2001....................................... 104.625%
2002....................................... 103.083%
2003....................................... 101.542%
and thereafter at 100% of the principal amount, in each case, together with
accrued and unpaid interest to the redemption date (subject to the right of
holders of record on relevant record dates to receive interest due on an
interest payment date).
If less than all of the Notes are to be redeemed, the Trustee shall
select the Notes or portions thereof to be redeemed pro rata, by lot or by any
other method the Trustee shall deem fair and reasonable.
Sinking Fund
The Notes are not subject to the benefit of any sinking fund.
Change in Control
Upon the occurrence of any of the following events, each holder of the
Notes shall have the right to require that the Company repurchase such holder's
Notes in whole or in part in integral multiples of $1,000, at a purchase price
in cash in an amount equal to 101% of the principal amount thereof, together
with
-55-
<PAGE>
accrued and unpaid interest, if any, to the date of purchase, pursuant to an
offer (the "Change in Control Offer") made in accordance with the procedures
described below and the other provisions in the Indenture.
A "Change in Control" shall occur at any time that (i) any "person" (as
such term is used in Sections 13(d) and 14(d) of the Exchange Act), in a single
transaction or through a series of related transactions, is or becomes the
"beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly
or indirectly, of more than 50% of the total Voting Stock of the Company; (ii)
the Company consolidates or merges with or into another corporation or conveys,
transfers or leases all or substantially all of its assets to any Person, or any
corporation consolidates or merges with or into the Company, in any such event
pursuant to a transaction in which the outstanding Voting Stock of the Company
is changed into or exchanged for cash, securities or other property, other than
any such transaction where (A) the outstanding Voting Stock of the Company is
changed into or exchanged for (x) Voting Stock of the surviving corporation
which is not Redeemable Capital Stock or (y) cash, securities or other property
in an amount which could be paid by the Company as a Restricted Payment as
described under "Certain Covenants--Limitation on Restricted Payments" (and such
amount shall be treated as a Restricted Payment subject to the provisions in the
Indenture described under "Certain Covenants--Limitation on Restricted
Payments"), and (B) the holders of the Voting Stock of the Company immediately
prior to such transaction own, directly or indirectly, not less than 50% of the
Voting Stock of the surviving corporation immediately after such transaction;
(iii) during any period of two consecutive years, individuals who at the
beginning of such period constituted the Board of Directors of the Company
(together with any new directors whose election by such Board of Directors or
whose nomination for election by the stockholders of the Company was approved by
a vote of at least 66 2/3% of the directors then still in office who were either
directors at the beginning of such period or whose election or nomination for
election was previously so approved) cease for any reason to constitute a
majority of the Board of Directors of the Company then in office; or (iv) the
Company is liquidated or dissolved or adopts a plan of liquidation.
Within 30 days following a Change in Control and prior to the mailing
of the notice to the holders of Notes provided for in the next paragraph, the
Company covenants to (i) notify the lenders under the Credit Facility that a
"Change in Control" under the Indenture has occurred and (ii) either (A) repay
in full all Indebtedness under the Credit Facility and permanently reduce the
commitments of the lenders thereunder or offer to repay in full all such
Indebtedness and permanently reduce such commitments and repay the Indebtedness
and permanently reduce the commitment of each lender who has accepted such offer
or (B) obtain the requisite consent under the Credit Facility to permit the
repurchase of the Notes as provided for in this covenant. The Company shall
first comply with the provisions of this paragraph before it shall be required
to repurchase the Notes in accordance with this covenant, but any failure to
comply with the covenant to offer to purchase the Notes upon a Change in Control
shall constitute an Event of Default under the Indenture.
Within 30 days following any Change in Control, the Company shall send
by first-class mail, postage prepaid, to the Trustee and to each holder of
Notes, at his address appearing in the security register, a notice stating,
among other things, that a Change in Control has occurred, the purchase price,
the purchase date, which shall be a business day no earlier than 30 days nor
later than 60 days from the date such notice is mailed, and certain other
procedures that a holder of the Notes must follow to accept a Change in Control
Offer or to withdraw such acceptance.
The Company will comply, to the extent applicable, with the
requirements of Rule 14e-1 under the Exchange Act and other securities laws or
regulations in connection with the repurchase of the Notes as described above.
-56-
<PAGE>
The use of the term "all or substantially all" in Indenture provisions
such as clause (ii) of the definition of "Change in Control" and under "Merger
and Sale of Assets, etc." has no clearly established meaning under New York law
(which governs the Indenture) and has been the subject of limited judicial
interpretation in a few jurisdictions. Accordingly, there may be a degree of
uncertainty in ascertaining whether a particular transaction would involve a
disposition of "all or substantially all" of the assets of a person, which
uncertainty should be considered by prospective purchasers of the Notes.
The occurrence of certain of the events which would constitute a Change
in Control would constitute a default under the Credit Facility (currently in
the principal amount of up to $265,950,000) and would require the Company to
offer to redeem the 9 1/4 % First Mortgage Bonds, Series A (the "First Mortgage
Bonds") (currently in the principal amount of $23,700,000), Convertible
Debentures (currently in the principal amount of $43,904,000) and 9 3/4 % Notes
(currently in the principal amount of $120,000,000). Future Indebtedness of the
Company may contain prohibitions of certain events which would constitute a
Change in Control or require the Company to offer to redeem such Indebtedness
upon a Change in Control. Moreover, the exercise by the holders of the Notes of
their right to require the Company to purchase the Notes could cause a default
under such Indebtedness, even if the Change in Control itself does not, due to
the financial effect of such purchase on the Company. Finally, the Company's
ability to pay cash to the holders of the Notes upon a purchase may be limited
by the Company's then existing financial resources. There can be no assurance
that sufficient funds will be available when necessary to make any required
purchases. Under its current financial condition, the Company believes that
sufficient funds would not be available to make such required purchases. Even if
sufficient funds were otherwise available, the terms of the Credit Facility will
prohibit, subject to certain exceptions, the Company's prepayment of the Notes
prior to their scheduled maturity. Consequently, if the Company is not able to
prepay indebtedness outstanding under the Credit Facility and any other Senior
Indebtedness containing similar restrictions or obtain requisite consents, the
Company will be unable to fulfill its repurchase obligations if holders of the
Notes exercise their purchase rights following a Change in Control, thereby
resulting in a default under the Indenture. Furthermore, the Change in Control
provisions may in certain circumstances make more difficult or discourage a
takeover of the Company and the removal of incumbent management.
Subordination
The payment of the principal of, premium, if any, and interest on, the
Notes will be subordinated, as described below, in right of payment to the prior
payment in full in cash or Cash Equivalents of all Senior Indebtedness. The
Notes will be senior subordinated indebtedness of the Company ranking pari passu
with all other existing and future senior subordinated indebtedness of the
Company and senior to all existing and future Subordinated Indebtedness of the
Company.
Upon the occurrence of any default in the payment of any Designated
Senior Indebtedness, no payment (other than any payments made pursuant to the
provisions described under "Satisfaction and Discharge of Indenture; Covenant
Defeasance" which have been deposited with the Trustee for at least 124 days) or
distribution of any assets of the Company or any Subsidiary of any kind or
character (excluding certain permitted equity or subordinated securities) shall
be made by the Company or any Subsidiary or on behalf of, or out of the property
of, the Company, or received by the Trustee or any Noteholder on account of the
principal of, premium, if any, or interest on, the Notes or on account of the
purchase, redemption, defeasance or other acquisition of or in respect of the
Notes unless and until such default has been cured, waived or has ceased to
exist or such Designated Senior Indebtedness shall have been paid in full in
cash or Cash Equivalents.
-57-
<PAGE>
Upon the occurrence of any non-payment default with respect to any
Designated Senior Indebtedness pursuant to which the maturity thereof may be
accelerated (a "Non-payment Default") and after the receipt by the Trustee and
the Company from a representative or the holder of any Designated Senior
Indebtedness of written notice of such Non-payment Default, no payment (other
than any payments made pursuant to the provisions described under "--
Satisfaction and Discharge of Indenture; Covenant Defeasance" which have been
deposited with the Trustee for at least 124 days) or distribution of any assets
of the Company or any Subsidiary of any kind or character (excluding certain
permitted equity or subordinated securities) may be made by the Company or any
Subsidiary or on behalf of, or out of the property of, the Company or received
by the Trustee or any Noteholder on account of any principal of, premium, if
any, or interest on, the Notes or on account of the purchase, redemption,
defeasance or other acquisition of or in respect of the Notes for the period
specified below (the "Payment Blockage Period").
The Payment Blockage Period shall commence upon the receipt of notice
of the Non-payment Default by the Trustee and the Company from a representative
or the holder of any Designated Senior Indebtedness and shall end on the
earliest of (subject to any blockage of payments that may then or thereafter be
in effect pursuant to the second preceding paragraph) (i) 179 days after receipt
of such notice by the Trustee (provided any Designated Senior Indebtedness as to
which notice was given shall not theretofore have been accelerated), (ii) the
date such Non-payment Default and all other Non-payment Defaults as to which
notice is also given after such period is initiated shall have been cured or
waived or shall have ceased to exist or the Senior Indebtedness related thereto
shall have been paid in full or (iii) the date such Payment Blockage Period and
any Payment Blockage Periods initiated during such period shall have been
terminated by written notice to the Company or the Trustee from the senior
representative and the holders of the Designated Senior Indebtedness that have
given notice of a Non-payment Default at or after the initiation of such Payment
Blockage Period, after which, in the case of clause (i), (ii) or (iii), the
Company shall resume making any and all required payments in respect of the
Notes, including any missed payments. In no event will a Payment Blockage Period
extend beyond 179 days from the date of the receipt by the Trustee of the notice
initiating the first such Payment Blockage Period (such 179-day period referred
to as the "Initial Period"). Any number of notices of events of default may be
given during the Initial Period; provided that during any 365-day consecutive
period only one such period during which payment of principal of, or interest
on, the Notes may not be made may commence and the duration of such period may
not exceed 179 days. No Non-payment Default with respect to Designated Senior
Indebtedness which existed or was continuing on the date of the commencement of
any Payment Blockage Period will be, or can be, made the basis for the
commencement of a second Payment Blockage Period whether or not within a period
of 365 consecutive days, unless such default has been cured or waived for a
period of not less than 90 consecutive days.
If the Company fails to make any payment on the Notes when due or
within any applicable grace period, whether or not on account of the payment
blockage provisions referred to above, such failure would constitute an Event of
Default under the Indenture and would enable the holders of the Notes to
accelerate the maturity thereof. See "Events of Default."
The Indenture will provide that in the event of any insolvency or
bankruptcy case or proceeding, or any receivership, liquidation, reorganization
or other similar case or proceeding in connection therewith, relative to the
Company or its assets, or any liquidation, dissolution or other winding up of
the Company, whether voluntary or involuntary, or any assignment for the benefit
of creditors or other marshaling of assets or liabilities of the Company, all
Senior Indebtedness must be paid in full in cash or Cash Equivalents before any
payment or distribution (excluding certain permitted equity or subordinated
securities) is made on account of the principal of, premium, if any, or interest
on the Notes.
-58-
<PAGE>
By reason of such subordination, in the event of liquidation or
insolvency, creditors of the Company who are holders of Senior Indebtedness may
recover more, ratably, than the holders of the Notes and funds which would be
otherwise payable to the holders of the Notes will be paid to the holders of the
Senior Indebtedness to the extent necessary to pay the Senior Indebtedness in
full in cash or Cash Equivalents, and the Company may be unable to meet its
obligations fully with respect to the Notes.
"Senior Indebtedness" means all obligations of the Company or any
Subsidiary or Affiliate of the Company, now or hereafter existing, under or in
respect of the Credit Facility, whether for principal, interest (including
interest accruing after the filing of a petition by or against the Company under
any state or federal Bankruptcy Laws, whether or not such interest is allowed as
a claim after such filing in any proceeding under such law) or otherwise
(including obligations in respect of the lease financing facility of the Credit
Facility) and the principal of, premium, if any, and interest on all other
Indebtedness of the Company (other than the Notes), whether outstanding on the
date of the Indenture or thereafter created, incurred or assumed, unless, in the
case of any particular Indebtedness, the instrument creating or evidencing the
same or pursuant to which the same is outstanding expressly provides that such
Indebtedness shall not be senior in right of payment to the Notes.
Notwithstanding the foregoing, "Senior Indebtedness" shall not include (i)
Indebtedness evidenced by the Notes, (ii) Indebtedness evidenced by the
Convertible Debentures, (iii) Indebtedness that is by its terms subordinate or
junior in right of payment to any Indebtedness of the Company, (iv) Indebtedness
which when incurred and without respect to any election under Section 1111(b) of
the Bankruptcy Law is without recourse to the Company, (v) Indebtedness which is
represented by Redeemable Capital Stock, (vi) Indebtedness for goods, materials
or services purchased in the ordinary course of business or Indebtedness
consisting of trade payables or other current liabilities (other than any
current liabilities owing under, or in respect of, the Credit Facility), (vii)
Indebtedness of or amounts owed by the Company for compensation to employees or
for services, (viii) any liability for federal, state, local or other taxes owed
or owing by the Company, (ix) Indebtedness of the Company to a Subsidiary of the
Company or any other Affiliate of the Company or any of such Affiliate's
subsidiaries, (x) that portion of any Indebtedness which at the time of issuance
is issued in violation of the Indenture, and (xi) amounts owing under leases
(other than Capital Lease Obligations and obligations in respect of the lease
financing facility of the Credit Facility). The Notes shall rank pari passu in
right of payment with the Indebtedness evidenced by the Convertible Debentures
and the 9 3/4% Notes.
"Designated Senior Indebtedness" is defined as (i) all Senior
Indebtedness under, or in respect of, the Credit Facility and (ii) any other
Senior Indebtedness which, at the time of determination, has an aggregate
principal amount outstanding, together with any commitments to lend additional
amounts, of at least $30,000,000 and is specifically designated in the
instrument evidencing such Senior Indebtedness as "Designated Senior
Indebtedness."
As of June 30, 1996, after giving effect to the National Health
Transaction and GMC Transaction and the Offering and the use of the proceeds
therefrom, the aggregate amount of Senior Indebtedness outstanding would have
been approximately $402,123,000 (which includes approximately $9,980,000 of
indebtedness and approximately $61,000,000 of lease obligations of subsidiaries
and approximately $6,000,000 of indebtedness of other persons, all of which are
guaranteed by the Company, and approximately $15,900,000 of letters of credit
issued under the Credit Facility primarily related to the Company's
self-insurance programs) and, as of such date, the aggregate amount of
liabilities of the subsidiaries of the Company, which consist primarily of trade
payables and accrued compensation, that will effectively rank senior to the
Notes was approximately $64,163,000. See "Risk Factors -- Ranking" and
"Capitalization."
-59-
<PAGE>
Certain Covenants
The Indenture contains, among others, the following covenants:
Limitation on Indebtedness. The Company will not, and will not permit
any of its Subsidiaries to, create, incur, assume, or directly or indirectly
guarantee or in any other manner become directly or indirectly liable for the
payment of, any Indebtedness (including any Acquired Indebtedness but excluding
Permitted Indebtedness) unless at the time of such event and after giving effect
thereto on a pro forma basis the Company's Fixed Charge Coverage Ratio for the
four full fiscal quarters immediately preceding such event, taken as one period,
calculated on the assumption that (i) such Indebtedness had been incurred on the
first day of such four-quarter period and (ii) any acquisition or disposition by
the Company and its Subsidiaries of any assets out of the ordinary course of
business, or any company or business facility, in each case since the first day
of its last four completed fiscal quarters, had been consummated on such first
day of such four-quarter period, would have been at least 2.00 to 1.00.
Limitation on Restricted Payments. The Company will not, and will not
permit any Subsidiary to, directly or indirectly:
(i) declare or pay any dividend on, or make any distribution to holders
of, any Capital Stock of the Company (other than dividends or distributions
payable solely in shares of Qualified Capital Stock of the Company or in
options, warrants or other rights to acquire Qualified Capital Stock of the
Company);
(ii) purchase, redeem, defease or otherwise acquire or retire for value
any Capital Stock of the Company or any Affiliate thereof (other than any Wholly
Owned Subsidiary of the Company) or any option, warrant or other right to
acquire such Capital Stock of the Company or any Affiliate thereof;
(iii) make any principal payment on, or redeem, repurchase, defease or
otherwise acquire or retire for value in each case, prior to any scheduled
repayment, or maturity, any Subordinated Indebtedness; or
(iv) make any Investment in any Person (other than any Permitted
Investment) unless the Person thereby becomes a Wholly Owned Subsidiary; (such
payments described in (i) through (iv) collectively, "Restricted Payments")
unless at the time of and after giving effect to the proposed Restricted Payment
(the amount of any such Restricted Payment, if other than cash, as determined by
the Board of Directors, whose determination shall be conclusive and evidenced by
a Board Resolution), (x) no Default or Event of Default shall have occurred and
be continuing and such Restricted Payment shall not be an event which is, or
after notice or lapse of time or both, would be, an "event of default" under the
terms of any Indebtedness of the Company or any Subsidiary; (y) immediately
before and immediately after giving effect to such transaction on a pro forma
basis, the Company could incur $1.00 of additional Indebtedness under the
provisions of "--Limitation on Indebtedness" (other than Permitted
Indebtedness); and (z) the aggregate amount of all Restricted Payments (plus,
without duplication, dividends and distributions paid to any Person other than
the Company, a Wholly Owned Subsidiary or a Permitted Joint Venture as permitted
by paragraph (b) under "-- Restrictions on Preferred Stock of Subsidiaries and
Subsidiary Distributions" herein and any Restricted Payments made pursuant to
clauses (i), (iv), (v) and (vi) of the succeeding paragraph) declared or made
after the date of the Indenture shall not exceed the sum of:
(A) 50% of the Consolidated Net Income of the Company accrued on a
cumulative basis during the period beginning on the date of the Indenture and
ending on the last day of the Company's last fiscal quarter ending prior to the
date of such proposed Restricted Payment (or, if such aggregate cumulative
Consolidated Net Income shall be a loss, minus 100% of such loss);
-60-
<PAGE>
(B) the aggregate Net Cash Proceeds received after the date of the
Indenture by the Company as capital contributions to the Company;
(C) the aggregate Net Cash Proceeds received after the date of the
Indenture by the Company from the issuance or sale (other than to any of its
Subsidiaries) of shares of Capital Stock (other than Redeemable Capital Stock)
of the Company or any options or warrants to purchase such shares (other than
issuances in respect of clause (ii) of the subsequent paragraph) of Capital
Stock (other than Redeemable Capital Stock) of the Company;
(D) the aggregate Net Cash Proceeds received after the date of the
Indenture by the Company (other than from any of its Subsidiaries) upon the
exercise of any options or warrants to purchase shares of Capital Stock of the
Company;
(E) the aggregate Net Cash Proceeds received after the date of the
Indenture by the Company for debt securities that have been converted into or
exchanged for Qualified Capital Stock of the Company to the extent such debt
securities are originally sold for cash plus the aggregate cash received by the
Company at the time of such conversion or exchange; and
(F) other Restricted Payments in an aggregate amount not to exceed
$10,000,000.
None of the foregoing provisions shall be deemed to prohibit the
following Restricted Payments so long as in the case of clauses (ii), (iii), (v)
and (vi) there is no Default or Event of Default continuing:
(i) dividends paid within 60 days after the date of declaration if at
the date of declaration, such payment would be permitted by the provisions of
the preceding paragraph and such payment shall be deemed to have been paid on
such date of declaration for purposes of the calculation required by the
provisions of the foregoing paragraph;
(ii) the redemption, repurchase or other acquisition or retirement of
any shares of any class of Capital Stock of the Company or Subordinated
Indebtedness in exchange for, or out of the net proceeds of, a substantially
concurrent issue and sale (other than to a Subsidiary) of shares of Qualified
Capital Stock of the Company; provided that any net proceeds from the issue and
sale of such Qualified Capital Stock are excluded from clause 3(C) of the
foregoing paragraph;
(iii) the redemption, repurchase, or other acquisition or retirement of
Subordinated Indebtedness of the Company (other than Redeemable Capital Stock)
made by exchange for, or out of the proceeds of the substantially concurrent
sale of, new Indebtedness of the Company so long as (A) the principal amount of
such new Indebtedness does not exceed the principal amount of the Indebtedness
being so redeemed, repurchased, acquired or retired for value (plus the amount
of any premium required to be paid under the terms of the instrument governing
the Indebtedness being so redeemed, repurchased, acquired or retired), (B) such
Indebtedness is subordinated to Senior Indebtedness and the Notes at least to
the same extent as such Subordinated Indebtedness so purchased, exchanged,
redeemed, repurchased, acquired or retired for value, (C) such Indebtedness has
a Stated Maturity for its final scheduled principal payment later than the
Stated Maturity for the final scheduled principal payment of the Notes and (D)
such Indebtedness has an Average Life to Stated Maturity equal to or greater
than the remaining Average Life to Stated Maturity of the Notes;
-61-
<PAGE>
(iv) any purchase, redemption or other acquisition of Capital Stock of
a Permitted Joint Venture from a physician or other healthcare provider which is
required to be purchased, redeemed or otherwise acquired by applicable law;
(v) in addition to the transactions covered by clause (iv) of this
paragraph, any purchase, redemption or other acquisition of Capital Stock of a
Permitted Joint Venture; or
(vi) the making of any payment pursuant to any guarantee of
Indebtedness of a Permitted Joint Venture.
Restrictions on Preferred Stock of Subsidiaries and Subsidiary
Distributions. (a) The Company will not permit any Subsidiary to issue any
Preferred Stock (other than Preferred Stock issued (i) prior to the date of the
Indenture or (ii) to the Company or a Wholly Owned Subsidiary (collectively,
"Permitted Preferred Stock")) or permit any Person (other than the Company or a
Wholly Owned Subsidiary) to own or hold any interest in any Preferred Stock of
any Subsidiary, other than with respect to any Preferred Stock issued prior to
the date of the Indenture, unless a Subsidiary would be entitled to create,
incur or assume Indebtedness pursuant to the covenant described under "--
Limitation on Indebtedness" in the aggregate principal amount equal to the
aggregate liquidation value of the Preferred Stock to be issued.
(b) The Company will not, and will not permit any Subsidiary to,
declare or pay dividends or distributions on any Capital Stock of such
Subsidiary to any Person (other than to the Company or any Wholly Owned
Subsidiary or any lender in its capacity as a pledgee of Capital Stock of any
Subsidiary under the Credit Facility); provided, that the foregoing shall not
prohibit (i) (A) the Company or any Subsidiary from making any payment of
dividends or distributions on the Capital Stock of any Subsidiary in the
aggregate up to the amount of Restricted Payments that the Company could make at
any time pursuant to the covenant described under "-- Limitation on Restricted
Payments;" (B) the purchase, redemption, or other acquisition of the Capital
Stock of a Permitted Joint Venture from a physician or other healthcare provider
which is required to be purchased, redeemed or otherwise acquired by applicable
law; or (C) the payment of pro rata dividends or distributions to holders of
minority interests in the Capital Stock of a Subsidiary made in accordance with
the terms of the Agreement pursuant to which such payment is made or (ii) in
addition to the transactions covered by clause (i) (B) of this paragraph, in the
event no Default or Event of Default has occurred and is continuing, the
purchase, redemption, or other acquisition of the Capital Stock of a Permitted
Joint Venture.
Limitation on Transactions with Affiliates. The Company will not, and
will not permit any of its Subsidiaries to, directly or indirectly, enter into
or suffer to exist any transaction or series of related transactions (including,
without limitation, the sale, purchase, exchange or lease of assets, property or
services) with any Affiliate of the Company (other than a Wholly Owned
Subsidiary or a Permitted Joint Venture) unless (i) such transaction or series
of related transactions is on terms that are no less favorable to the Company or
such Subsidiary, as the case may be, than would be available in a comparable
transaction in arm's-length dealings with an unrelated third party and (ii) with
respect to a transaction or series of related transactions involving payments in
excess of $5,000,000 in the aggregate, the Company delivers an Officers'
Certificate to the Trustee certifying that (A) such transaction complies with
clause (i) above and (B) such transaction or series of related transactions
shall have been approved by a majority of the independent directors of the Board
of Directors of the Company; provided, however, that the foregoing restriction
shall not apply to (x) any transaction or series of related transactions entered
into prior to the date of the Indenture, (y) the payment of reasonable and
customary regular fees to directors of the Company or any of its Subsidiaries
who are not employees of the Company or any Affiliate or (z) the Company's
employee compensation and other benefit arrangements.
-62-
<PAGE>
Disposition of Proceeds of Asset Sales. (a) The Company will not, and
will not permit any Subsidiary to, make any Asset Sale unless (i) the Company or
such Subsidiary receives consideration at the time of such Asset Sale at least
equal to the Fair Market Value of the shares or assets subject to such Asset
Sale (as determined by the Board of Directors of the Company and evidenced in a
board resolution whose determination shall be conclusive) and (ii) at least 75%
of the proceeds from such Asset Sale when received consists of cash or Cash
Equivalents; provided however, any Asset Sale which constitutes a Permitted
Investment under clause (vii) or (viii) of the definition of Permitted
Investment shall not be subject to the condition set forth in clause (ii) of
this sentence.
(b) If all or a portion of the Net Cash Proceeds of any Asset Sale are
not required to be applied to repay permanently any outstanding Senior
Indebtedness as required by the terms thereof, or, if not so required to be
applied, the Company determines not to apply such Net Cash Proceeds to the
prepayment of such Senior Indebtedness or if no such Senior Indebtedness is
outstanding, then the Company may within one year of the Asset Sale, invest (or
enter into a legally binding agreement to invest) the Net Cash Proceeds in
properties and assets that (as determined by the Board of Directors, whose
determination shall be conclusive and evidenced by a Board Resolution) replace
the properties and assets that were the subject of the Asset Sale or in
properties and assets that will be used in the businesses of the Company, its
Wholly Owned Subsidiaries or its Permitted Joint Ventures existing on the date
of the Indenture or in any Healthcare Related Business. If any such legally
binding agreement to invest any Net Cash Proceeds is terminated, then the
Company may invest such Net Cash Proceeds, prior to the end of such one-year
period or six months from such termination, whichever is later, in the business
of the Company, its Wholly Owned Subsidiaries or Permitted Joint Ventures or in
any Healthcare Related Business as provided above. The amount of such Net Cash
Proceeds neither used to repay or prepay Senior Indebtedness nor used or
invested as set forth in this paragraph (after the periods specified in this
paragraph) constitutes "Excess Proceeds."
(c) Subject to paragraph (f) below, when the aggregate amount of Excess
Proceeds equals $10,000,000 or more, the Company shall apply the Excess Proceeds
to the repayment of the Notes as follows: the Company shall make an offer to
purchase (an "Offer") from all holders of the Notes in accordance with the
procedures set forth in the Indenture in the maximum principal amount (expressed
as a multiple of $1,000) of Notes that may be purchased out of an amount (the
"Note Amount") equal to the product of such Excess Proceeds multiplied by a
fraction, the numerator of which is the outstanding principal amount of the
Notes, and the denominator of which is the sum of the outstanding principal
amount of the Notes (subject to proration in the event such amount is less than
the aggregate Offered Price (as defined herein) of all Notes tendered). The
offer price shall be payable in cash in an amount equal to 100% of the principal
amount of the Notes plus accrued and unpaid interest, if any, to the date such
Offer is consummated (the "Offered Price"), in accordance with the procedures
set forth in the Indenture. To the extent that the aggregate Offered Price of
the Notes tendered pursuant to an Offer is less than the Note Amount relating
thereto (such shortfall constituting a "Deficiency"), the Company may use such
Deficiency, or a portion thereof, in the business of the Company, its Wholly
Owned Subsidiaries or its Permitted Joint Ventures or any Healthcare Related
Business. Upon completion of the purchase of all the Notes tendered pursuant to
an Offer, the amount of Excess Proceeds shall be reset at zero.
(d) Whenever the Excess Proceeds received by the Company exceed
$10,000,000, such Excess Proceeds shall be set aside by the Company in a
separate account pending (i) deposit with the Trustee or a paying agent of the
amount required to purchase the Notes tendered in an Offer, (ii) delivery by the
Company of the Offered Price to the holders of the Notes tendered in an Offer
and (iii) application, as set forth above, of Excess Proceeds for general
corporate purposes. Such Excess Proceeds may be invested in Temporary Cash
Investments, provided that the maturity date of any investment made after the
amount of Excess
-63-
<PAGE>
Proceeds exceeds $10,000,000 shall not be later than the Offer Date. The Company
shall be entitled to any interest or dividends accrued, earned or paid on such
Temporary Cash Investments.
(e) If the Company becomes obligated to make an Offer pursuant to
clause (c) above, the Notes shall be purchased by the Company, at the option of
the holder thereof, in whole or in part in integral multiples of $1,000, on a
date that is not earlier than 30 days and not later than 60 days from the date
the notice is given to holders, or such later date as may be necessary for the
Company to comply with the requirements under the Exchange Act, subject to
proration in the event the amount of Excess Proceeds is less than the aggregate
Offered Price of all Notes tendered and to satisfaction by or on behalf of the
holder of the requirements set forth in clause (f) below.
(f) In the event that the Company shall be unable to purchase Notes
from holders thereof in an Offer because of the provisions (i) of applicable
law, (ii) of the Company's loan agreements, indentures or other contracts in
existence on the date of the Indenture, (iii) permitted to exist or become
effective by subparagraph (h)(ii) below or (iv) of the Credit Facility, the
Company need not make an Offer. The Company shall then be obligated to (i)
invest the Excess Proceeds in properties and assets to replace the properties
and assets that were the subject of the Asset Sale or in properties and assets
that (as determined by the Board of Directors, whose determination shall be
conclusive and evidenced by a Board Resolution) will be used in the businesses
of the Company, its Wholly Owned Subsidiaries or its Permitted Joint Ventures
existing on the date of the Indenture or in any Healthcare Related Business or
(ii) apply the Excess Proceeds to repay Senior Indebtedness.
(g) The Company shall comply with the applicable tender offer rules,
including Rule 14e-1 under the Exchange Act, in connection with an Offer.
(h) The Company will not, and will not permit any Subsidiary to, create
or permit to exist or become effective any restriction (other than restrictions
existing under (i) Indebtedness as in effect on the date of the Indenture or
(ii) any Senior Indebtedness existing on the date of the Indenture or
thereafter) that would materially impair the ability of the Company to make an
Offer to purchase the Notes upon an Asset Sale or, if such Offer is made, to pay
for the Notes tendered for purchase.
Limitation on Liens Securing Subordinated Indebtedness. The Company
will not, and will not permit any Subsidiary to, create, incur, assume or suffer
to exist any Liens of any kind upon any of their respective assets or properties
now owned or acquired after the date of the Indenture or any income or profits
therefrom securing (i) any Indebtedness of the Company which is expressly by its
terms subordinate or junior in right of payment to any other Indebtedness of the
Company, unless the Notes are equally and ratably secured; provided that, if
such Indebtedness which is expressly by its terms subordinate or junior in right
of payment to any other Indebtedness of the Company is expressly subordinate to
the Notes, the Lien securing such subordinated or junior Indebtedness shall be
subordinate and junior to the Lien securing the Notes with the same relative
priority as such subordinated or junior Indebtedness shall have with respect to
the Notes; provided, further, that this clause (i) shall not be applicable to
any Liens securing any such Indebtedness which became Indebtedness of the
Company pursuant to a transaction permitted under "-- Merger and Sale of Assets,
etc." or Liens securing Acquired Indebtedness and, in each case, which Liens
were in existence at the time of such transaction or incurrence of such Acquired
Indebtedness (unless such Indebtedness was incurred in connection with, or in
contemplation of, such transaction or incurrence of such Acquired Indebtedness),
so long as such Liens do not extend to or cover any property or assets of the
Company or any Subsidiary other than property or assets acquired in such
transaction or securing such Acquired Indebtedness, or (ii) any assumption,
guarantee or other liability of any Subsidiary in respect of any Indebtedness of
the Company which is expressly by its terms subordinate or junior in right of
payment to any other Indebtedness
-64-
<PAGE>
of the Company, unless the substantially similar assumption, guarantee or other
liability of such Subsidiary in respect of the Notes is equally and ratably
secured; provided that, if such subordinated Indebtedness is expressly by its
terms subordinate or junior to the Notes, then the Lien securing the assumption,
guarantee or other liability of such Subsidiary in respect of such subordinated
or junior Indebtedness shall be subordinate and junior to the Lien securing the
assumption, guarantee or other liability of such Subsidiary in respect of the
Notes with the same relative priority as such subordinated or junior
Indebtedness shall have with respect to the Notes; provided, further, that this
clause (ii) shall not be applicable to Liens securing any such assumption,
guarantee or other liability which existed at the time such Subsidiary became a
Subsidiary and which Liens were in existence at the time of such transaction
(unless such assumption, guarantee or other liability was incurred in connection
with, or in contemplation of, such Person becoming a Subsidiary), so long as
such Liens do not extend to or cover any property or assets of the Company or
any Subsidiary other than the property or assets of such Person.
Limitation on Other Senior Subordinated Indebtedness. The Company will
not create, incur, assume, guarantee or in any other manner become liable with
respect to any Indebtedness, other than the Notes, that is subordinate in right
of payment to any Senior Indebtedness, unless such Indebtedness is also pari
passu with, or subordinate in right of payment to, the Notes pursuant to
subordination provisions substantially similar to those contained in the
Indenture.
Limitation on Issuance of Guarantees of Subordinated Indebtedness. (a)
The Company will not permit any Subsidiary, directly or indirectly, to assume,
guarantee or in any other manner become liable with respect to any Indebtedness
of the Company which is expressly by its terms subordinate or junior in right of
payment to any other Indebtedness of the Company unless (i) such Subsidiary
simultaneously executes and delivers a supplemental indenture to the Indenture
providing for a guarantee of payment of the Notes by such Subsidiary and (A) if
any such assumption, guarantee or other liability is subordinated, the guarantee
under the supplemental indenture shall be subordinated to the same extent as the
Notes are subordinated to Senior Indebtedness of the Company under the Indenture
and (B) if such subordinated or junior Indebtedness is by its terms expressly
subordinated to the Notes, any such assumption, guarantee or other liability of
such Subsidiary with respect to such subordinated or junior Indebtedness shall
be subordinated to such Subsidiary's assumption, guarantee or other liability
with respect to the Notes to the same extent as such subordinated or junior
Indebtedness is subordinated or junior to the Notes under the Indenture; and
(ii) such Subsidiary waives and will not in any manner whatsoever claim or take
the benefit or advantage of, any rights of reimbursement, indemnity or
subrogation or any other rights against the Company or any other Subsidiary as a
result of any payment by such Subsidiary under its Guarantee.
(b) Each guarantee created pursuant to the provisions described in the
foregoing paragraph is referred to as a "Guarantee" and the issuer of each such
Guarantee is referred to as a "Guarantor." Notwithstanding the foregoing, any
Guarantee by a Subsidiary of the Notes shall provide by its terms that it
(together with any Liens arising from such Guarantee) shall be automatically and
unconditionally released and discharged upon (i) any sale, exchange or transfer,
to any Person not an affiliate of the Company, of all of the Company's Capital
Stock in, or all or substantially all the assets of, such Subsidiary, which is
in compliance with the Indenture or (ii) the release or discharge of the
assumption, guarantee or other liability which resulted in the creation of such
Guarantee.
Limitation on Dividends and Other Payment Restrictions Affecting
Subsidiaries. The Company will not, and will not permit any Subsidiary to,
create or otherwise cause or suffer to exist or become effective any restriction
of any kind, on the ability of any Subsidiary to (i) pay dividends or make any
other distribution on its Capital Stock to the Company or any other Subsidiary,
(ii) pay any Indebtedness owed to the Company or any other Subsidiary, (iii)
make any Investment in the Company or any other Subsidiary
-65-
<PAGE>
or (iv) transfer any of its property or assets to the Company or any other
Subsidiary, except (a) any encumbrance or restriction existing under or by
reason of applicable law; (b) any encumbrance or restriction existing under or
by reason of customary non-assignment provisions of any lease governing a
leasehold interest of the Company, or any Subsidiary; (c) any restriction
pursuant to an agreement in effect at or entered into on the date of the
Indenture as set forth in a schedule to the Indenture; (d) any restriction
existing under the Credit Facility as in effect on the date of the Indenture;
(e) any restriction, with respect to a Subsidiary that is not a Subsidiary on
the date of the Indenture, in existence at the time such Person becomes a
Subsidiary or created on the date it becomes a Subsidiary and not incurred in
connection with, or in contemplation of, such Person becoming a Subsidiary; and
(f) any restriction existing under any agreement that extends, renews,
refinances or replaces the agreements containing the restrictions in the
foregoing clauses (c) through (e), provided that the terms and conditions of any
such restrictions are not materially less favorable to the holders of the Notes
than those under or pursuant to the agreement evidencing the Indebtedness so
extended, renewed, refinanced or replaced (in the opinion of the Board of
Directors of the Company whose determination shall be conclusive).
Reporting Requirements. The Indenture will require that the Company
file with the Commission the annual reports, quarterly reports and other
documents required to be filed with the Commission pursuant to Sections 13 and
15 of the Exchange Act, whether or not the Company has a class of securities
registered under the Exchange Act. The Company will be required to file copies
of such reports and documents with the Trustee within 15 days after it files
them with the Commission.
Additional Covenants. The Indenture also contains covenants with
respect to the following matters: (i) payment of principal, premium and
interest; (ii) maintenance of an office or agency in the City of New York; (iii)
arrangements regarding the handling of money held in trust; (iv) maintenance of
corporate existence; (v) payment of taxes and other claims; (vi) maintenance of
properties; and (vii) maintenance of insurance.
Merger and Sale of Assets, etc. The Company shall not, in a single
transaction or through a series of related transactions, consolidate with or
merge with or into any other Person or sell, assign, convey, transfer or lease
or otherwise dispose of all or substantially all of its properties and assets as
an entirety to any Person or group of affiliated Persons, or permit any of its
Subsidiaries to enter into any such transaction or transactions if such
transaction or transactions, in the aggregate, would result in a sale,
assignment, transfer, lease or disposal of all or substantially all of the
properties and assets of the Company and its Subsidiaries on a consolidated
basis to any other Person or group of affiliated Persons, unless at the time and
after giving effect thereto (i) either (A) the Company shall be the continuing
corporation, or (B) the Person (if other than the Company) formed by such
consolidation or into which the Company is merged or the Person which acquires
by conveyance, transfer, lease or disposition the properties and assets of the
Company, substantially as an entirety (the "Surviving Entity") shall be a
corporation duly organized and validly existing under the laws of the United
States of America, any state thereof or the District of Columbia and shall, in
either case, expressly assume, by an indenture supplemental to the Indenture,
executed and delivered to the Trustee, in form satisfactory to the Trustee, all
the obligations of the Company under the Notes and the Indenture, and the
Indenture shall remain in full force and effect; (ii) immediately before and
immediately after giving effect to such transaction on a pro forma basis (and
treating any Indebtedness not previously an obligation of the Company or a
Subsidiary which becomes the obligation of the Company or any of its
Subsidiaries in connection with or as a result of such transaction as having
been incurred at the time of such transaction), no Default or Event of Default
shall have occurred and be continuing; (iii) immediately after giving effect to
such transaction on a pro forma basis, the Consolidated Net Worth of the Company
(or the Surviving Entity if the Company is not the continuing obligor under the
Indenture) is at least equal to the Consolidated Net Worth of the Company
immediately before such transaction;
-66-
<PAGE>
(iv) immediately before and immediately after giving effect to such transaction
on a pro forma basis (and treating any Indebtedness not previously an obligation
of the Company or a Subsidiary which becomes the obligation of the Company or
any of its Subsidiaries in connection with or as a result of such transaction
having been incurred at the time of such transaction), the Company (or the
Surviving Entity if the Company is not the continuing obligor under the
Indenture) could incur $1.00 of additional Indebtedness under the provisions of
"-- Certain Covenants -- Limitation on Indebtedness" (other than Permitted
Indebtedness); (v) each Guarantor, if any, unless it is the other party to the
transactions described above, shall have by supplemental indenture confirmed
that its Guarantee of the Notes shall apply to such person's obligations under
the Indenture and the Notes; and (vi) the Company or the Surviving Entity shall
have delivered to the Trustee an Officers' Certificate and an opinion of
counsel, each stating that such consolidation, merger, transfer, lease or
disposition and such supplemental indenture comply with the terms of the
Indenture.
Each Guarantor, if any (other than any Subsidiary whose Guarantee is
being released pursuant to the provisions under "Certain Covenants -- Limitation
on Issuance of Guarantees of Subordinated Indebtedness" as a result of such
transaction), shall not, and the Company will not permit a Guarantor to, in a
single transaction or through a series of related transactions, merge or
consolidate with or into any other corporation or other entity (other than the
Company or any Guarantor), or sell, assign, convey, transfer, lease or otherwise
dispose of its properties and assets on a consolidated basis substantially as an
entirety to any entity unless (i) either (A) such Guarantor shall be the
continuing corporation or partnership or (B) the entity (if other than such
Guarantor) formed by such consolidation or into which such Guarantor is merged
or the entity which acquires by sale, assignment, conveyance, transfer, lease or
disposition the properties and assets of such Guarantor substantially as an
entirety shall be a corporation or partnership organized and validly existing
under the laws of the United States, any state thereof or the District of
Columbia and shall expressly assume by an indenture supplemental to the
Indenture, executed and delivered to the Trustee, in form satisfactory to the
Trustee, all the obligations of such Guarantor under the Notes and the
Indenture; (ii) immediately before and immediately thereafter (and treating any
Indebtedness not previously an obligation of the Company or a Subsidiary which
becomes the obligation of the Company or any of its Subsidiaries in connection
with or as a result of such transaction as having been incurred at the time of
such transaction), no Default or Event of Default shall have occurred and be
continuing; and (iii) such Guarantor shall have delivered to the Trustee an
Officers' Certificate and an opinion of counsel, each stating that such
consolidation, merger, sale, assignment, conveyance, transfer, lease or
disposition and such supplemental indenture comply with the Indenture, and
thereafter all obligations of the predecessor shall terminate.
Notwithstanding the foregoing, any Wholly Owned Subsidiary may (i)
merge or consolidate with or into any other Wholly Owned Subsidiary or the
Company or (ii) sell, assign, convey, transfer, lease, or otherwise dispose of
all or substantially all of its properties and assets to any other Wholly Owned
Subsidiary or the Company; provided, that (A) any Person surviving any such
merger or consolidation with a Guarantor or which acquires substantially all of
the assets of any Guarantor (the "Acquisition Survivor") shall expressly assume
by a supplemental indenture or guarantee executed and delivered to the Trustee,
in form satisfactory to the Trustee, any obligations of such Subsidiary to
guarantee the obligations owing under the Indenture; and (B) the Acquisition
Survivor shall have delivered to the Trustee an Officers' Certificate and an
opinion of counsel, each stating that the transaction and the supplemental
guarantee or indenture executed in connection therewith comply with this
provision and that all conditions precedent provided for in the Indenture
relating to such transaction have been complied with.
Upon any consolidation or merger, or any sale, assignment, conveyance,
transfer, lease or disposition of all or substantially all of the properties and
assets of the Company or any Guarantor in accordance with the immediately
preceding paragraphs, the successor Person formed by such consolidation or into
which the Company or such Guarantor, as the case may be, is merged or the
successor Person to which such sale,
-67-
<PAGE>
assignment, conveyance, transfer, lease or disposition is made shall succeed to,
and be substituted for, and may exercise every right and power of, the Company
or such Guarantor, as the case may be, under the Indenture and/or the
Guarantees, as the case may be, with the same effect as if such successor had
been named as the Company or such Guarantor, as the case may be, herein and/or
in the Guarantees, as the case may be. When a successor assumes all the
obligations of its predecessor under the Indenture, the Notes or a Guarantee, as
the case may be, the predecessor shall be released from those obligations;
provided that in the case of a transfer by lease, the predecessor shall not be
released from the payment of principal and interest on the Notes or a Guarantee,
as the case may be.
Events of Default
An Event of Default will occur under the Indenture if:
(i) there shall be a default in the payment of any interest on any Note
when it becomes due and payable, and such default shall continue for a period of
30 days;
(ii) there shall be a default in the payment of the principal of (or
premium, if any, on) any Note at its Stated Maturity;
(iii) (A) there shall be a default in the performance, or breach, of
any covenant or agreement of the Company or of any Guarantor under the Indenture
(other than a default in the performance or breach of a covenant or agreement
which is specifically dealt with elsewhere in the Indenture) and such default or
breach shall continue for a period of 30 days after written notice has been
given, by certified mail (x) to the Company by the Trustee or (y) to the Company
and the Trustee by the holders of at least 25% in aggregate principal amount of
the outstanding Notes; (B) there shall be a default in the performance or breach
of the provisions of "-- Merger and Sale of Assets, etc;" (C) the Company shall
have failed to make or consummate an Offer in accordance with the provisions of
"-- Certain Covenants -- Dispositions of Proceeds of Asset Sales;" or (D) the
Company shall have failed to make or consummate a Change in Control Offer in
accordance with the provisions of "Change in Control;"
(iv) one or more defaults shall have occurred under any agreements,
indentures or instruments under which the Company or any Subsidiary then has
outstanding Indebtedness in excess of $5,000,000 in the aggregate and, if not
already matured at its final maturity in accordance with its terms, such
Indebtedness shall have been accelerated;
(v) one or more judgments, orders or decrees for the payment of money
in excess of $5,000,000, either individually or in the aggregate, shall be
entered against the Company or any Subsidiary or any of their respective
properties which is not fully covered by insurance, bond, surety or similar
instrument and shall not be discharged and there shall have been a period of 60
days during which a stay of enforcement of such judgment or order, by reason of
an appeal or otherwise, shall not be in effect; or
(vi) certain events of bankruptcy, insolvency or reorganization with
respect to the Company or any Subsidiary shall have occurred.
If an Event of Default (other than as specified in clause (vi) occurs
and is continuing, the Trustee or the holders of not less than 25% in aggregate
principal amount of the Notes then outstanding may, and the Trustee upon the
request of the holders of not less than 25% in aggregate principal amount of the
Notes then outstanding shall, declare the principal of all the Notes due and
payable immediately in an amount equal to the principal amount of the Notes,
together with accrued and unpaid interest to the date the Notes become
-68-
<PAGE>
due and payable, by a notice in writing to the Company (and to the Trustee, if
given by the holders of the Notes and, if the Credit Facility is in effect, to
the representative of the Credit Facility) and, upon any such declaration such
principal shall become immediately due and payable and the Trustee may, at its
discretion, proceed to protect and enforce the rights of the holders of Notes by
appropriate judicial proceedings. If an Event of Default specified in clause
(vi) above occurs and is continuing, then the principal of all the Notes shall
ipso facto become and be immediately due and payable without any declaration or
other act on the part of the Trustee or any holder of the Notes.
At any time after a declaration of acceleration has been made and
before a judgment or decree for payment of the money due has been obtained by
the Trustee, the holders of a majority in aggregate principal amount of the
Notes then outstanding, by written notice to the Company and the Trustee, may
rescind and annul such declaration and its consequences if (a) the Company has
paid or deposited with the Trustee a sum sufficient to pay (i) all sums paid or
advanced by the Trustee under the Indenture and the reasonable compensation,
expenses, disbursements and advances of the Trustee, its agents and counsel,
(ii) all overdue interest on all Notes, (iii) the principal of and premium, if
any, on any Notes which have become due otherwise than by such declaration of
acceleration and interest thereon at the rate borne by the Notes, and (iv) to
the extent that payment of such interest is lawful, interest upon overdue
interest at the rate borne by the Notes; and (b) all Events of Default, other
than the non-payment of principal of the Notes which have become due solely by
such declaration of acceleration, have been cured or waived.
The holders of not less than a majority in aggregate principal amount
of the Notes then outstanding may on behalf of the holders of all the Notes
waive any past Defaults under the Indenture, except a Default in the payment of
the principal of, premium, if any, or interest on any Note, or in respect of a
covenant or provision which under the Indenture cannot be modified or amended
without the consent of the holder of each Note then outstanding.
The Company is also required to notify the Trustee within five days of
the occurrence of any Default.
The Trust Indenture Act contains limitations on the rights of the
Trustee, should it become a creditor of the Company or any Guarantor, to obtain
payment of claims in certain cases or to realize on certain property received by
it in respect of any such claims, as security or otherwise. The Trustee is
permitted to engage in other transactions, provided that if it acquires any
conflicting interest it must eliminate such conflict upon the occurrence of an
Event of Default or else resign.
Satisfaction and Discharge of the Indenture; Covenant Defeasance
The Indenture will cease to be of further effect as to all outstanding
Notes (except as to (i) rights of registration of transfer and exchange and the
Company's right of optional redemption; (ii) substitution of apparently
mutilated, defaced, destroyed, lost or stolen Notes; (iii) rights of holders of
the Notes to receive payments of principal and interest on the Notes; (iv)
rights, obligations and immunities of the Trustee under the Indenture; and (v)
rights of the holders of the Notes as beneficiaries of the Indenture with
respect to the property so deposited with the Trustee payable to all or any of
them), if (A) the Company will have paid or caused to be paid the principal of
and interest on the Notes as and when the same will have become due and payable
or (B) all outstanding Notes (except lost, stolen or destroyed Notes which have
been replaced or paid) have been delivered to the Trustee for cancellation or
(C) (x) the Notes not previously delivered to the Trustee for cancellation will
have become due and payable or are by their terms to become due and payable
within one year or are to be called for redemption under arrangements
satisfactory to the Trustee upon delivery of notice and (y) the Company will
have irrevocably deposited with the Trustee, as trust funds, cash, in an amount
sufficient to pay principal of and interest on the outstanding
-69-
<PAGE>
Notes, to maturity or redemption, as the case may be. Such trust may only be
established if such deposit will not result in a breach or violation of, or
constitute a default under, any agreement or instrument pursuant to which the
Company is a party or by which it is bound and the Company has delivered to the
Trustee an Officers' Certificate and an opinion of counsel, each stating that
all conditions related to such defeasance have been complied with.
The Indenture will also cease to be in effect (except as described in
(i)-(v) in the immediately preceding paragraph) and the Indebtedness on all
outstanding Notes will be discharged on the 123rd day after the irrevocable
deposit by the Company with the Trustee, in trust, specifically pledged as
security for, and dedicated solely to, the benefit of the holders of the Notes,
of cash, U.S. Government Obligations (as defined in the Indenture), or a
combination thereof, in an amount sufficient, in the opinion of a nationally
recognized firm of independent public accountants expressed in a written
certification thereof delivered to the Trustee, to pay the principal of and
interest on the Notes then outstanding in accordance with the terms of the
Indenture and the Notes. Such a trust may only be established if (i) such
deposit will not result in a breach or violation of, or constitute a default
under, any agreement or instrument to which the Company is a party or by which
it is bound; (ii) the Company has delivered to the Trustee an opinion of counsel
stating that (A) the Company has received from, or there has been published by,
the Internal Revenue Service a ruling, or (B) since the date of this Indenture
there has been a change in the applicable federal income tax law, in either case
to the effect that, based thereon such opinion shall confirm that, the holders
of the Notes will not recognize income, gain or loss for federal income tax
purposes as a result of such deposit, defeasance and discharge and will be
subject to federal income tax on the same amount and in the same manner and at
the same times as would have been the case if such deposit, defeasance and
discharge had not occurred; (iii) the Company has delivered to the Trustee an
opinion of counsel to the effect that after the 123rd day following the deposit,
the trust funds will not be subject to the effect of any applicable bankruptcy,
insolvency, reorganization or similar laws affecting creditors' rights
generally; and (iv) the Company has delivered to the Trustee an Officer's
Certificate and an opinion of counsel, each stating that all conditions related
to the defeasance have been complied with.
The Company and any Guarantor may also be released from its obligations
under certain covenants that are described in the Indenture and shall cease to
be subject to clause (iii) of the first paragraph under "Events of Default,"
with respect to the Notes outstanding on the 123rd day after the irrevocable
deposit by the Company with the Trustee, in trust, specifically pledged as
security for, and dedicated solely to, the benefit of the holders of the Notes,
cash, U.S. Government Obligations, or a combination thereof, in an amount
sufficient, in the opinion of a nationally recognized firm of independent public
accountants expressed in a written certification thereof delivered to the
Trustee, to pay the principal of and interest on the Notes then outstanding in
accordance with the terms of the Indenture and the Notes ("covenant
defeasance"). Such covenant defeasance may only be effected if (i) such deposit
will not result in a breach or violation of, or constitute a default under, any
agreement or instrument to which the Company or any Guarantor is party or by
which it is bound; (ii) the Company delivers to the Trustee an Officers'
Certificate and an opinion of counsel to the effect that the holders of the
Notes will not recognize income, gain or loss for federal income tax purposes as
a result of such deposit and covenant defeasance and will be subject to federal
income tax on the same amount, in the same manner and at the same times as would
have been the case if such deposit and covenant defeasance had not occurred;
(iii) the Company has delivered to the Trustee an opinion of counsel to the
effect that after the 123rd day following the deposit, the trust funds will not
be subject to the effect of any applicable bankruptcy, insolvency,
reorganization or similar laws affecting creditors' rights generally; and (iv)
the Company has delivered to the Trustee an Officer's Certificate and an opinion
of counsel, each stating that all conditions related to the covenant defeasance
have been complied with. Following such covenant defeasance, the Company may
omit to comply with and will have no liability in respect of any term, condition
or limitation set forth in such sections of the Indenture, whether directly or
-70-
<PAGE>
indirectly by reason of any reference elsewhere in the Indenture of such
sections or by reason of any reference in such sections to any other provision
in the Indenture or in any other document, and such omission will not constitute
an Event of Default.
Modifications and Amendments
Modifications and amendments of the Indenture may be made by the
Company, the Guarantors, if any, and the Trustee with the consent of the holders
of not less than a majority in aggregate principal amount of the outstanding
Notes; provided, however, that no such modification or amendment may, without
the consent of the holder of each outstanding Note affected thereby: (i) change
the Stated Maturity of the principal of, or any installment of interest on, any
Note, or reduce the principal amount thereof or the rate of interest thereon or
any premium payable upon the redemption thereof, or change the coin or currency
in which the principal of any Note or any premium or the interest thereon is
payable, or impair the right to institute suit for the enforcement of any such
payment after the Stated Maturity thereof (or, in the case of redemption, on or
after the redemption date); (ii) amend, change or modify the obligation of the
Company to make and consummate a Change in Control Offer in the event of a
Change in Control or make and consummate the Offer with respect to any Asset
Sales or modify any of the provisions or definitions with respect thereto; (iii)
reduce the percentage in principal amount of outstanding Notes, the consent of
whose holders is required for any such supplemental indenture or the consent of
whose holders is required for any waiver of compliance with certain provisions
of the Indenture or certain Defaults thereunder and their consequences provided
for in the Indenture or with respect to any Guarantee; (iv) modify any of the
provisions relating to supplemental indentures requiring the consent of holders
or relating to the waiver of past defaults or relating to the waiver of certain
covenants, except to increase the percentage of outstanding Notes required for
such actions or to provide that certain other provisions of the Indenture cannot
be modified or waived without the consent of the holder of each Note affected
thereby; (v) except as otherwise permitted under "-- Merger and Sale of Assets,
etc.," consent to the assignment or transfer by the Company or any Guarantor of
any of their rights and obligations under the Indenture; or (vi) modify any of
the provisions of the Indenture relating to the subordination of the Notes or
any Guarantee in a manner adverse to the holders of the Notes. Any amendment to
the subordination provisions of the Notes will also require the consent of the
holders of Designated Senior Indebtedness.
The holders of a majority in aggregate principal amount of the Notes
then outstanding may waive compliance with certain restrictive covenants and
provisions of the Indenture.
Governing Law
The Indenture, the Notes and any Guarantees will be governed by, and
construed in accordance with, the laws of the State of New York, without giving
effect to the conflicts of law principles thereof.
Certain Definitions
"Acquired Indebtedness" means Indebtedness of a Person (i) existing at
the time such Person becomes a Subsidiary or (ii) assumed in connection with the
acquisition of assets from such Person, in each case, other than Indebtedness
incurred in connection with, or in contemplation of, such Person becoming a
Subsidiary or such acquisition. Acquired Indebtedness shall be deemed to be
incurred on the date of the related acquisition of assets from any Person or the
date the acquired Person becomes a Subsidiary.
"Affiliate" means with respect to any specified Person, (i) any other
Person directly or indirectly controlling or controlled by or under direct or
indirect common control with such specified Person, (ii) any
-71-
<PAGE>
other Person that owns, directly or indirectly, 5% or more of such specified
Person's Capital Stock, (iii) any officer or director of (A) any such specified
Person, (B) any Subsidiary of such specified Person or (C) any Person described
in clauses (i) or (ii) above or (iv) any other Person having a relationship with
any natural Person described in clauses (i), (ii) or (iii) above by blood,
marriage or adoption not more remote than first cousin or any Person directly or
indirectly controlling or controlled by or under direct or indirect common
control with such other Person described in this clause (iv). For the purposes
of this definition, "control" when used with respect to any specified Person
means the power to direct the management and policies of such Person directly or
indirectly, whether through ownership of voting securities, by contract or
otherwise; and the terms "controlling" and "controlled" have meanings
correlative to the foregoing.
"Asset Sale" means any sale, issuance, conveyance, transfer, lease or
other disposition (including, without limitation, by way of merger,
consolidation or sale and leaseback transaction) (collectively, a "transfer"),
directly or indirectly, in one or a series of related transactions, of (i) any
Capital Stock of any Subsidiary; (ii) all or substantially all of the properties
and assets of any division or line of business of the Company or its
Subsidiaries; or (iii) any other properties or assets of the Company or any
Subsidiary, other than in the ordinary course of business. For the purposes of
this definition, the term "Asset Sale" shall not include (i) any transfer of
properties and assets that is governed by the provisions described under
"--Merger, Sale of Assets, etc.," (ii) any transfer of properties or assets of
the Company to any Wholly Owned Subsidiary, or of any Subsidiary to the Company
or any Wholly Owned Subsidiary in accordance with the terms of the Indenture or
(iii) transfers of properties or assets in any twelve month period (A) the Fair
Market Value of which does not, in the aggregate, exceed 2.5% of the Company's
Consolidated Total Assets and (B) the Consolidated EBITDA related to such
properties or assets does not, in the aggregate, exceed 2.5% of the Company's
Consolidated EBITDA.
"Attributable Debt" in respect of a sale-leaseback transaction or an
operating lease in respect of a healthcare facility means, at the time of
determination, the present value (discounted at the interest rate implicit in
the lease, compounded semiannually) of the obligation of the lessee of the
property subject to such sale-leaseback transaction or operating lease in
respect of a healthcare facility for rental payments during the remaining term
of the lease included in such transaction including any period for which such
lease has been extended or may, at the option of the lessor, be extended or
until the earliest date on which the lessee may terminate such lease without
penalty or upon payment of penalty (in which case the rental payments shall
include such penalty), after excluding all amounts required to be paid on
account of maintenance and repairs, insurance, taxes, assessments, water,
utilities and similar charges.
"Average Life to Stated Maturity" means, as of the date of
determination with respect to any Indebtedness, the quotient obtained by
dividing (i) the sum of the products of (A) the number of years from the date of
determination to the date or dates of each successive scheduled principal
payment of such Indebtedness multiplied by (B) the amount of each such principal
payment by (ii) the sum of all such principal payments.
"Bankruptcy Law" means Title 11, United States Code, as amended, or any
similar United States Federal or State law relating to bankruptcy, insolvency,
receivership, winding-up, liquidation, reorganization or relief of debtors or
any amendment to, succession to or change in any such law.
"Capital Lease Obligation" of any Person means any obligation of such
Person and its Subsidiaries on a Consolidated basis under any capital lease of
real or personal property which, in accordance with GAAP, has been recorded on
the balance sheet of such Person as a capitalized lease obligation.
-72-
<PAGE>
"Capital Stock" of any Person means any and all shares, interests,
participations or other equivalents (however designated) of such Person's
capital stock or equity interests.
"Cash Equivalent" means (i) any security, maturing not more than six
months after the date of acquisition, issued by the United States of America, or
an instrumentality or agency thereof and guaranteed fully as to principal,
premium, if any, and interest by the United States of America, (ii) any
certificate of deposit, time deposit, money market account or bankers'
acceptance, maturing not more than six months after the date of acquisition,
issued by any commercial banking institution that is a member of the Federal
Reserve System and that has combined capital and surplus and undivided profits
of not less than $500,000,000, whose debt has a rating, at the time as of which
any investment therein is made, of "P-1" (or higher) according to Moody's
Investors Service, Inc. or any successor rating agency, or "A-1" (or higher)
according to Standard & Poor's Corporation or any successor rating agency and
(iii) commercial paper, maturing not more than three months after the date of
acquisition, issued by any corporation (other than an Affiliate or Subsidiary of
the Company) organized and existing under the laws of the United States of
America with a rating, at the time as of which any investment therein is made,
of "P-1" (or higher) according to Moody's Investors Service, Inc. or any
successor rating agency, or "A-1" (or higher) according to Standard & Poor's
Corporation or any successor rating agency.
"Code" means the Internal Revenue Code of 1986, as amended.
"Commission" means the Securities and Exchange Commission, as from time
to time constituted, created under the Exchange Act, or if at any time after the
date of the Indenture such Commission is not existing and performing the duties
now assigned to it under the Trust Indenture Act, then the body performing such
duties at such time.
"Company" means Genesis Health Ventures, Inc., a corporation
incorporated under the laws of Pennsylvania, until a successor Person shall have
become such pursuant to the applicable provisions of the Indenture, and
thereafter "Company" shall mean such successor Person. To the extent necessary
to comply with the requirements of the provisions of Trust Indenture Act
Sections 310 through 317 as they are applicable to the Company, the term
"Company" shall include any other obligor with respect to the Notes for purposes
of complying with such provisions.
"Consolidated EBITDA" of any Person means with respect to any
determination date, Consolidated Net Income before extraordinary items and gains
or losses realized in connection with Asset Sales, plus (i) Consolidated Income
Tax Expense, plus (ii) consolidated depreciation expense, plus (iii)
consolidated amortization expense, plus (iv) Consolidated Interest Expense, plus
(v) all other non-cash items reducing Consolidated Net Income of such Person and
its Subsidiaries, determined on a consolidated basis in accordance with GAAP,
and less all non-cash items increasing Consolidated Net Income of such Person
and its Subsidiaries, determined on a consolidated basis in accordance with
GAAP, in each case, for such Person's prior four full fiscal quarters for which
financial results have been reported immediately preceding the determination
date.
"Consolidated Income Tax Expense" means for any period, as applied to
any Person, the provision for federal, state, local and foreign income taxes of
such Person and its Consolidated Subsidiaries for such period as determined in
accordance with GAAP.
"Consolidated Interest Expense" of any Person means, without
duplication, for any period, as applied to any Person, the sum of (i) the
interest expense of such Person and its Consolidated Subsidiaries for such
period, on a consolidated basis, including, without limitation, (A) amortization
of debt discount, (B) the net
-73-
<PAGE>
cost under interest rate contracts (including amortization of discounts), (C)
the interest portion of any deferred payment obligation and (D) accrued
interest, plus (ii) the interest component of the Capital Lease Obligations
paid, accrued and/or scheduled to be paid, or accrued by such Person during such
period, in each case as determined in accordance with GAAP, plus (iii) Preferred
Stock dividends in respect of Preferred Stock of the Company or any Subsidiary
held by Persons other than the Company or a Wholly Owned Subsidiary. For
purposes of clause (c) of the preceding sentence, dividends shall be deemed to
be an amount equal to the actual dividends paid divided by one minus the
applicable actual combined Federal, state, local and foreign income tax rate of
the Company and its Consolidated Subsidiaries (expressed as a decimal).
"Consolidated Net Income (Loss)" of any Person means, for any period,
the Consolidated net income (or loss) of the Company and its Consolidated
Subsidiaries for such period as determined in accordance with GAAP, adjusted, to
the extent included in calculating such net income (loss), by excluding (i) all
extraordinary gains or losses (less all fees and expenses relating thereto),
(ii) the portion of net income of the Company and its Consolidated Subsidiaries
allocable to investments in unconsolidated Persons to the extent that cash
dividends or distributions have not actually been received by the Company or one
of its Consolidated Subsidiaries, (iii) net income (or loss) of any Person
combined with the Company or any of its Subsidiaries in a "pooling of interests"
basis attributable to any period prior to the date of combination, (iv) any gain
or loss, net of taxes, realized upon the termination of any employee pension
benefit plan, (v) any gains or losses (less all fees and expenses relating
thereto) in respect of dispositions of assets other than in the ordinary course
of business, or (vi) the net income of any Subsidiary to the extent that the
declaration of dividends or similar distributions by that Subsidiary of that
income is not at the time permitted, directly or indirectly, by operation of the
terms of its charter or any agreement, instrument, judgment, decree, order,
statute, rule or governmental regulations applicable to that Subsidiary or its
shareholders.
"Consolidated Net Worth" of any Person means the Consolidated
stockholders' equity (excluding Redeemable Capital Stock) of such Person and its
Consolidated Subsidiaries, as set forth on the most recent consolidated balance
sheet of such Person and its Consolidated Subsidiaries determined in accordance
with GAAP.
"Consolidated Rental Payments" of any Person means, for any period, the
aggregate rental obligations of such Person and its Consolidated Subsidiaries
(not including taxes, insurance, maintenance and similar expenses that the
lessee is obligated to pay under the terms of the relevant leases), determined
on a consolidated basis in conformity with GAAP, payable in respect of such
period under Attributable Debt or leases of real or personal property not
constituting Attributable Debt (net of income from subleases thereof, not
including taxes, insurance, maintenance and similar expenses that the sublessee
is obligated to pay under the terms of such sublease), whether or not such
obligations are reflected as liabilities or commitments on a consolidated
balance sheet of such Person and its Subsidiaries or in the notes thereto,
excluding, however, in any event, (i) that portion of Consolidated Interest
Expense of such Person representing payments by such person or any of its
Consolidated Subsidiaries in respect of Capital Lease Obligations (net of
payments to such Person or any of its Consolidated Subsidiaries under subleases
qualifying as capitalized lease subleases to the extent that such payments would
be deducted in determining Consolidated Interest Expense) and (ii) the aggregate
amount of amortization of obligations of such Person and its Consolidated
Subsidiaries in respect of such Capital Lease Obligations for such period (net
of payments to such Person or any of its Consolidated Subsidiaries and subleases
qualifying as capitalized lease subleases to the extent that such payments would
be deducted in determining such amortization amount).
"Consolidated Total Assets" of any Person means the Consolidated total
assets of such Person and its Consolidated Subsidiaries, as set forth on the
most recent consolidated balance sheet of such Person and its Consolidated
Subsidiaries determined in accordance with GAAP.
-74-
<PAGE>
"Consolidation" means, with respect to any Person, the consolidation of
the accounts of such Person and each of its subsidiaries if and to the extent
the accounts of such Person and each of its subsidiaries would normally be
consolidated with those of such Person, all in accordance with GAAP. The term
"Consolidated" shall have a similar meaning.
"Credit Facility" means (i) the Credit Agreement, dated as of November 22, 1993,
among the Company, the other borrowers parties thereto, the lenders parties
thereto, Mellon Bank, N.A. as issuing bank and Mellon Bank, N.A. as agent for
such lenders and such issuing bank, as the same may be amended, restated,
renewed, extended, restructured, supplemented or otherwise modified from time to
time, (ii) any Loan Documents (as defined in the Credit Agreement as in effect
from time to time) and any other documents or instruments executed by the
Company pursuant to or in connection with the Credit Agreement and (iii) any
credit agreement, loan agreement, note purchase agreement, indenture or other
agreement, document or instrument refinancing, refunding or otherwise replacing
the Credit Agreement or any other agreement deemed a Credit Facility under
clauses (i), (ii) or (iii) hereof, whether or not with the same agent, trustee,
representative, lenders or holders, regardless of whether the Credit Agreement
or Credit Facility or any portion thereof was outstanding or in effect at the
time of such restatement, renewal, extension, restructuring, supplement or
modification (including without limitation, the Second Amended and Restated
Credit Agreement, dated October 7, 1996, among the Company, the other borrowers
parties thereto, the lenders parties thereto, Mellon Bank, N.A. as issuing bank
and Mellon Bank, N.A. as agent for such lenders and the Amended and Restated
Participation Agreement, dated October 7, 1996, among Genesis ElderCare
Properties, Inc., Mellon Financial Services Corporation #4, the lenders parties
thereto and Mellon Bank, N.A. as agent for such lenders, as the same may be
amended, restated, renewed, extended, restructured, supplemented and otherwise
modified from time to time). Without limiting the generality of the foregoing,
the term "Credit Facility" shall include any amendment, restatement, renewal,
extension, restructuring, supplement or modification to any Credit Facility and
all refundings, refinancings and replacements of any Credit Facility, including
any agreement (a) extending the maturity of any Indebtedness incurred thereunder
or contemplated thereby, (b) adding or deleting borrowers or guarantors
thereunder, so long as such borrowers and guarantors include one or more of the
Company and its Subsidiaries and their respective successors and assigns,
provided that on the date thereof the addition of such borrower or guarantor
would not be prohibited by the definition of "Permitted Indebtedness" and the
provisions described under "-- Certain Covenants--Limitation on Liens securing
Subordinated Indebtedness" and "-- Certain Covenants--Limitation on Issuance of
Guarantees of Subordinated Indebtedness," (c) increasing the amount of
Indebtedness incurred thereunder or available to be borrowed thereunder provided
such increase is permitted to be incurred under the definition of "Permitted
Indebtedness" or is or will be permitted to be incurred under the provisions
described under "-- Certain Covenants--Limitation on Indebtedness" or (d)
otherwise altering the terms and conditions thereof in a manner not prohibited
by the definition of "Permitted Indebtedness" and the provisions described under
"-- Certain Covenants--Limitation on Liens Securing Subordinated Indebtedness",
"-- Certain Covenants-- Limitation on Issuance of Guarantees of Subordinated
Indebtedness" and "-- Certain Covenants--Limitation on Dividends and Other
Payment Restrictions Affecting Subsidiaries" and as such agreement may be
amended, renewed, extended, substituted, refinanced, replaced or otherwise
modified from time to time, and includes any agreement extending the maturity of
all or any portion of the Indebtedness thereunder.
"Default" means any event which is, or after notice or passage of time
or both would be, an Event of Default.
"Eligible Accounts Receivables" as of any date means the book value of
all accounts receivables of the Company and its Subsidiaries that would be shown
on a Consolidated balance sheet of the Company and its Subsidiaries prepared on
such date in accordance with GAAP, which are not more than 180 days past their
due date and were entered into on normal payment terms.
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
-75-
<PAGE>
"Fair Market Value" means, with respect to any asset or property, the
sale value that would be obtained in an arm's-length transaction between an
informed and willing seller under no compulsion to sell and an informed and
willing buyer.
"Fiscal Year" with respect to the Company shall mean the fiscal year of
the Company.
"Fixed Charge Coverage Ratio" of any Person means, for any period, the
ratio of (i) the sum of Consolidated Net Income, Consolidated Interest Expense,
Consolidated Income Tax Expense, and one-third of Consolidated Rental Payments
plus, without duplication, all depreciation, amortization and all other non-cash
charges (excluding any such non-cash charge constituting an extraordinary item
or loss or any non-cash charge which requires an accrual of or a reserve for
cash charges for any future period), in each case, for such period, of the
Company and its Subsidiaries on a Consolidated basis, as determined in
accordance with GAAP to (ii) the sum of (A) Consolidated Interest Expense for
such period and (B) one-third of Consolidated Rental Payments for such period;
provided that in making such computation, the Consolidated Interest Expense
attributable to interest on any Indebtedness computed on a pro forma basis and
bearing a floating interest rate shall be computed as if the rate in effect on
the date of computation had been the applicable rate for the entire period.
"Generally Accepted Accounting Principles" or "GAAP" means generally
accepted accounting principles in the United States, consistently applied, as in
effect on the date of the Indenture.
"Guarantee" means the guarantee by any Guarantor which guarantees the
Indenture Obligations pursuant to a guarantee given in accordance with the
Indenture.
"Guaranteed Debt" of any Person means, without duplication, all
Indebtedness of any other Person guaranteed directly or indirectly in any manner
by such Person, or in effect guaranteed directly or indirectly by such Person
through an agreement (i) to pay or purchase such Indebtedness or to advance or
supply funds for the payment or purchase of such Indebtedness, (ii) to purchase,
sell or lease (as lessee or lessor) property, or to purchase or sell services,
primarily for the purpose of enabling the debtor to make payment of such
Indebtedness or to assure the holder of such Indebtedness against loss, (iii) to
supply funds to, or in any other manner invest in, the debtor (including any
agreement to pay for property or services without requiring that such property
be received or such services be rendered), (iv) to maintain working capital or
equity capital of the debtor, or otherwise to maintain the net worth, solvency
or other financial condition of the debtor or (v) otherwise to assure a creditor
against loss; provided that the term "Guaranteed Debt" shall not include
endorsements for collection or deposit, in either case in the ordinary course of
business.
"Guarantor" means any Person which guarantees the Indenture Obligations
pursuant to the Indenture.
"Healthcare Related Business" means a business, the majority of whose
revenues result from healthcare, long-term care, or managed care related
businesses or facilities, including businesses which provide insurance relating
to the costs of healthcare, long-term care or managed care services.
"Indebtedness" means, with respect to any Person, without duplication,
(i) all indebtedness of such Person for borrowed money or for the deferred
purchase price of property or services, excluding any trade payables and other
accrued current liabilities arising in the ordinary course of business, but
including, without limitation, all obligations, contingent or otherwise, of such
Person in connection with any letters of credit or acceptances issued under
letter of credit facilities, acceptance facilities or other similar facilities
and in connection with any agreement to purchase, redeem, exchange, convert or
otherwise acquire for value any Capital Stock of such Person, or any warrants,
rights or options to acquire such Capital Stock, now or
-76-
<PAGE>
hereafter outstanding, (ii) all obligations of such Person evidenced by bonds,
notes, debentures or other similar instruments, (iii) every obligation of such
Person issued or contracted for as payment in consideration of the purchase by
such Person or an Affiliate of such Person of the Capital Stock or substantially
all of the assets of another Person or in consideration for the merger or
consolidation with respect to which such Person or an Affiliate of such Person
was a party (other than any obligation of such Person to pay an amount to
another Person based on income in respect of Capital Stock or assets which were
purchased or in respect of such merger to which such Person or an Affiliate was
a party except for such obligations which are required in accordance with GAAP
to be classified as a liability on the balance sheet of such Person), (iv) all
indebtedness created or arising under any conditional sale or other title
retention agreement with respect to property acquired by such Person (even if
the rights and remedies of the seller or lender under such agreement in the
event of default are limited to repossession or sale of such property), but
excluding trade payables and other accrued current liabilities arising in the
ordinary course of business, (v) all obligations under Interest Rate Contracts
of such Person, (vi) all Capital Lease Obligations of such Person, (vii) all
indebtedness referred to in clauses (i) through (vi), (ix) and (x) of other
Persons and all dividends of other Persons, the payment of which is secured by
(or for which the holder of such Indebtedness has an existing right, contingent
or otherwise, to be secured by) any Lien, upon any property (including, without
limitation, accounts and contract rights) owned by such Person, even though such
Person has not assumed or become liable for the payment of such Indebtedness,
(viii) all Guaranteed Debt of such Person, (ix) all Redeemable Capital Stock
valued at the greater of its voluntary or involuntary maximum fixed repurchase
price plus accrued and unpaid dividends and (x) all Attributable Debt of such
Person. For purposes hereof, the "maximum fixed repurchase price" of any
Redeemable Capital Stock which does not have a fixed repurchase price shall be
calculated in accordance with the terms of such Redeemable Capital Stock as if
such Redeemable Capital Stock were purchased on any date on which Indebtedness
shall be required to be determined pursuant to the Indenture, and if such price
is based upon, or measured by, the Fair Market Value of such Redeemable Capital
Stock, such Fair Market Value to be determined in good faith by the Board of
Directors of the issuer of such Redeemable Capital Stock.
"Indenture Obligations" means the obligations of the Company and any
other obligor under the Indenture or under the Notes, including any Guarantor,
to pay principal of, premium, if any, and interest when due and payable, and all
other amounts due or to become due under or in connection with the Indenture,
the Notes and the performance of all other obligations to the Trustee and the
holders under the Indenture and the Notes, according to the terms thereof.
"Interest Rate Contracts" means interest rate swap agreements, interest
rate cap agreements, interest rate collar agreements, interest rate insurance,
and other agreements or arrangements designed to provide protection against
fluctuations in interest rates.
"Investments" means, with respect to any Person, directly or
indirectly, any advance, loan or other extension of credit (including any
guarantee) or capital contribution to (by means of any transfer of cash or other
property (tangible or intangible) to others, or any payment for property or
services for the account or use of others or otherwise), or any purchase,
acquisition or ownership by such Person of any Capital Stock, bonds, notes,
debentures or other securities (including, without limitation, any interests in
any partnership or joint venture) issued or owned by any other Person.
"Lien" means any mortgage, charge, pledge, lien (statutory or
otherwise), privilege, security interest, hypothecation or other encumbrance
upon or with respect to any property of any kind, real or personal, movable or
immovable, now owned or hereafter acquired.
-77-
<PAGE>
"Maturity" when used with respect to any Note means the date on which
the principal of such Note becomes due and payable as therein provided or as
provided in the Indenture, whether at Stated Maturity, or any redemption date
and whether by declaration of acceleration, Offer in respect of Excess Proceeds,
Change in Control Offer in respect of a Change in Control, call for redemption
or otherwise.
"Net Cash Proceeds" means, with respect to any Asset Sale by any
Person, the proceeds thereof in the form of cash or Cash Equivalents including
payments in respect of deferred payment obligations when received in the form
of, or stock or other assets when disposed for, cash or Cash Equivalents (except
to the extent that such obligations are financed or sold with recourse to the
Company or any Subsidiary) net of (i) brokerage commissions and other reasonable
fees and expenses (including fees and expenses of counsel and investment
bankers) related to such Asset Sale, (ii) provisions for all taxes payable as a
result of such Asset Sale, (iii) payments made to retire Indebtedness where
payment of such Indebtedness is secured by the assets or properties the subject
of such Asset Sale, (iv) amounts required to be paid to any Person (other than
the Company or any Subsidiary) owning a beneficial interest in the assets
subject to the Asset Sale and (v) appropriate amounts to be provided by the
Company or any Subsidiary, as the case may be, as a reserve, in accordance with
GAAP, against any liabilities associated with such Asset Sale and retained by
the Company or any Subsidiary, as the case may be, after such Asset Sale,
including, without limitation, pension and other post-employment benefit
liabilities, liabilities related to environmental matters and liabilities under
any indemnification obligations associated with such Asset Sale, all as
reflected in an Officers' Certificate delivered to the Trustee.
"Permitted Indebtedness" means:
(a) Indebtedness of up to $300,000,000 outstanding principal amount
under the Credit Facility;
(b) any guarantee by the Company or any Subsidiary under the Credit
Facility;
(c) Indebtedness (other than Indebtedness included in clause (d) below)
in existence on the date of the Indenture;
(d) Indebtedness of the Company pursuant to the Convertible Debentures;
(e) Indebtedness of the Company pursuant to the Notes;
(f) Indebtedness evidenced by letters of credit issued in the ordinary
course of business consistent with past practice to support the Company's or any
Subsidiary's insurance or self-insurance obligations (including to secure
workers' compensation and other similar insurance coverages);
(g) Interest Rate Contracts, to the extent that the notional principal
amount of such obligations does not exceed the amount of Indebtedness
outstanding or committed to be incurred on the date such Interest Rate Contracts
are entered into;
(h) Indebtedness of the Company to a Wholly Owned Subsidiary and
Indebtedness of a Subsidiary to the Company or another Subsidiary; provided,
however, that any subsequent issuance or transfer of any Capital Stock or any
other event which results in any such Wholly Owned Subsidiary ceasing to be a
Wholly Owned Subsidiary or any other subsequent transfer of any such
Indebtedness (except to the Issuer or a Wholly Owned Subsidiary) shall be
deemed, in each case to be incurred and shall be treated as an incurrence for
purposes of the covenant described under "-- Limitation on Indebtedness" at the
time the Wholly Owned Subsidiary in question ceased to be a Wholly Owned
-78-
<PAGE>
Subsidiary;
(i) any guarantees of Indebtedness by a Subsidiary entered into in
accordance with "-- Certain Covenants--Limitation on Issuance of Guarantees of
Subordinated Indebtedness";
(j) Indebtedness incurred by the Company or any Subsidiary consisting
of Purchase Money Obligations in an amount not to exceed $15,000,000 at any one
time outstanding;
(k) Indebtedness incurred by the Company or any Wholly Owned Subsidiary
consisting of Capital Lease Obligations in an amount not to exceed $15,000,000
at any time outstanding;
(l) Indebtedness of the Company or any Wholly Owned Subsidiary, in
addition to that described in clauses (a) through (k) of this definition of
"Permitted Indebtedness," in an aggregate principal amount outstanding at any
given time not to exceed $40,000,000; and
(m) any renewals, extensions, substitutions, refundings, refinancings
or replacements of any Indebtedness described in clauses (a) through (e) of this
definition of "Permitted Indebtedness," including any successive renewals,
extensions, substitutions, refundings, refinancings or replacements, so long as
(i) any such new Indebtedness shall be in a principal amount that does not
exceed the principal amount (or, if such Indebtedness being refinanced provides
for an amount less than the principal amount thereof to be due and payable upon
a declaration of acceleration thereof, such lesser amount as of the date of
determination) so refinanced, plus the amount of any premium required to be paid
under the terms of the instrument governing such Indebtedness being refinanced
or the amount of any premium reasonably determined by the Company as necessary
to accomplish such refinancing through means of a tender offer or privately
negotiated transactions and, in each case, actually paid, plus the amount of
expenses of the Company incurred in connection with such refinancing; (ii) in
the case of any refinancing of Subordinated Indebtedness, such new Indebtedness
is made subordinate to the Notes at least to the same extent as the Indebtedness
being refinanced; and (iii) any such new Subordinated Indebtedness has an
Average Life to Stated Maturity longer than the Average Life to Stated Maturity
of the refinanced Subordinated Indebtedness and a final Stated Maturity later
than the final Stated Maturity of the Notes.
"Permitted Investment" means (i) the Notes or any Guarantees; (ii)
Temporary Cash Investments; (iii) Indebtedness of the Company to a Subsidiary
and Indebtedness of a Subsidiary to the Company or another Subsidiary; (iv)
Investments in existence on the date of the Indenture; (v) Investments in any
Wholly Owned Subsidiary by the Company or any Wholly Owned Subsidiary or any
Investment in the Company by any Wholly Owned Subsidiary; (vi) receivables owing
to the Company and its Subsidiaries if created or acquired in the ordinary
course of business and payable or dischargeable in accordance with customary
trade terms; (vii) Investments in any Permitted Joint Ventures; (viii)
Investments in any Healthcare Related Businesses, provided that the Company is
able, at the time of such Investment and immediately after giving pro forma
effect thereto, to incur at least $1.00 of additional Indebtedness (other than
Permitted Indebtedness) in compliance with the "Limitation on Indebtedness"
covenant; (ix) Investments acquired or retained from another Person in
connection with any sale, conveyance, transfer, lease or other disposition of
any properties or assets to such Person in accordance with the covenant
described under "-- Disposition of Asset Sales"; and (x) in addition to
Permitted Investments described in the foregoing clauses (i) through (ix),
Investments in the aggregate amount of $20,000,000 at any one time outstanding.
"Permitted Joint Venture" means any Subsidiary which owns, operates or
services Healthcare Related Businesses.
-79-
<PAGE>
"Person" means any individual, corporation, limited or general
partnership, joint venture, association, joint stock company, trust,
unincorporated organization or government or any agency or political subdivision
thereof.
"Preferred Stock," as applied to any Person, means Capital Stock of any
class or classes (however designated) which is preferred as to the payment of
dividends or distributions, or as to the distribution of assets upon any
voluntary or involuntary liquidation or dissolution of such corporation, over
shares of Capital Stock of any other class of such corporation.
"Property" means, with respect to any Person, all types of real,
personal, tangible, intangible or mixed property owned by such Person whether or
not included in the most recent consolidated balance sheet of such Person.
"Purchase Money Obligations" means any Indebtedness of the Company or
any Subsidiary incurred to finance the acquisition or construction of any
Property or business (including Indebtedness incurred within 90 days following
such acquisition or construction), including Indebtedness of a Person existing
at the time such Person becomes a Subsidiary or assumed by the Company or a
Subsidiary in connection with the acquisition of assets from such Person;
provided, however, that any Lien on such Indebtedness shall not extend to any
Property other than the Property so acquired or constructed.
"Qualified Capital Stock" of any Person means any and all Capital Stock
of such Person other than Redeemable Capital Stock.
"Redeemable Capital Stock" means any Capital Stock that, either by its
terms, by the terms of any security into which it is convertible or exchangeable
or otherwise, is, or upon the happening of an event or passage of time would be,
required to be redeemed prior to any Stated Maturity of the principal of the
Notes or is redeemable at the option of the holder thereof at any time prior to
any such Stated Maturity, or is convertible into or exchangeable for debt
securities at any time prior to any such Stated Maturity at the option of the
holder thereof.
"Redemption Date" when used with respect to any Note to be redeemed
pursuant to any provision in the Indenture means the date fixed for such
redemption by or pursuant to the Indenture.
"Securities Act" means the Securities Act of 1933, as amended.
"Stated Maturity" when used with respect to any Indebtedness or any
installment of interest thereon, means the dates specified in such Indebtedness
as the fixed date on which the principal of such Indebtedness or such
installment of interest is due and payable.
"Subordinated Indebtedness" means Indebtedness of the Company
subordinated in right of payment to the Notes.
"Subsidiary" means (i) a corporation (A) at least 50% of the Voting
Stock of which is at the time owned, directly or indirectly, by the Company and
(B) of which the Company, directly or indirectly, has the right to elect a
majority of the members of the Board of Directors either as a result of the
ownership of a majority of the Voting Stock of such corporation or pursuant to a
shareholders or other voting agreement or (ii) any partnership, joint venture,
limited liability company or similar entity at least 50% of the total equity and
voting interests of which (x) is at the time owned, directly or indirectly, by
the Company whether in the
-80-
<PAGE>
form of membership, general, special or limited partnership, or otherwise and
(y) the Company or any Wholly Owned Subsidiary is a controlling general partner
or otherwise controls such entity.
"Temporary Cash Investments" means (i) any evidence of Indebtedness,
maturing not more than one year after the date of acquisition, issued by the
United States of America, or an instrumentality or agency thereof and guaranteed
fully as to principal, premium, if any, and interest by the United States of
America, (ii) any certificate of deposit, maturing not more than one year after
the date of acquisition, issued by, or time deposit of, a commercial banking
institution that is a member of the Federal Reserve System and that has combined
capital and surplus and undivided profits of not less than $500,000,000, whose
debt has a rating, at the time as of which any investment therein is made, of
"P-1" (or higher) according to Moody's Investors Service, Inc. or any successor
rating agency, or "A-1" (or higher) according to Standard & Poor's Corporation
or any successor rating agency and (iii) commercial paper, maturing not more
than one year after the date of acquisition, issued by a corporation (other than
an Affiliate or Subsidiary of the Company) organized and existing under the laws
of the United States of America with a rating, at the time as of which any
investment therein is made, of "P-1" (or higher) according to Moody's Investors
Service, Inc. or any successor rating agency, or "A-1" (or higher) according to
Standard & Poor's Corporation or any successor rating agency.
"Trust Indenture Act" means the Trust Indenture Act of 1939, as
amended.
"Voting Stock" means stock of the class or classes pursuant to which
the holders thereof have the general voting power under ordinary circumstances
to elect at least a majority of the board of directors, managers or trustees of
a corporation (irrespective of whether or not at the time stock of any other
class or classes shall have or might have voting power by reason of the
happening of any contingency).
"Wholly Owned Subsidiary" means a Subsidiary all the Capital Stock of
which is owned by the Company or another Wholly Owned Subsidiary.
Trustee
The Trustee is expected to be the trustee for the First Mortgage Bonds
and the 9 3/4% Notes.
Book-Entry Delivery and Form
The certificates representing the Notes will be issued in fully
registered form. Except as described in the next paragraph, the Notes initially
will be represented by a Global Note in fully registered form without interest
coupons (the "Global Note") and will be deposited with, or on behalf of, the
Depository Trust Company, New York, New York ("DTC") and registered in the name
of a nominee of DTC.
Existing Notes (i) originally purchased by or transferred to
institutional "accredited investors" (as defined in Rule 501(a)(1), (2), (3) or
(7) under the Securities Act) ("Institutional Accredited Investors") who are not
"qualified institutional buyers" (as defined in Rule 144A) ("Qualified
Institutional Buyers"), (ii) except as described below, purchased by or
transferred to Persons outside the United States pursuant to sales in accordance
with Regulation S under the Securities Act or (iii) held by Qualified
Institutional Buyers who elect to take physical delivery of their certificates
instead of holding their interest through the Global Note (and which are then
unable to trade through DTC) (collectively referred to herein as the "Non-Global
Purchasers"), will be in registered form without interest coupons ("Certificated
Notes"). Upon the transfer of Certificated Notes initially issued to a
Non-Global Purchaser or to a Qualified Institutional Buyer, such
-81-
<PAGE>
Certificated Notes will, unless the transferee requests otherwise or the Global
Note has previously been exchanged in whole for Certificated Notes, be exchanged
for an interest in the Global Note.
DTC has advised the Company as follows: DTC is a limited purpose trust
company organized under the laws of the State of New York, a "banking
organization" within the meaning of the New York Banking Law, a member of the
Federal Reserve System, a "clearing corporation" within the meaning of the
Uniform Commercial Code and a "Clearing Agency" registered pursuant to the
provision of Section 17A of the Exchange Act. DTC was created to hold securities
for its participants and facilitate the clearance and settlement of securities
transactions between participants through electronic book-entry changes in
accounts of its participants, thereby eliminating the need for physical movement
of certificates. Participants include securities brokers and dealers, banks,
trust companies and clearing corporations and certain other organizations.
Indirect access to the DTC system is available to others such as banks, brokers,
dealers and trust companies that clear through or maintain a custodial
relationship with a participant, either directly or indirectly ("indirect
participants").
Upon the issuance of the Global Note, DTC or its custodian will credit,
on its internal system, the respective principal amount of the individual
beneficial interests represented by such Global Note to the accounts of persons
who have accounts with such depositary. Ownership of beneficial interests in the
Global Note will be limited to persons who have accounts with DTC
("participants") or persons who hold interests through participants. Ownership
of beneficial interests in the Global Note will be shown on, and the transfer of
that ownership will be effected only through, records maintained by DTC or its
nominee (with respect to interests of participants) and the records of
participants (with respect to interests of persons other than participants).
So long as DTC or its nominee is the registered owner or holder of the
Global Note, DTC or such nominee, as the case may be, will be considered the
sole record owner or holder of the Notes represented by such Global Note for all
purposes under the Indenture and the Notes. No beneficial owners of an interest
in the Global Note will be able to transfer that interest except in accordance
with DTC's applicable procedures, in addition to those provided for under the
Indenture. Payments of the principal of, premium, if any, and interest on the
Global Note will be made to DTC or its nominee, as the case may be, as the
registered owner thereof. Neither the Company, the Trustee, nor any paying agent
will have any responsibility or liability for any aspect of the records relating
to or payments made on account of beneficial ownership interests in the Global
Note or for maintaining, supervising or reviewing any records relating to such
beneficial ownership interests.
The Company expects that DTC or its nominee, upon receipt of any
payment of principal, premium, if any, or interest in respect of the Global Note
will credit participants' accounts with payments in amounts proportionate to
their respective beneficial ownership interests in the principal amount of such
Global Note, as shown on the records of DTC or its nominee. The Company also
expects that payments by participants to owners of beneficial interests in such
Global Note held through such participants will be governed by standing
instructions and customary practices, as is now the case with securities held
for the accounts of customers registered in the names of nominees for such
customers. Such payments will be the responsibility of such participants.
Transfers between participants in DTC will be effected in the ordinary
way in accordance with DTC rules. If a Holder requires physical delivery of
Certificated Notes for any reason, including to sell Notes to persons in states
which require such delivery of such Notes or to pledge such Notes, such holder
must transfer its interest in the Global Note, in accordance with the normal
procedures of DTC and the procedures set forth in the Indenture. Neither the
Company nor the Trustee will have any responsibility for the
-82-
<PAGE>
performance by DTC or its participants or indirect participants of their
respective obligations under the rules and procedures governing their
operations. Subject to certain conditions, any person having a beneficial
interest in the Global Note may, upon request to the Trustee, exchange such
beneficial interest for Notes in the form of Certificated Notes. Upon any such
issuance, the Trustee is required to register such Certificated Notes in the
name of, and cause the same to be delivered to, such person or persons (or the
nominee of any thereof). In addition, if DTC is at any time unwilling or unable
to continue as a depositary for the Global Note and a successor depositary is
not appointed by the Company within 90 days, the Company will issue Certificated
Notes in exchange for the Global Note.
PLAN OF DISTRIBUTION
Each Participating Broker-Dealer that receives Exchange Notes for its
own account pursuant to the Exchange Offer must acknowledge that it will deliver
a prospectus in connection with any resale of such Exchange Notes. This
Prospectus, as it may be amended or supplemented from time to time, may be used
by a Participating Broker-Dealer in connection with resales of Exchange Notes
received in exchange for Existing Notes where such Existing Notes were acquired
as a result of market-making activities or other trading activities. The Company
has agreed that it will furnish to each Participating Broker-Dealer as many
copies of this Prospectus, as amended or supplemented, as such Participating
Broker-Dealer may reasonably request. In addition, each Participating
Broker-Dealer shall be authorized to deliver this Prospectus in connection with
the sale or transfer of the Exchange Notes. In addition, all dealers effecting
transactions in the Exchange Notes may be required to deliver a Prospectus.
The Company will not receive any proceeds from any sales of the
Exchange Notes by Participating Broker-Dealers. Exchange Notes received by
Participating Broker-Dealers for their own account pursuant to the Exchange
Offer may be sold from time to time in one or more transactions in the
over-the-counter market, in negotiated transactions, through the writing of
options on the Exchange Notes or a combination of such methods of resale, at
market prices prevailing at the time of resale, at prices related to such
prevailing market prices or negotiated prices. Any such resale may be made
directly to purchasers or to or through brokers or dealers who may receive
compensation in the form of commissions or concessions from any such
Participating Broker-Dealer and/or the purchasers of any such Exchange Notes.
Any Participating Broker-Dealer that resells the Exchange Notes that were
received by it for its own account pursuant to the Exchange Offer and any broker
or dealer that participates in a distribution of such Exchange Notes may be
deemed to be an "underwriter" within the meaning of the Securities Act and any
profit on any such resale of Exchange Notes and any omissions or concessions
received by any such persons may be deemed to be underwriting compensation under
the Securities Act. The Letter of Transmittal states that by acknowledging that
it will deliver and by delivering a prospectus, a Participating Broker-Dealer
will not be deemed to admit that it is an "underwriter" within the meaning of
the Securities Act.
The Company will promptly send additional copies of this Prospectus and
any amendment or supplement to this Prospectus to any Participating
Broker-Dealer that requests such documents in the Letter of Transmittal. See
"Exchange Offer -- Purpose and Effect of the Exchange Offer."
LEGAL MATTERS
Certain legal matters with respect to the legality of the issuance of
the Exchange Notes offered hereby will be passed upon for the Company by Blank
Rome Comisky & McCauley, Philadelphia, Pennsylvania. As to matters of New York
laws, Blank Rome Comisky & McCauley will rely upon the
-83-
<PAGE>
opinion of Simpson Thacher & Bartlett (a partnership which includes professional
corporations) New York, New York. Stephen Luongo, a partner in Blank Rome
Comisky & McCauley, is the beneficial owner of 36,847 shares of Common Stock and
is a director of the Company.
EXPERTS
The consolidated financial statements of Genesis Health Ventures, Inc.
and subsidiaries as of September 30, 1994 and 1995, and for each of the years in
the three-year period ended September 30, 1995 have been included herein and in
the Registration Statement in reliance upon the reports of KPMG Peat Marwick
LLP, independent certified public accountants, appearing elsewhere herein or
incorporated by reference herein and upon the authority of said firm as experts
in accounting and auditing.
The financial statements of McKerley Health Care Centers, Inc. for the
years ended December 31, 1994 and 1993, the financial statements of McKerley
Health Facilities for the years ended December 31, 1994 and 1993, and the
financial statements and other financial information of McKerley Health Care
Center -- Concord Limited Partnership for the period from March 11, 1994 to
December 31, 1994, appearing in Genesis Health Ventures, Inc.'s Current Report
on Form 8-K/A dated April 5, 1996, and the financial statements of National
Health Care Affiliates, Inc. and Related Entities for the year ended December
31, 1995, appearing in Genesis Health Venture, Inc.'s Current Report on Form
8-K/A dated May 3, 1996, have been audited by Ernst & Young LLP, independent
auditors, as set forth in their reports thereon included therein and
incorporated herein by reference in reliance upon such reports given upon the
authority of such firm as experts in accounting and auditing.
The consolidated financial statements of Geriatric & Medical Companies,
Inc. and subsidiaries as of May 31, 1996 and for each of the years in the
two-year period ended May 31, 1996 appearing in the Genesis Health Ventures,
Inc.'s Current Report on Form 8-K/A dated July 11, 1996 have been audited by BDO
Seidman, LLP, independent auditors, as set forth in their report therein and
incorporated herein by reference in reliance upon such reports given upon the
authority of such firm as experts in accounting and auditing.
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in
accordance therewith files reports, proxy statements and other information with
the Securities and Exchange Commission (the "Commission") . Such reports, proxy
statements and other information can be inspected and copied at the public
reference facilities maintained by the Commission at Room 1024, 450 Fifth
Street, N.W., Washington, D.C. 20549, and at the Commission's regional offices
located at Northwestern Atrium Center, 500 West Madison Street, Suite 1400,
Chicago, Illinois 60621 and 75 Park Place, 14th Floor, New York, New York 10007.
Copies of such material can be obtained from the Public Reference Section of the
Commission at 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed
rates.
In addition, the Company's Common Stock, Convertible Debentures and
9 3/4% Notes are listed on the New York Stock Exchange. The Company's reports,
proxy statements and other information filed under the Exchange Act may also be
inspected and copied at the offices of the New York Stock Exchange, 120 Broad
Street, New York, New York 10005.
This Prospectus constitutes a part of a Registration Statement filed by
the Company with the Commission under the Securities Act. This Prospectus omits
certain of the information contained in that
-84-
<PAGE>
Registration Statement, and reference is hereby made to that Registration
Statement and the exhibits filed therewith for further information with respect
to the Company and the Common Stock offered hereby. Any statements contained
herein concerning the provisions of any document are not necessarily complete,
and, in each instance, reference is made to the copy of such document filed as
an exhibit to the Registration Statement or otherwise filed with the Commission.
Each such statement is qualified in its entirety by such reference.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents and portions of documents filed by the Company
with the Commission are hereby incorporated by reference into this Prospectus
and made a part hereof: (i) the Annual Report on Form 10-K for the year ended
September 30, 1995; (ii) the Quarterly Reports on Form 10-Q for the quarters
ended December 31, 1995, March 31, 1996 and June 30, 1996, as amended; (iii) the
Current Report on Form 8-K dated November 30, 1995, as amended; (iv) the Current
Report on Form 8-K dated April 21, 1996; (v) the Current Report on Form 8-K
dated May 3, 1996, as amended; (vi) the Current Report on Form 8-K dated May 8,
1996; (vii) the Current Report on Form 8-K dated July 11, 1996, as amended;
(viii) the Current Report on Form 8-K dated July 26, 1996; (ix) the Current
Report on Form 8-K dated October 2, 1996; and (x) the Current Report on Form 8-K
dated October 11, 1996.
All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and
prior to the termination of the offering of the Common Stock offered hereby
shall be deemed to be incorporated by reference in this Prospectus and to be
part of this Prospectus from the date of filing of such documents. Any statement
contained herein or in any document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any such statement so
modified or superseded shall not be deemed to constitute a part of this
Prospectus, except as so modified or superseded.
The Company hereby undertakes to provide without charge to each person,
including any beneficial owner to whom a copy of this Prospectus has been
delivered, upon written or oral request of such person, a copy of any or all of
the information that has been incorporated by reference in this Prospectus (not
including exhibits to such information unless such exhibits are specifically
incorporated by reference into the information that this Prospectus
incorporates). Written or oral requests for such copies should be directed to
Genesis Health Ventures, 148 West State Street, Kennett Square, Pennsylvania
19348, Attention: Investor Relations, telephone: (610) 444-6350.
-85-
<PAGE>
INDEX TO FINANCIAL INFORMATION
<TABLE>
<CAPTION>
Page
--------
<S> <C>
Consolidated Financial Statements
Genesis Health Ventures, Inc. and Subsidiaries
Independent Auditors' Report ...................................................................... F-3
Consolidated Balance Sheets as of September 30, 1994 and 1995 ..................................... F-4
Consolidated Statements of Operations for the years ended September 30, 1993, 1994 and 1995 ....... F-5
Consolidated Statements of Shareholders' Equity for the years ended September 30, 1993, 1994 and
1995 ............................................................................................. F-6
Consolidated Statements of Cash Flows for the years ended September 30, 1993, 1994 and 1995 ....... F-7
Notes to Consolidated Financial Statements ........................................................ F-8
Unaudited Condensed Consolidated Balance Sheet as of June 30, 1996 ................................ F-18
Unaudited Condensed Consolidated Statements of Operations for the three months and for the nine
months ended June 30, 1995 and 1996 .............................................................. F-19
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended June 30, 1995
and 1996 ......................................................................................... F-20
Notes to Condensed Unaudited Consolidated Financial Statements .................................... F-21
Pro Forma Condensed Consolidated Financial Information
Unaudited Pro Forma Condensed Consolidated Statements of Operations for the year ended September
30, 1995 and the nine months ended June 30, 1996 ................................................. F-23
Unaudited Pro Forma Condensed Consolidated Balance Sheet at June 30, 1996 ......................... F-31
</TABLE>
F-1
<PAGE>
(THIS PAGE INTENTIONALLY LEFT BLANK)
F-2
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
INDEPENDENT AUDITORS' REPORT
The Board of Directors
Genesis Health Ventures, Inc.:
We have audited the accompanying consolidated balance sheets of Genesis
Health Ventures, Inc. and subsidiaries as of September 30, 1994 and 1995, and
the related consolidated statements of operations, shareholders' equity, and
cash flows for each of the years in the three-year period ended September 30,
1995. These consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Genesis
Health Ventures, Inc. and subsidiaries as of September 30, 1994 and 1995, and
the results of their operations, and their cash flows for each of the years
in the three-year period ended September 30, 1995 in conformity with
generally accepted accounting principles.
As discussed in Note 8 to the consolidated financial statements, Genesis
Health Ventures, Inc. and subsidiaries adopted the provisions of Statement of
Financial Accounting Standards No. 109, Accounting for Income Taxes, in 1994.
KPMG Peat Marwick LLP
Philadelphia, Pennsylvania
November 29, 1995, except for Note 2
which is as of November 30, 1995, and
Note 13 which is as of March 29, 1996
F-3
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
September 30, September 30,
1994 1995
--------------- ---------------
<S> <C> <C>
Assets
Current assets:
Cash and equivalents ........................ $ 3,817,425 $ 10,387,506
Accounts receivable, net of allowance for
doubtful accounts of $4,553,364 in 1994 and
$6,178,673 in 1995 ........................ 72,920,814 101,123,573
Other receivables ........................... 22,107,924 36,739,637
Cost report receivables ..................... 12,035,953 26,270,819
Inventory ................................... 6,231,118 9,600,551
Prepaid expenses and other current assets ... 3,038,699 6,934,725
--------------- ---------------
Total current assets ...................... 120,151,933 191,056,811
--------------- ---------------
Property, plant and equipment, net ............... 243,549,782 243,660,567
Funds held by trustee ............................ 1,121,000 1,121,000
Contract rights, net ............................. 3,105,325 2,217,522
Other long-term assets ........................... 41,851,014 49,603,457
Goodwill, net .................................... 101,919,173 112,729,811
--------------- ---------------
Total assets ................................. $511,698,227 $600,389,168
=============== ===============
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable ............................ $ 10,709,815 $ 19,401,254
Accrued expenses ............................ 14,251,912 13,951,011
Current installments of long-term debt ...... 9,942,806 2,538,675
Accrued compensation ........................ 14,589,921 13,656,490
Interest .................................... 3,321,236 5,513,003
Income taxes payable ........................ 481,805 1,882,594
--------------- ---------------
Total current liabilities ................. 53,297,495 56,943,027
--------------- ---------------
Long-term debt ................................... 250,806,778 308,052,441
Deferred income taxes ............................ 9,268,272 8,698,272
Deferred gain and other long-term liabilities .... 2,859,522 5,147,891
Shareholders' equity:
Common stock, par $.02, authorized 60,000,000
shares; issued and outstanding 21,829,365
and 21,773,125 at September 30, 1994;
22,081,267 and 22,035,666 at September 30,
1995 ...................................... 291,057 294,460
Additional paid-in capital .................. 153,573,281 155,927,049
Retained earnings ........................... 41,961,608 65,569,282
Treasury stock, at cost ..................... (359,786) (243,254)
--------------- ---------------
Total shareholders' equity .................. 195,466,160 221,547,537
--------------- ---------------
Total liabilities and shareholders' equity .. $511,698,227 $600,389,168
=============== ===============
</TABLE>
See accompanying notes to consolidated financial statements.
F-4
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
Year ended September 30,
------------------------------------------------
1993 1994 1995
------------- ------------ ------------
<S> <C> <C> <C>
Net revenues:
Basic healthcare services . $133,370,007 $240,263,861 $278,120,711
Specialty medical services 75,226,895 125,717,823 180,326,730
Management services and
other ................... 11,212,275 22,634,576 27,945,341
----------- ------------ ------------
Total net revenues ...... 219,809,177 388,616,260 486,392,782
----------- ------------ ------------
Operating expenses:
Salaries, wages, and
benefits ................ 112,293,001 192,533,861 237,610,082
Other operating expenses .. 61,791,025 109,059,421 137,944,784
General corporate expense . 7,595,972 17,649,907 17,584,487
Depreciation and amortization .. 7,157,110 14,982,173 18,792,823
Lease expense .................. 7,026,491 11,376,029 13,798,412
Interest expense, net .......... 5,042,254 15,305,139 20,366,456
----------- ------------ ------------
Earnings before income
taxes, extraordinary
items and cumulative
effect of a change in
accounting principle .... 18,903,324 27,709,730 40,295,738
Income taxes ................... 6,994,230 10,018,535 14,764,941
----------- ------------ ------------
Earnings before
extraordinary items and
cumulative effect of a
change in accounting
principle ............... 11,909,094 17,691,195 25,530,797
Extraordinary items, net of tax -- (552,585) (1,923,123)
Cumulative effect of a change in
accounting principle ......... -- 534,659 --
----------- ------------ ------------
Net income ................. $ 11,909,094 $ 17,673,269 $ 23,607,674
=========== ============ ============
Per common share data:
Primary:
Earnings before
extraordinary items and
cumulative effect of a
change in accounting
principle ............... $ 0.67 $ 0.89 $ 1.13
Net income ................ $ 0.67 $ 0.89 $ 1.05
Weighted average shares of
common stock and
equivalents ............. 17,800,200 19,930,828 22,587,035
----------- ------------ ------------
Fully diluted:
Earnings before
extraordinary items and
cumulative effect of a
change in accounting
principle ............... $ 0.67 $ 0.84 $ 1.03
Net income ................ $ 0.67 $ 0.84 $ 0.97
Weighted average shares of
common stock and
equivalents ............. 17,928,522 24,819,711 28,452,436
----------- ------------ ------------
</TABLE>
See accompanying notes to consolidated financial statements.
F-5
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
Additional
Common Paid-in Retained Treasury
Stock Capital Earnings Stock Total
---------- -------------- ------------- ------------ -------------
<S> <C> <C> <C> <C> <C>
Balance at September 30,
1992 .................. $206,389 $ 70,576,932 $12,379,245 $(459,786) $ 82,702,780
Issuance of additional
common stock net of
issuance costs ........ 38,700 30,051,359 -- -- 30,090,059
Exercise of common stock
options and issuance of
stock bonus awards .... 1,856 644,356 -- -- 646,212
1993 net earnings ...... -- -- 11,909,094 -- 11,909,094
---------- -------------- ------------- ------------ -------------
Balance at September 30,
1993 .................. 246,945 101,272,647 24,288,339 (459,786) 125,348,145
========== ============== ============= ============ =============
Issuance of additional
common stock, net of
issuance costs ........ 42,926 51,572,278 -- -- 51,615,204
Issuance of shares from
Treasury .............. -- -- -- 100,000 100,000
Exercise of common stock
options ............... 1,186 728,356 -- -- 729,542
1994 net earnings ...... -- -- 17,673,269 -- 17,673,269
---------- -------------- ------------- ------------ -------------
Balance at September 30,
1994 .................. 291,057 153,573,281 41,961,608 (359,786) 195,466,160
========== ============== ============= ============ =============
Issuance of additional
common stock .......... 486 620,860 -- -- 621,346
Issuance of shares from
Treasury .............. -- -- -- 116,532 116,532
Exercise of common stock
options and issuance of
stock bonus awards .... 2,917 1,732,908 -- -- 1,735,825
1995 net earnings ...... -- -- 23,607,674 -- 23,607,674
---------- -------------- ------------- ------------ -------------
Balance at September 30,
1995 .................. $294,460 $155,927,049 $65,569,282 $(243,254) $221,547,537
========== ============== ============= ============ =============
</TABLE>
See accompanying notes to consolidated financial statements.
F-6
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Year ended September 30,
---------------------------------------------------
1993 1994 1995
-------------- --------------- ---------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net income ........................................ $ 11,909,094 $ 17,673,269 $ 23,607,674
Adjustments to reconcile net income to net cash
provided by operating activities:
Charges (credits) included in operations not
requiring funds:
Provision for deferred taxes ................. 2,671,000 4,483,022 (1,270,000)
Depreciation and amortization ................ 7,157,110 14,982,173 18,792,823
Amortization of deferred gain ................ (319,073) (319,000) (460,000)
Extraordinary loss ........................... -- 552,585 1,923,123
Cumulative effect of a change in accounting
principle ................................. -- (534,659) --
Changes in assets and liabilities excluding
effects of acquisitions and dispositions:
Increase in accounts receivable .............. (7,633,812) (15,485,474) (25,563,759)
Increase in cost report receivables .......... (2,269,892) (1,769,744) (15,064,866)
Increase in inventory ........................ (680,965) (936,575) (3,176,433)
Increase in prepaid expenses and other current
assets .................................... (2,416,862) (6,705,392) (420,516)
Increase (decrease) in accounts payable and
accrued expenses .......................... (673,355) 4,418,452 7,235,133
Increase in accrued compensation and interest 159,806 4,558,311 1,258,336
Increase (decrease) in income taxes payable .. (986,268) (353,955) 871,443
-------------- --------------- ---------------
Total adjustments ................................... (4,992,311) 2,889,744 (15,874,716)
-------------- --------------- ---------------
Net cash provided by operating activities .... 6,916,783 20,563,013 7,732,958
-------------- --------------- ---------------
Cash flows from investing activities:
Capital expenditures .............................. (23,151,427) (18,784,116) (24,718,616)
Cash paid net -- acquisitions ..................... (579,000) (214,306,437) (8,194,000)
Other long-term asset additions ................... (11,874,540) (9,224,541) (13,130,338)
(Increase) decrease in funds held by trustee ...... 710,913 (48,781) 25,777
-------------- --------------- ---------------
Net cash used in investing activities .......... (34,894,054) (242,363,875) (46,017,177)
-------------- --------------- ---------------
Cash flows from financing activities:
Net borrowings (repayments) under working capital
revolving credit ............................... 34,644,287 (10,200,000) 30,100,000
Repayment of long-term debt ....................... (92,068,067) (26,059,621) (102,450,468)
Proceeds from issuance of long-term debt .......... 60,828,534 125,000,000 119,700,000
Proceeds from issuance of convertible debentures .. -- 86,250,000 --
Proceeds from issuance of common stock ............ 30,505,275 52,047,896 100,000
Stock issuance costs .............................. (415,216) (432,692) --
Common stock options exercised .................... 576,588 522,542 1,735,825
Debt issuance costs ............................... (3,433,526) (5,050,930) (4,331,057)
-------------- --------------- ---------------
Net cash provided by financing activities ...... 30,637,875 222,077,195 44,854,300
-------------- --------------- ---------------
Net increase in cash and equivalents ................ 2,660,604 276,333 6,570,081
Cash and equivalents:
Beginning of year ................................. 880,488 3,541,092 3,817,425
End of year ....................................... $ 3,541,092 $ 3,817,425 $ 10,387,506
============== =============== ===============
Supplemental disclosure of cash flow information:
Interest paid ..................................... $ 5,455,423 $ 12,085,369 $ 18,174,689
Income taxes paid ................................. $ 5,310,100 $ 5,159,000 $ 13,037,150
============== =============== ===============
</TABLE>
See accompanying notes to consolidated financial statements.
F-7
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of Genesis
Health Ventures, Inc. (the Company) and its wholly-owned subsidiaries. All
significant intercompany accounts and transactions have been eliminated in
consolidation.
The Company provides a broad range of healthcare services to the geriatric
population, principally within five geographic markets in the eastern United
States. These services include basic healthcare services traditionally
provided in geriatric care facilities; specialty medical services, such as
rehabilitation therapy, institutional pharmacy and medical supply services
and subacute care; and management services to independent geriatric care
providers.
PROPERTY, PLANT AND EQUIPMENT
Land, land improvements, buildings, and equipment are stated at cost.
Subsequent additions are recorded at cost. Depreciation of land improvements,
buildings and equipment is calculated on the straight-line method over their
estimated useful lives that range from three years to 35 years.
Expenditures for maintenance and repairs necessary to maintain property
and equipment in efficient operating condition are charged to operations.
Costs of additions and betterments are capitalized. Interest costs associated
with construction or renovation are capitalized in the period in which they
are incurred.
INVENTORIES
Inventories of drugs and supplies are stated at the lower of cost or
market. Cost is determined primarily on the first-in, first-out (FIFO)
method.
CONTRACTUAL ADJUSTMENTS
Patient revenues are recorded based on standard charges applicable to all
patients. Under Medicare, Medicaid, and other cost-based reimbursement
programs, each facility is reimbursed for services rendered to covered
program patients as determined by reimbursement formulas. The differences
between established billing rates and the amounts reimbursable by the
programs and patient payments are recorded as contractual adjustments and
deducted from revenues.
Retroactively calculated third-party contractual adjustments are accrued
on an estimated basis in the period the related services are rendered.
Revisions to estimated contractual adjustments are recorded based upon audits
by third-party payors, as well as other communications with third-party
payors such as desk reviews, regulation changes and policy statements. These
revisions are made in the year such amounts are determined.
INVESTMENTS
Investments are carried at cost, which approximates fair value, and
interest income is recognized as earned.
DEFERRED FINANCING COSTS
Financing costs have been deferred and are being amortized on a
straight-line basis over the term of the related debt. Net deferred financing
costs included in other long term assets were $8,123,000 and $9,425,000 at
September 30, 1994 and 1995, respectively.
F-8
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
CONTRACT RIGHTS
Contract rights represent the value assigned to a management contract
obtained in conjunction with the Company's acquisition of Genesis Management
Resources, Inc. (formerly, Total Care Systems, Inc.). The contract is with a
company that owns life care communities and provides for a management fee in
exchange for management, marketing and development services provided to the
communities. The Company obtained an independent appraisal with respect to
the assigned value of the contract rights. Contract rights are being
amortized over ninety-four months which represents the term of the related
contract.
GOODWILL
Goodwill represents the excess of the purchase price over the fair market
value of net assets acquired and is amortized on a straight-line basis from
ten to forty years. Accumulated amortization at September 30, 1994 and 1995
was $3,300,000 and $6,200,000, respectively. Goodwill is reviewed for
impairment whenever events or circumstances provide evidence that suggest
that the carrying amount of goodwill may not be recoverable. The Company
assesses the recoverability of goodwill by determining whether the
amortization of the goodwill balance can be recovered through projected
undiscounted future cash flows.
INCOME TAXES
Statement of Financial Accounting Standards No. 109, "Accounting for
Income Taxes" (Statement 109) was adopted by the Company in 1994. Statement
109 required a change from the deferred method to the asset and liability
method of accounting for income taxes. Under the asset and liability method,
deferred income taxes are recognized for the tax consequences of "temporary
differences" by applying enacted statutory tax rates applicable to future
years to differences between the financial statement carrying amounts and the
tax bases of existing assets and liabilities. Under Statement 109, the effect
on deferred taxes of a change in tax rates is recognized in income in the
period that includes the enactment date.
Provision is made for deferred income taxes applicable to temporary
differences between financial statement and taxable income.
EARNINGS PER SHARE
Primary earnings per share is based on the average number of shares of
common stock outstanding during the period and the dilutive effect of stock
options and other common stock equivalents. Fully diluted earnings per share
reflect the conversion of the Convertible Senior Subordinated Debentures as
if such conversion had occurred on the date of issuance and the related
interest expense had not been incurred.
CASH EQUIVALENTS
Short-term investments which have a maturity of ninety days or less at
acquisition are considered cash equivalents.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The fair value of financial instruments is determined by reference to
various market data and other valuation considerations. The fair value of
financial instruments approximates their recorded values.
NEW ACCOUNTING PRONOUNCEMENTS
In March, 1995, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards No. 121 "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of"
(Statement 121). Statement 121 provides guidance for recognition and
measurement of impairment of long-lived assets, certain identifiable
intangibles and goodwill related both to
F-9
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
assets to be held and used and assets to be disposed of. The Company is
required to adopt Statement 121 for the year ending September 30, 1997. The
Company has not yet quantified the impact, if any, of the adoption of
Statement 121 may have on its consolidated financial statements.
In October, 1995, the FASB issued Statement 123, "Accounting for
Stock-Based Compensation" (Statement 123). Statement 123 allows companies the
option to retain the current accounting approach for recognizing stock-based
expense in the financial statements or to adopt a new accounting method based
on the estimated fair value of employee stock options. Companies that do not
follow the new fair value based method will be required to provide expanded
disclosures in the footnotes. The Company is required to adopt Statement 123
for the year ending September 30, 1997. The Company expects to continue
applying its current accounting approach and upon adoption will present the
required footnote disclosures.
(2) ACQUISITIONS/DISPOSITIONS
On November 30, 1995, subsequent to fiscal year end, the Company acquired
McKerley Health Care Centers, Inc. and related entities (collectively,
"McKerley") for total consideration of approximately $68,700,000. The
transaction also provides for up to an additional $6,000,000 of contingent
consideration payable upon the achievement of certain financial objectives
through October 1997. McKerley owns or leases 15 geriatric care facilities in
New Hampshire and Vermont with a total of 1,535 beds and operates a home
healthcare company. The acquisition was financed with long-term debt.
On September 30, 1995, the Company sold, subject to a three year
management contract, five facilities totaling 606 beds to the AGE Institute
of Massachusetts ("AIMASS") for $19,570,000.
On June 1, 1995, the Company acquired Eastern Medical Supplies, Inc. and
its affiliate Eastern Rehab Services, Inc. (collectively, "Eastern Medical")
for approximately $2,000,000. Eastern Medical sells and leases home medical
equipment, respiratory products and services and rehabilitation equipment to
patients at home throughout Maryland.
On April 1, 1995, the Company acquired TherapyCare Systems, L.P.
("TherapyCare") for approximately $7,000,000. TherapyCare provides physical
therapy, occupational therapy and speech therapy to 73 long-term care
facilities throughout Pennsylvania.
On March 1, 1995, a joint venture in which the Company is a 55% partner
acquired Delta Drug, Inc. ("Delta Drug") for approximately $1,700,000. Delta
Drug, an institutional pharmacy company located in Providence, Rhode Island,
serves over 2,000 long-term care beds.
On November 30, 1993, the Company acquired substantially all of the assets
of Meridian, Inc., Meridian Healthcare, Inc. and their affiliated entities
(Meridian). The purchase price was approximately $205,000,000, which included
approximately $70,000,000 of debt paid prior to the consummation of the
transaction. The transaction (Meridian Transaction) was financed with
approximately $84,000,000 in proceeds from an offering of 6% Convertible
Senior Subordinated Debentures issued in November 1993 and a bank credit
facility. Meridian operated 36 geriatric care facilities and provided
specialty medical and management services in six geographic markets in the
United States. The Company allocated $121,000,000 of the excess purchase
price to tangible assets and recorded approximately $84,000,000 in goodwill
as a result of this transaction.
The following unaudited pro forma statement of operations information
gives effect to the Meridian Transaction described above as though it had
occurred on October 1, 1992, after giving effect to certain adjustments,
including amortization of goodwill, additional depreciation expense,
increased interest expense on debt related to the acquisition and related
income tax effects. The pro forma financial information does not necessarily
reflect the results of operations that would have occurred had the
acquisition occurred on October 1, 1992.
F-10
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
<TABLE>
<CAPTION>
Year Ended
September 30,
------------------------
1993 1994
---------- ----------
(In thousands except per
share data)
<S> <C> <C>
Pro Forma Statement of Operations Information:
Total net revenues ................................................ $364,266 $416,819
Income before extraordinary items and cumulative effect of an
accounting change ................................................ 14,013 18,143
Net income ........................................................ 14,013 18,125
Primary earnings per share before extraordinary items and
cumulative effect of an accounting change ........................ 0.78 0.91
Fully diluted earnings per share before extraordinary items and
cumulative effect of an accounting change ........................ 0.73 0.85
</TABLE>
(3) PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment at September 30, 1994 and 1995 consist of
the following:
<TABLE>
<CAPTION>
September 30,
-----------------------------------
1994 1995
-------------- -------------
<S> <C> <C>
Land ............................. $ 18,357,703 $ 17,606,305
Land improvements ................ 2,849,424 3,193,296
Buildings ........................ 222,355,216 219,636,621
Equipment ........................ 39,966,560 46,196,213
Construction in progress ......... 3,061,394 8,136,354
-------------- -------------
286,590,297 294,768,789
Less accumulated depreciation .... 43,040,515 51,108,222
-------------- -------------
Net property, plant and equipment $243,549,782 $243,660,567
============== =============
</TABLE>
(4) LONG-TERM DEBT
Long-term debt at September 30, 1994 and 1995 was as follows:
<TABLE>
<CAPTION>
September 30,
--------------------------------
1994 1995
-------------- --------------
<S> <C> <C>
Secured--due 1996 to 2014; 7.88% to 12.00% (weighted
average interest rate 1994--6.8%; 1995--8.22%) ........... $172,958,506 $101,138,191
Unsecured--due 1996 to 2008; 5.5% to 11.00% (weighted
average interest rate 1994--8.3%; 1995-- 9.6%) ........... 1,572,492 123,523,700
Convertible Senior Subordinated Debentures due 2003--6% ... 86,250,000 86,250,000
-------------- --------------
260,780,998 310,911,891
Less:
Debt discount, net of amortization ................... 31,414 320,775
Current installments and short-term borrowings ....... 9,942,806 2,538,675
-------------- --------------
$250,806,778 $308,052,441
============== ==============
</TABLE>
At September 30, 1995, the Company has approximately $66,500,000 of
floating rate debt based on prime or LIBOR with a weighted average interest
rate of 7.19%. At September 30, 1995, the Company has $244,411,891 of fixed
rate debt with a weighted average interest rate of 8.3%.
On or after November 30, 1996, the Company may redeem the 6% Convertible
Senior Subordinated Debentures (the Debentures) in whole or in part at a
redemption price initially equal to 104.2% of the principal amount and
decreasing annually thereafter. The Debentures are convertible into Common
Stock at the option of the holder at anytime prior to maturity unless
previously redeemed at a conversion price of $15.104 per share.
F-11
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
In connection with financing the Meridian Transaction, the Company
obtained a $200,000,000 bank facility to replace the then existing
$65,000,000 term loan/revolving credit facility. The agreement provided for a
$125,000,000 term loan and a $75,000,000 revolving credit facility which bore
interest at the prime rate plus 1.5% or LIBOR plus 2.5%.
In September 1995, the Company amended and restructured its bank credit
facility to provide for a $200,000,000 revolving credit facility and a
$100,000,000 acquisition credit facility. Both credit facilities bear
interest at a floating rate equal, at the Company's option, to the prime rate
or LIBOR plus 1.25%. Amounts outstanding under the credit facilities in
September 1998 convert to a term loan that provides for equal annual
amortization payable quarterly. At September 30, 1995, $66,500,000 was
outstanding under the revolving credit facility. The credit facilities are
secured by the stock of the Company's subsidiaries and first priority liens
on the Company's accounts receivable, inventory and all other personal
property.
In June 1995, the Company completed an offering of $120,000,000 of 9 3/4 %
Senior Subordinated Notes due 2005 (the Notes). Interest is payable on the
Notes on June 15 and December 15 of each year commencing December 15, 1995.
The Notes are redeemable at the option of the Company in whole or in part, at
any time, on or after June 15, 2000 at a redemption price initially equal to
104.05% of the principal amount and decreasing annually thereafter. The
Company used the net proceeds from the Notes offering to repay a portion of
the bank credit facility.
At September 30, 1995, sinking fund requirements and installments of
long-term debt are as follows:
<TABLE>
<CAPTION>
Year ending Principal
September 30, Amount
--------------- -------------
<S> <C>
1996 .......... $ 2,538,675
1997 .......... 2,291,318
1998 .......... 3,015,885
1999 .......... 18,863,477
2000 .......... 18,771,255
Thereafter .... $265,431,281
</TABLE>
In November 1995, the Company entered into two separate interest rate swap
agreements with two financial institutions. The first agreement is for a term
of five years and a notional amount of $15,000,000 whereby the Company will
make quarterly payments at a fixed rate of 5.86% and receive quarterly
payments at a floating rate based on three month LIBOR (5.97% at September
30, 1995). The second agreement is for a term of three years and a notional
amount of $5,000,000 whereby the Company will make quarterly payments based
on a fixed rate of 5.66% and receive quarterly payments at a floating rate
based on three month LIBOR
In November 1995, the Company entered into an interest rate collar
agreement for five years for a notional amount of $10,000,000. The agreement
requires the Company to receive payments when three month LIBOR rate exceeds
6.25% and make payments when the three month LIBOR rate falls below 5.05%.
Interest of $405,118 in 1994 and $457,000 in 1995 was capitalized in
connection with facility renovations.
During 1994 and 1995, the Company recorded an extraordinary loss, net of
tax, of $552,585 and $1,923,123, related to the early retirement of debt.
The Company is restricted from declaring any dividends or authorizing any
other distribution on account of ownership of its capital stock unless
certain conditions are met.
(5) LEASES AND LEASE COMMITMENTS
The Company leases certain facilities and equipment under operating
leases. Future minimum payments for the next five years under operating
leases at September 30, 1995 were as follows:
F-12
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
<TABLE>
<CAPTION>
Year ending Minimum
September 30, payments
--------------- -------------
<S> <C>
1996 .......... $14,835,340
1997 .......... 14,298,366
1998 .......... 11,083,307
1999 .......... 10,568,196
2000 .......... 8,504,859
</TABLE>
In connection with the Meridian Transaction, the Company entered into
agreements to lease seven geriatric care facilities for ten years, including
a purchase option, that will continue to be owned by certain of Meridian's
former shareholders. The annual lease payment is $6,000,000. If the Company
exercised its option to purchase the leased facilities, the price at the end
of the lease term would be $59,000,000.
(6) PATIENT SERVICE REVENUE
The distribution of net patient service revenue by class of payor for the
years ended September 30, 1993, 1994 and 1995 was as follows:
<TABLE>
<CAPTION>
Year ended September 30,
----------------------------------------------------
Class of payor 1993 1994 1995
--------------------- -------------- -------------- --------------
<S> <C> <C> <C>
Private pay and other $ 87,122,847 $148,945,566 $175,205,592
Medicaid ............ 92,885,512 156,893,671 185,611,801
Medicare ............ 28,588,543 60,142,447 97,630,048
-------------- -------------- --------------
$208,596,902 $365,981,684 $458,447,441
============== ============== ==============
</TABLE>
The above revenue amounts are net of third-party contractual allowances of
$46,170,589, $81,544,600 and $98,494,511 in 1993, 1994 and 1995,
respectively.
The Company has recorded cost report receivables from third-party payors
(i.e., Medicare and Medicaid) of approximately $12,036,000 and $26,271,000 at
September 30, 1994 and 1995, respectively. These amounts at September 30,
1995 are due primarily from Massachusetts ($6,900,000), Pennsylvania
($3,600,000) and Medicare ($15,600,000) for the 1987 through 1995 cost
reporting periods.
(7) RELATED PARTY TRANSACTIONS
During 1987, certain directors and officers of the Company formed a
partnership, Salisbury Medical Office Building General Partnership ("SMOB"),
and purchased a building, a pharmacy and a medical center located in
Salisbury, Maryland. The Company has entered into annual lease agreements
with SMOB to lease the building. In Fiscal 1989, the Company entered into a
five-year lease agreement to finance approximately $1,100,000 of equipment
from SMOB. In accordance with the equipment lease agreement, the Company
purchased the equipment at fair market value. The total lease payments and
equipment purchase payments to SMOB for Fiscal 1993, 1994 and 1995 were
$382,000, $420,000 and $198,000, respectively.
In August 1993, the Company guaranteed a loan in the amount of $1,000,000
to Samuel H. Howard which amount was invested by Mr. Howard in Phoenix
Healthcare Corporation. The guarantee is secured by a pledge of Mr. Howard's
stock in Phoenix Healthcare Corporation. In return for such guarantee the
Company received an option to purchase up to 25% of the stock of Phoenix
Healthcare Corporation at a price of $.25 per share, subject to Mr. Howard's
right to purchase the option for $1,000,000 upon release of the guarantee.
In September 1994, Mr. Howard exercised his right to purchase the option
for $1,000,000. The Company received as consideration $150,000 in cash and an
$850,000 note bearing interest at 12% from Mr. Howard. At September 30, 1995,
the balance of the note was $718,000 which was repaid in full subsequent to
year end. Samuel H. Howard, a director of the Company, is the principal
shareholder of Phoenix Healthcare Corporation.
F-13
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
(8) INCOME TAXES
As discussed in Note 1, the Company adopted Statement 109 as of October 1,
1993. The cumulative effect of this change in accounting for income taxes of
$534,659 is determined as of October 1, 1993 and is reported separately in
the consolidated statement of operations for the year ended September 30,
1994. As a result of applying Statement 109, earnings before income taxes for
the years ended September 30, 1995 and 1994 were decreased $390,000 due to
the effects of adjustments for prior purchase business combinations. Prior
years financial statements have not been restated to apply the provisions of
Statement 109.
The Company has provided no valuation allowance for deferred tax assets.
The Company believes it is more likely than not that the results of future
operations will generate sufficient taxable income to realize the deferred
tax assets.
Total income tax expense for the years ended September 30, 1994 and 1995
was allocated as follows:
<TABLE>
<CAPTION>
Year ended September 30,
-----------------------------------
1994 1995
------------- -------------
<S> <C> <C>
Income from continuing operations $10,018,536 $14,764,941
Extraordinary item .............. (324,534) (1,129,452)
------------- -------------
Total .......................... $ 9,694,001 $13,635,489
============= =============
</TABLE>
The components of the provision for income taxes for the years ended
September 30, 1993, 1994 and 1995 were as follows:
<TABLE>
<CAPTION>
Year ended September 30,
---------------------------------------------------------
1993 1994 1995
------------ ------------- -------------
<S> <C> <C> <C>
Current:
Federal .. $3,859,230 $ 4,768,513 $13,483,941
State .... 464,000 767,000 2,551,000
------------ ------------- -------------
4,323,230 5,535,513 16,034,941
------------ ------------- -------------
Deferred:
Federal .. 2,603,000 3,973,022 (650,000)
State .... 68,000 510,000 (620,000)
------------ ------------- -------------
2,671,000 4,483,022 (1,270,000)
------------ ------------- -------------
Total ..... $6,994,230 $10,018,535 $14,764,941
============ ============= =============
</TABLE>
Total income tax expense differed from the amounts computed by applying
the U.S. federal income tax rates of 34.75% for 1993 and 35% for 1994 and
1995 to net income before income taxes and extraordinary items as a result of
the following:
<TABLE>
<CAPTION>
Year ended September 30,
---------------------------------------------
1993 1994 1995
------------ ------------- -------------
<S> <C> <C> <C>
Computed "expected" tax expense ....................... $6,568,905 $ 9,698,246 $14,103,508
Increase (reduction) in income taxes resulting from:
State and local income taxes, net of federal tax
benefit ........................................ 348,000 830,000 1,255,000
Amortization of goodwill ............................ 260,000 154,000 197,000
Targeted jobs credits ............................... (128,000) (600,000) (528,000)
Other, net .......................................... (54,675) (63,711) (262,567)
------------ ------------- -------------
Total income tax expense .............................. $6,994,230 $10,018,535 $14,764,941
============ ============= =============
</TABLE>
F-14
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
The sources of the differences between consolidated earnings for financial
statement purposes and tax purposes and the tax effects are as follows:
<TABLE>
<CAPTION>
Year ended September 30,
----------------------------------------------
1993 1994 1995
------------ ------------- --------------
<S> <C> <C> <C>
Excess tax depreciation expense versus book depreciation $ 311,000 $ 1,007,000 $ 1,064,000
Excess tax gain versus book gain ....................... -- (302,000) (2,879,000)
Accounts receivable allowance for doubtful accounts .... -- (312,000) (221,000)
Amortization of deferred gain on sale and leaseback .... 125,000 128,000 103,000
Targeted jobs credit carryforward ...................... (128,000) 446,000 --
Accrued liabilities and reserves ....................... (58,000) (1,401,000) (280,000)
Goodwill ............................................... -- 3,790,000 920,000
Alternative minimum tax credit ......................... 2,421,000 1,192,000 --
Other .................................................. -- (64,978) 23,000
------------ ------------- --------------
Net deferred tax provision ............................ $2,671,000 $ 4,483,022 $(1,270,000)
============ ============= ==============
</TABLE>
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities at September
30, 1994 and 1995 are presented below:
<TABLE>
<CAPTION>
1994 1995
-------------- --------------
<S> <C> <C>
Deferred Tax Assets
Accounts receivable .......... $ 970,000 $ 1,303,000
Accrued compensation ......... 220,000 532,000
Amortization of deferred gain 440,000 297,000
Goodwill ..................... 4,995,000 4,075,000
Accrued liabilities and
reserves .................. 961,000 24,000
Other, net ................... 109,000 --
-------------- --------------
Net deferred tax assets ........ 7,695,000 6,231,000
-------------- --------------
Deferred Tax Liabilities
Goodwill and Contract Rights . (7,061,000) (6,590,000)
Depreciation ................. (9,770,000) (8,272,000)
Other, net ................... (132,000) (67,000)
-------------- --------------
Total deferred tax liability ... (16,963,000) 14,929,000
-------------- --------------
Net deferred liability ......... $ (9,268,000) $(8,698,000)
============== ==============
</TABLE>
(9) STOCK OPTION PLANS
The Company has two stock option plans (the "Employee Plan" and the
"Directors Plan"). Under the Employee Plan, 2,000,000 shares of Common Stock
were reserved for issuance to employees including officers and directors.
Generally, the options granted in the Employee Plan become exercisable over a
5 year period and expire 10 years from the date of grant. All options granted
under the Employee Plan have been at the fair market value of the common
stock on the date of grant.
F-15
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
<TABLE>
<CAPTION>
Option Price Available
per Share Outstanding Exercisable for Grant
-------------- ------------- ------------- -----------
<S> <C> <C> <C> <C>
Balance at September 30, 1993 $ 2.22-$13.33 1,164,033 514,429 161,517
------------- ---------- --------- ----------
Authorized ................... -- -- -- 450,000
Granted ...................... 13.17-17.00 691,500 -- (691,500)
Became Exercisable ........... -- -- 305,156 --
Exercised .................... 4.45-10.50 (88,980) (88,980) --
Cancelled .................... -- (156,450) -- 156,450
------------- ----------- --------- ----------
Balance at September 30, 1994 2.22-17.00 1,610,103 730,605 76,467
------------- ----------- --------- ----------
Authorized ................... -- -- -- 1,050,000
Granted ...................... 19.67-20.25 740,625 -- (740,625)
Became Exercisable ........... -- -- 400,692 --
Exercised .................... 5.33-16.83 (204,585) (204,585) --
Cancelled .................... -- (51,975) -- 51,975
------------- ---------- --------- ----------
Balance at September 30, 1995 $ 2.22-$20.25 2,094,168 926,712 437,817
============= ========== ========= ==========
</TABLE>
(10) RETIREMENT PLAN
The Company has a defined contribution plan covering all employees having
1,000 hours or more of service and one year of service in a plan year.
Employees' contributions to the plan may be matched by the Company based on
years of service. During the plan years ended December 31, 1993, 1994 and
1995, the Company accrued a match of 50% of employee contributions up to 3%
of the employee's annual gross salary.
Additionally, the Plan provides for discretionary employer contributions,
based on profits of the Company, in the form of Company common stock and/or
cash. The Company recorded retirement plan expense for the 401(k) match and
the discretionary contribution of approximately $500,000, $959,000, and
$1,128,000 for the years ended September 30, 1993, 1994, 1995, respectively.
Certain employees of Meridian were eligible to participate in plans which
qualified under Section 401(K) of the Internal Revenue Service Code. In
accordance with the terms of the plans, employees elected to contribute a
percentage of their respective annual compensation to the plans, subject to
certain limitations. The Company was obligated to match 50% of each
employee's contribution up to 3% of their respective annual compensation.
Beginning January 1, 1995 one of these plans was merged into the Genesis
Health Ventures, Inc. Retirement Plan.
(11) COMMITMENTS AND CONTINGENCIES
In connection with certain management agreements, the Company has
guaranteed $23,240,000 of indebtedness of others, has lent $12,881,000 at
various interest rates ranging from 7% to 10% and has agreed to provide
working capital advances totalling $21,909,500. At September 30, 1995,
$15,713,800 was outstanding related to cash advances under these working
capital arrangements.
In August 1995, the Company entered into a software license agreement for
clinical operating system. The total commitment under the license agreement
is $12,000,000 of which the Company has paid $3,500,000. The license
agreement provides for a refund of amounts paid in the event the software
does not meet the acceptance requirements as defined in the license
agreement. The Company has estimated the cost to install the system and
related hardware, not including amounts paid for the software license, to be
approximately $18,000,000 over the next four years.
The Company is self-insured for a portion of its workers' compensation and
health insurance exposures. The Company's maximum self-insured exposure is
$500,000 per claim with certain maximum aggregate policy limits per claim
year.
F-16
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements - (Continued)
The Company's exposure to credit loss in the event of non-performance by
the other party to the financial instrument for guarantees, loan commitments
and letters of credit is represented by the dollar amount of those
instruments. The Company uses the same credit policies in making commitments
and conditional obligations as it does for on-balance sheet financial
instruments. The Company does not anticipate any material losses as a result
of these commitments.
Genesis is a party to litigation arising in the ordinary course of
business. Genesis does not believe the results of such litigation, even if
the outcome is unfavorable to the Company, would have a material adverse
effect on its consolidated financial position or results of operations.
(12) QUARTERLY FINANCIAL DATA (UNAUDITED)
The Company's unaudited quarterly financial information is as follows:
<TABLE>
<CAPTION>
Fully-diluted
Earnings Earnings Per
before Share before
Cumulative Cumulative
Effect of Effect of
Accounting Accounting
Change and Change and Fully-diluted
Total Net Extraordinary Net Extraordinary Earnings
(In thousands, except per share data) Revenues Items Earnings Items Per Share
---------------------------------- ----------- --------------- ---------- --------------- ---------------
<S> <C> <C> <C> <C> <C>
Quarter ended:
December 31, 1994 ................ $111,553 $ 4,810 $ 4,810 $ .21 $.21
March 31, 1995 ................... 116,953 5,813 5,813 .24 .24
June 30, 1995 .................... 125,959 6,885 4,962 .28 .21
September 30, 1995 ............... 131,928 8,023 8,023 .31 .31
----------- --------------- ---------- --------------- ---------------
$486,393 $25,531 $23,608 $1.03 $.97
----------- --------------- ---------- --------------- ---------------
Quarter ended:
December 31, 1993 ................ $ 71,913 $ 2,915 $ 3,055 $ .15 $.16
March 31, 1994 ................... 98,640 3,584 3,584 .19 .19
June 30, 1994 .................... 105,361 4,708 4,550 .23 .22
September 30, 1994 ............... 112,702 6,484 6,484 .27 .27
----------- --------------- ---------- --------------- ---------------
$388,616 $17,691 $17,673 $ .84 $.84
=========== =============== ========== =============== ===============
</TABLE>
(13) SUBSEQUENT EVENT
Effective March 29, 1996, the Company issued a three for two stock
dividend on the Common Stock. Share and per share information in the
accompanying consolidated financial statements has been adjusted accordingly.
F-17
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
<TABLE>
<CAPTION>
September 30, June 30,
1995 1996
-------------- -----------
(Unaudited)
<S> <C> <C>
ASSETS
Current Assets:
Cash and cash equivalents ..................................... $ 10,387 $ 70,626
Accounts receivable, net of allowance for doubtful accounts of
$6,179 at September 30, 1995 and $9,674 at June 30, 1996 ... 101,124 144,036
Cost report receivables ....................................... 26,271 31,413
Inventory ..................................................... 9,601 16,872
Other current assets .......................................... 43,674 34,062
-------------- -----------
Total current assets ..................................... 191,057 297,009
-------------- -----------
Property, plant and equipment ................................... 294,769 375,628
Accumulated depreciation ........................................ (51,108) (62,240)
-------------- -----------
243,661 313,388
Goodwill and other intangibles, net ............................. 114,947 196,119
Other assets .................................................... 50,724 71,832
-------------- -----------
TOTAL ASSETS ............................................. $600,389 $878,348
============== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses ......................... $ 52,522 $ 64,163
Current installments of long-term debt ........................ 2,539 2,512
Income taxes payable .......................................... 1,882 2,735
-------------- -----------
Total current liabilities ................................ 56,943 69,410
-------------- -----------
Long-term debt .................................................. 308,052 295,897
Deferred income taxes ........................................... 8,698 6,586
Deferred gain and other liabilities ............................. 5,149 6,217
Shareholders' Equity:
Common stock, par value $.02, authorized 60,000,000 shares,
issued and outstanding, 22,081,267 and 22,035,666 at
September 30, 1995; 31,981,680 and 31,936,079 at June 30,
1996 ....................................................... 294 476
Additional paid-in capital .................................... 155,927 411,677
Retained earnings ............................................. 65,569 88,328
-------------- -----------
221,790 500,481
Less treasury stock, at cost .................................... (243) (243)
-------------- -----------
Total shareholders' equity ............................... 221,547 500,238
-------------- -----------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY ............... $600,389 $878,348
============== ===========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
F-18
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
June 30, June 30,
---------------------------- ----------------------------
1995 1996 1995 1996
------------ ------------ ------------ ------------
(Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
Net revenues:
Basic healthcare services ....... $ 69,701 $ 85,846 $ 206,073 $ 241,107
Specialty medical services ...... 48,188 78,347 128,333 193,347
Management services and other,
net .......................... 8,070 8,643 20,059 25,900
------------ ------------ ------------ ------------
Total net revenues ........... 125,959 172,836 354,465 460,354
Operating expenses:
Salaries, wages and benefits .... 62,009 80,919 175,612 223,244
Other operating expenses ........ 34,978 52,786 99,778 132,180
General corporate expense ....... 4,449 6,515 12,730 17,617
Debenture conversion expense ...... -- 155 -- 1,245
Depreciation and amortization ..... 5,003 6,648 13,987 17,883
Lease expense ..................... 3,657 4,086 10,388 11,948
Interest expense, net ............. 4,976 6,125 14,369 19,104
------------ ------------ ------------ ------------
Earnings before income taxes and
extraordinary item ........... 10,887 15,602 27,601 37,133
Income taxes ...................... 4,002 5,511 10,093 13,374
------------ ------------ ------------ ------------
Earnings before extraordinary
item ......................... 6,885 10,091 17,508 23,759
Extraordinary item, net of tax .. (1,923) -- (1,923) --
------------ ------------ ------------ ------------
Net income ...................... $ 4,962 $ 10,091 $ 15,585 $ 23,759
============ ============ ============ ============
Per common share data:
Primary
Earnings excluding debenture
conversion expense and
extraordinary item, net of tax $ .30 $ .37 $ .78 $ .96
Debenture conversion expense .... -- -- -- (.03)
Extraordinary item, net of tax .. (.08) -- (.09) --
Net income ...................... $ .22 $ .37 $ .69 $ .93
Weighted average shares of Common
Stock and equivalents ........ 22,635,350 27,507,276 22,556,985 25,438,335
Fully diluted
Earnings excluding debenture
conversion expense and
extraordinary item, net of tax $ .28 $ .35 $ .72 $ .91
Debenture conversion expense .... -- -- -- (.03)
Extraordinary item, net of tax .. (.07) -- (.06) --
Net income ...................... $ .21 $ .35 $ .66 $ .88
Weighted average shares of Common
Stock and equivalents ........ 28,387,825 31,108,391 28,284,792 29,358,861
</TABLE>
See accompanying notes to condensed consolidated financial statements.
F-19
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
<TABLE>
<CAPTION>
Nine Months Ended
June 30,
--------------------------
1995 1996
----------- -----------
(Unaudited)
<S> <C> <C>
Cash flows from operating activities:
Net income ......................................................... $ 15,585 $ 23,759
Adjustments to reconcile net income to net cash provided by
operating activities:
Charges (credits) included in operations not requiring funds:
Provision for deferred taxes ..................................... 2,902 3,343
Depreciation and amortization .................................... 13,987 17,883
Amortization of deferred gain .................................... (345) (345)
Debenture conversion expense ..................................... -- 1,245
Extraordinary item, net of tax ................................... 1,923 --
Changes in assets and liabilities excluding effects of acquisitions:
Increase in accounts receivable .................................. (16,425) (16,348)
Increase in cost report receivables .............................. (8,000) (6,418)
Increase in inventory ............................................ (492) (2,207)
(Increase) decrease in other current assets ...................... 1,562 (9,012)
Increase (decrease) in accounts payable and accrued expenses ..... (4,265) 3,144
Increase (decrease) in income taxes payable ...................... 759 (816)
----------- -----------
Total adjustments ................................................ (8,394) (9,531)
----------- -----------
Net cash provided by operating activities ........................ 7,191 14,228
----------- -----------
Cash flows from investing activities:
Capital expenditures ............................................. (19,681) (26,151)
Cash paid, net-- acquisitions .................................... (8,194) (140,816)
Deferred and other long-term asset additions, net ................ (10,376) (8,856)
Increase in trustee-held funds ................................... (490) (50)
----------- -----------
Net cash used in investing activities ............................ (38,741) (175,873)
----------- -----------
Cash flows from financing activities:
Proceeds from issuance of Common Stock ........................... -- 211,250
Stock issuance costs ............................................. -- (9,248)
Net borrowings under bank credit facility ........................ 19,600 20,300
Repayment of long-term debt ...................................... (101,353) (1,673)
Proceeds from issuance of long-term debt ......................... 119,700 --
Debenture conversion expense ..................................... -- (1,245)
Proceeds from exercise of common stock options ................... 981 2,500
Debt issuance costs .............................................. (3,600) --
----------- -----------
Net cash provided by financing activities .......................... $ 35,328 $ 221,884
----------- -----------
Net increase in cash and cash equivalents .......................... $ 3,778 $ 60,239
----------- -----------
Cash and cash equivalents:
Beginning of the period .......................................... 3,817 10,387
End of the period ................................................ $ 7,595 $ 70,626
----------- -----------
Supplemental disclosure of cash flow information:
Interest paid .................................................... $ 15,818 $ 22,755
----------- -----------
Income taxes paid ................................................ $ 9,509 $ 12,451
=========== ===========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
F-20
<PAGE>
GENESIS HEALTH VENTURES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. GENERAL
The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the consolidated financial statements and
the notes thereto included in the Company's annual report for the fiscal year
ended September 30, 1995. The information furnished is unaudited but reflects
all adjustments which are, in the opinion of management, necessary for a fair
presentation of the financial information for the periods shown. Such
adjustments are of a normal recurring nature. Interim results are not
necessarily indicative of results expected for the full year.
2. EARNINGS PER SHARE
Primary and fully-diluted earnings per share are based on the weighted
average number of common shares outstanding and the dilutive effect of stock
options, convertible debentures and other common stock equivalents.
3. PRO FORMA FINANCIAL INFORMATION
In July 1996, the Company and Geriatric & Medical Companies, Inc. ("GMC")
entered into an agreement providing for the merger of GMC into a wholly-owned
subsidiary of Genesis. The merger, and a related transaction with an
affiliate of GMC, will add 19 long-term care facilities and eight residential
care and independent living facilities with approximately 3,500 beds and
certain ancillary businesses to Genesis. Under the terms of the merger
agreement, unanimously approved by the board of directors of both companies,
GMC shareholders would receive $5.75 per share in cash for each GMC share.
The purchase price of GMC stock is approximately $91,000,000 and the total
value of the transaction, including approximately $132,000,000 of assumed
debt, is approximately $223,000,000. The Company expects to fund the cash
portion of the transaction through its bank credit facility. Consummation of
the transaction is expected in the fourth quarter of calendar 1996, and is
subject to normal closing conditions, regulatory approvals and GMC
shareholder approval.
In July 1996, the Company acquired the outstanding stock of National
Health Care Affiliates, Inc., Oak Hill Center, Inc., Derby Nursing Center
Corporation, EIDOS, Inc. and Versalink, Inc. (collectively, "National
Health"). Prior to the closing of the stock acquisitions, an affiliate of a
financial institution purchased nine of the eldercare centers for $67,700,000
and subsequently leased the centers to a subsidiary of Genesis under
operating lease agreements. The balance of the total consideration paid to
National Health was funded with available cash ($51,800,000) and assumed debt
($7,900,000). National Health owns six eldercare centers in Florida with 863
beds, leases four eldercare centers in Florida with 368 beds, owns five
eldercare centers in Virginia with 851 beds, and leases one eldercare center
in Connecticut with 120 beds. National Health also provides enteral nutrition
and rehabilitation therapy services to the eldercare centers which it owns
and leases. In addition, National Health manages four eldercare centers in
Colorado with 283 beds pursuant to an agreement which expires in October
1997.
In June 1996, the Company acquired the outstanding stock of NeighborCare
Pharmacies, Inc. ("NeighborCare"), a privately held institutional pharmacy,
infusion therapy and retail pharmacy business based in Baltimore, Maryland.
Total consideration was approximately $57,250,000, comprised of approximately
$47,250,000 in cash and 312,744 shares of Genesis common stock.
On November 30, 1995, the Company acquired all of the issued and
outstanding stock and partnership interests of McKerley Health Care Centers,
Inc., McKerley Health Care Center - Concord, Inc., McKerley Health Facilities
and McKerley Health Care Center - Concord, L.P. (collectively, the "McKerley
Entities"). The Company acquired the outstanding stock and partnership
interests of the McKerley Entities for approximately $68,700,000, including
assumed debt and after giving effect to the funds placed in escrow by the
principals as described below. An additional $6,000,000 of purchase price is
payable if certain financial objectives are achieved through October 1997.
The transaction was financed with borrowings under the Company's bank credit
facility.
F-21
<PAGE>
Pursuant to certain agreements executed on November 30, 1995, the Company
directly or through one or more subsidiaries, agreed to provide certain
services to the principals during the period ending November 30, 1998, and
the principals agreed to make certain lease payments on behalf of the Company
with respect to certain lease obligations of the McKerley Entities. As
security for the principals' or their affiliates' obligation to make the
required payments as they become due, the principals placed approximately
$6,500,000 in an account with a third party escrow agent.
The following unaudited pro forma statement of operations information
gives effect to the GMC, National Health, NeighborCare and McKerley
transactions described above as though they had occurred at the beginning of
the periods presented, after giving effect to certain adjustments, including
amortization of goodwill, additional depreciation expense, increased interest
expense on debt related to the acquisitions and related income tax effects.
The pro forma financial information does not necessarily reflect the results
of operations that would have occurred had the acquisitions occurred at the
beginning of the periods presented.
<TABLE>
<CAPTION>
(In thousands, except per
share data)
Nine Months Ended
June 30,
-------------------------
1995 1996
----------- ----------
<S> <C> <C>
Pro Forma Statement of Operations Information:
Total net revenues ............................ $654,092 $723,109
Net income before extraordinary item and
debenture conversion expense ................ 19,115 32,131
Primary earnings per share before extraordinary
item and debenture conversion expense ....... .83 1.03
Fully diluted earnings per share before
extraordinary item and debenture conversion
expense ..................................... .77 .97
</TABLE>
F-22
<PAGE>
PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
The following Unaudited Pro Forma Condensed Consolidated Statement of
Operations gives effect to: (i) the McKerley Transaction; (ii) the NeighborCare
Transaction; (iii) the National Health Transaction; (iv) the 1996 Equity
Offering and the application of the net proceeds therefrom; (v) the GMC
Transaction; and (vi) the Offering and the application of the net proceeds
therefrom, as if each had occurred at the beginning of the periods presented.
The pro forma condensed statements of operations are based upon assumptions
and include adjustments as described in the notes below. The pro forma
information should be read in conjunction with the Company's historical
consolidated financial statements, McKerley's historical combined financial
statements, National Health's historical combined financial statements and GMC's
historical combined financial statements. The column entitled "McKerley
Historical Results" represents the historical combined results of McKerley for
the year ended November 30, 1995. The column entitled "McKerley Historical
Results" for the nine months ended June 30, 1996 represents the two months ended
November 30, 1995. As a result of the differing year ends of Genesis and
McKerley, the two months ended November 30, 1995 are included in both periods.
The historical financial statements of NeighborCare for the year ended July 2,
1995 and the seven months ended April 30, 1996 are included in the columns
"NeighborCare" in the tables below. The historical combined financial statements
of National Health for the year ended December 31, 1995 and for the nine months
ended June 30, 1996 are included in the columns "National Health" in the tables
below. As a result of the differing year ends of Genesis and National Health,
the three months ended December 31, 1995 is included in both periods. The column
entitled "GMC Historical Results" for the year ended September 30, 1995
represents the historical results of GMC for the year ended May 31, 1995. The
column entitled "GMC Historical Results" for the nine months ended June 30, 1996
represents the historical results of GMC for the nine months ended May 31, 1996.
For purposes of this presentation, an effective tax rate of 37% has been assumed
for McKerley, NeighborCare, National Health and GMC, for the historical results,
and the resulting pro forma adjustments and offering adjustments. Such data is
not necessarily indicative of the historical financial results that would have
been achieved had the acquisitions occurred at the beginning of the periods
presented or that may be expected to result in the future as a result of such
transactions.
<PAGE>
<TABLE>
<CAPTION>
Year ended September 30, 1995
--------------------------------------------------------------------------------------------------------
National National
Genesis McKerley McKerley NeighborCare NeighborCare Health Health
Historical Historical Pro Forma Historical Pro Forma Historical Pro Forma
Results Results Adjustments Results Adjustments Results Adjustments
---------- ---------- -------------- ------------ -------------- ---------- ------------
(In thousands, except per share data)
<S> <C> <C> <C> <C> <C> <C> <C>
Net revenues ......... $486,393 $57,266 $ 114 (A)(B)(C) $52,751 $ -- $108,785 $(22,949)(L)(P)
Operating expense:
Operating expenses other
than depreciation,
amortization and lease
expense ............ 393,139 52,069 (6,063)(A)(D) 51,986 (1,849)(I)(K) 92,990 (26,435)(L)(O)(P)
Depreciation and
amortization ....... 18,793 1,900 1,079 (F) -- 2,547 (J) 4,055 1,067 (L)(M)
Lease expense ........ 13,798 2,759 (1,244)(G) -- -- 3,176 4,716 (L)(N)
Interest expense, net . 20,367 4,200 1,625 (A)(E) 1,276 1,880 (H) 6,177 (1,498)(L)(N)
--------- --------- ---------- --------- -------- --------- --------
Earnings from operations
before income taxes and
extraordinary items . 40,296 (3,662) 4,717 (511) (2,578) 2,387 (799)
--------- --------- ---------- --------- -------- --------- --------
Earnings from operations
before extraordinary
items .............. $ 25,531 $(2,307) $ 2,972 $ (322) $(1,624) $ 1,504 $(503)
--------- --------- ---------- --------- -------- --------- --------
Fully diluted earnings
per share before
extraordinary items . $1.03
Weighted average common
shares and equivalents 28,452 308 (H)
</TABLE>
(RESTUBBED TABLE CONTINUED FROM ABOVE)
<TABLE>
<CAPTION>
Pro Forma Pro Forma
Consolidated Consolidated
Genesis/McKerley/ Genesis/McKerley/
NeighborCare/ NeighborCare/
National Health National Health/
1996 Results Adjusted GMC Results
Equity for GMC GMC Adjusted for 1996
Offering 1996 Equity Historical Pro Forma Offering Equity Offering
Adjustment Offering Results Adjustments Adjustment and Offering
----------- ------------------- ---------- ----------- ---------- -----------------
<S> <C> <C> <C> <C> <C> <C>
Net revenues ........... $ -- $682,360 $192,234 $ -- $ -- $874,594
Operating expense:
Operating expenses other
than depreciation,
amortization and lease
expense ............... -- 555,837 163,769 (617)(S)(T) -- 718,989
Depreciation and
amortization .......... -- 29,441 8,734 -- -- 38,175
Lease expense .......... -- 23,205 -- -- -- 23,205
Interest expense, net .. (13,720)(Q) 20,307 14,666 4,987(S)(U) (2,368)(V) 37,592
--------- --------- ---------- -------- -------- --------
Earnings from operations
before income taxes and
extraordinary items ... 13,720 53,570 5,065 (4,370) 2,368 56,633
--------- --------- ---------- -------- -------- --------
Earnings from operations
before extraordinary
items ................. $ 8,644 $ 33,895 $ 3,191 $(2,753) $ 1,492 $ 35,825
--------- --------- ---------- -------- -------- --------
Fully diluted earnings per
share before
extraordinary items ... $1.12
Weighted average common
shares and equivalents . 6,500 35,260
</TABLE>
F-23
<PAGE>
<TABLE>
<CAPTION>
Nine Months ended June 30, 1996
---------------------------------------------------------------------------------------------------------
National National
Genesis McKerley McKerley NeighborCare NeighborCare Health Health
Historical Historical Pro Forma Historical Pro Forma Historical Pro Forma
Results Results Adjustments Results Adjustments Results Adjustments
---------- ---------- ------------- - ------------ ------------- ---------- -------------
(In thousands, except per share data)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Net revenues ......... $460,354 $ 9,671 $ 204(A)(B)(C) $39,765 $ -- $92,092 $(24,764)(L)(P)
Operating expenses:
Operating expenses other
than depreciation,
amortization and lease
expense ............ 373,041 11,537 (3,820)(A)(D) 36,697 (1,078)(I)(K) 79,865 (27,635)(L)(O)(P)
Debenture conversion
expense ............ 1,245 -- -- -- -- -- --
Depreciation and
amortization ....... 17,883 323 180 (F) 506 1,485(J) 3,556 286 (L)(M)
Lease expense ........ 11,948 460 (207)(G) 857 -- 2,617 3,389 (L)(N)
Interest expense, net . 19,104 1,158 (201)(A)(E) 1,171 671(H) 4,898 (1,432)(L)(N)
--------- --------- -------- -------- -------- -------- -------
Earnings from operations
before taxes and
extraordinary items . 37,133 (3,807) 4,252 534 (1,078) 1,156 628
--------- --------- -------- -------- -------- -------- -------
Earnings from operations
before extraordinary
items .............. $ 23,759 $(2,398) $2,678 $ 336 $ (679) $ 728 $ 396
--------- --------- -------- -------- -------- -------- -------
Fully diluted earnings
per share before
extraordinary items
and Debenture
conversion expense . $0.91
Weighted average common
shares and equivalents 29,359 239(H)
</TABLE>
<PAGE>
(RESTUBBED TABLE CONTINUED FROM ABOVE)
<TABLE>
<CAPTION>
Pro Forma
Consolidated
Pro Forma Genesis/McKerley/
Consolidated NeighborCare/
Genesis/McKerley/ National Health/
1996 NeighborCare/ GMC Results
Equity National Health GMC GMC Adjusted for 1996
Offering Results Adjusted Historical Pro Forma Offering Equity Offering
Adjustment for 1996 Equity Offering Results Adjustments Adjustment and Offering
---------- ------------------------ ---------- ---------------- ---------- -----------------
<S> <C> <C> <C> <C> <C> <C>
Net revenues ........... $ -- $577,322 $145,787 $ -- $ -- $723,109
Operating expenses:
Operating expenses other
than depreciation,
amortization and lease
expense ............... -- 468,607 125,455 (2,353)(R)(S)(T) 591,709
Debenture conversion
expense ............... -- 1,245 -- -- -- 1,245
Depreciation and
amortization .......... -- 24,219 6,537 -- -- 30,756
Lease expense .......... -- 19,064 -- -- -- 19,064
Interest expense, net .. (8,831)(Q) 16,538 12,408 2,210(R)(S)(U) (1,776)(V) 29,380
-------- --------- ---------- ------- -------- -------
Earnings from operations
before taxes and
extraordinary items ... 8,831 47,649 1,387 143 1,776 50,955
-------- --------- ---------- ------- -------- -------
Earnings from operations
before extraordinary
items ................. $ 5,563 $ 30,383 $ 874 $ 90 $ 1,119 $ 32,466
-------- --------- ---------- ------- -------- -------
Fully diluted earnings per
share before
extraordinary items and
Debenture conversion
expense ............... $1.01
Weighted average common
shares and equivalents . 5,958 35,556
</TABLE>
F-24
<PAGE>
PRO FORMA ADJUSTMENTS ARE AS FOLLOWS:
MCKERLEY TRANSACTION
(A) The historical financial statements of McKerley include unusual,
nonrecurring charges related to a provision to properly state certain
insurance program liabilities, record a loss related to the termination
of an interest rate swap agreement and to write off certain other
long-term assets.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Revenues, net ......................................... $ 204 $ 204
Operating expenses other than depreciation,
amortization and lease expense ....................... (3,248) (3,248)
Interest expense, net ................................. $ (566) $ (566)
</TABLE>
(B) Effective October 1, 1995 the State of New Hampshire issued a reduction
in payment rates under the Medical Assistance program. The annualized
impact of this rate reduction is approximately $1,500,000.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Revenues, net ................ $(1,500) --
</TABLE>
(C) The former owners have agreed to pay certain Genesis subsidiaries for
marketing and other services for approximately two years with annual
payments of approximately $900,000. The former owners also agreed to
lease 30,000 square feet of office space from the Company for
approximately two years at an annual rate of $510,000.
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
Revenues, net ............. $1,410 --
(D) As a result of the McKerley Transaction, corporate overhead functions
related to the prior owners, certain nursing staff and regional
management of the nursing facilities will be merged. The Company has
identified duplicative positions and the costs associated with such
positions, and plans to eliminate these costs according to a transition
plan within one year of the acquisition.
Salary costs and other payments associated with certain McKerley
principals who will not be joining Genesis have been identified and
eliminated, as well as costs associated with other management positions
which have already been vacated and will not be replaced. Support staff
associated with these positions have also been eliminated.
The components of the savings expected upon merging McKerley's operations
into Genesis are as follows:
<TABLE>
<CAPTION>
Annual Cost Nine Months Cost
------------- ----------------
(In thousands)
<S> <C> <C>
Principal salaries, payments and cost of support
personnel .............................................. $(1,693) $(418)
Management to be eliminated due to overlap, and vacated
management positions not to be replaced ................ (622) (104)
Personnel reduction in operating staff to eliminate
duplicative positions .................................. (500) (50)
------------- ----------------
$(2,815) $(572)
============= ================
</TABLE>
F-25
<PAGE>
The impact of the savings has been reflected in a pro forma adjustment as
follows:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C>
Operating expenses other than depreciation,
amortization and lease expense ....................... $(2,815) $(572)
</TABLE>
(E) The McKerley Transaction was financed with borrowings under the Company's
bank credit facilities aggregating approximately $68,700,000. The Company
has repaid approximately $27,000,000 of assumed McKerley debt. The
Company has also assumed a mortgage obligation of approximately
$9,100,000 which was not immediately repaid. Interest rate assumptions
are 7.25% for the Company's borrowing under its bank credit facilities.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Interest expense, net:
Interest expense -- bank facilities ............... $ 4,930 $ 822
Elimination of historical McKerley remaining
interest expense ............................... (2,739) (457)
------------------ -----------------
$ 2,191 $ 365
================== =================
</TABLE>
(F) In accordance with generally accepted accounting principles, the net
assets acquired are recorded at the lower of purchase price or fair
value. The estimated fair value adjustments have been determined based on
the most recent information available. The resultant excess of purchase
price over fair value of net assets acquired is required to be amortized.
The pro forma adjustment to reflect the increased depreciation and
amortization is as follows:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Depreciation and amortization expense... $1,079 $180
</TABLE>
(G) The former owners have agreed to make certain lease payments on behalf of
the Company with respect to certain lease obligations of the McKerley
entities. The following pro forma adjustment reflects the impact of
recognizing the resulting lease expense on a straight line basis over the
remaining lease term:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Lease expense .......... $(1,244) $(207)
</TABLE>
F-26
<PAGE>
NEIGHBORCARE TRANSACTION
(H) A portion of the NeighborCare Transaction will be financed with
borrowings under the Company's bank credit facilities aggregating
approximately $47,250,000. Genesis expects to repay approximately
$18,000,000 of NeighborCare debt assumed in the transaction. Interest
rate assumptions are 6.8% for the Company's borrowings under its credit
facilities.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Interest expense, net:
Interest expense -- bank facilities ............... $ 3,171 $ 1,842
Elimination of historical NeighborCare remaining
interest expense ............................... (1,291) (1,171)
------------------ -----------------
$ 1,880 $ 671
================== =================
</TABLE>
Adjustment to reflect the issuance of $10,000,000 of Genesis Common Stock
as a portion of the consideration. The stock issuance price has been
estimated at $32.50 per share resulting in the issuance of 307,692 shares.
(I) As a result of the NeighborCare Transaction, corporate and administrative
overhead functions related to the prior ownership structure will be
merged. Accordingly, Genesis has identified duplicative physical
locations which will be merged into existing Genesis pharmacy and medical
supply locations.
<TABLE>
<CAPTION>
Annual Cost Nine Months Cost
------------- ----------------
(In thousands)
<S> <C> <C>
Consolidation of institutional pharmacy locations ....... $ (300) $(175)
Consolidation of medical supply division ................ (300) (175)
Personnel reduction in operating staff to eliminate
duplicative positions .................................. (615) (360)
Other operating costs including legal and accounting
fees, advertising and office expense ................... (474) (275)
------------- ----------------
$(1,689) $(985)
============= ================
</TABLE>
The impact of the savings has been reflected in a pro forma adjustment as
follows:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Operating expenses other than depreciation,
amortization and lease expense ....................... $(1,689) $(985)
</TABLE>
(J) In accordance with generally accepted accounting principles, the net
assets acquired are recorded at the lower of purchase price or fair
value. The estimated fair value adjustments have been determined based on
the most recent information available. The resultant excess of purchase
price over fair value of net assets acquired is required to be amortized.
The elimination of historical depreciation expense is the result of
certain assets not being acquired by Genesis. The pro forma adjustment to
reflect the net increased depreciation and amortization is as follows:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Impact of step-up and allocation of goodwill . $2,706 $1,578
Elimination of historical depreciation expense (159) (93)
------------------ -----------------
Depreciation and amortization ................ $2,547 $1,485
================== =================
</TABLE>
F-27
<PAGE>
(K) In connection with the NeighborCare Transaction, certain corporate office
and furniture and fixture leases will be terminated. The pro forma
adjustment to reflect this is as follows:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Operating expenses other than depreciation,
amortization and lease expense ....................... $(160) $(93)
</TABLE>
NATIONAL HEALTH TRANSACTION
(L) In connection with the National Health Transaction certain assets and
liabilities were not acquired by Genesis. Additionally, certain
businesses, including home health care, infusion therapy and assisted
living facilities in New York State were not acquired. The statement of
operations data from these assets is presented in a pro forma footnote
below:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Net Revenues ......................................... $(24,949) $(26,264)
Operating expenses other than depreciation,
amortization and lease expense ...................... (27,375) (28,340)
Depreciation and amortization ........................ (1,290) (1,453)
Lease expense ........................................ (233) (323)
Interest expense, net ................................ (1,124) (1,151)
</TABLE>
(M) In accordance with generally accepted accounting principles, the net
assets acquired are recorded at the lower of the purchase price or fair
value. The estimated fair value adjustments have been determined based on
the most recent information available. The resultant excess of purchase
price over fair value of net assets acquired is required to be amortized.
The pro forma adjustment to reflect the increased depreciation and
amortization is as follows:
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Depreciation and amortization...... $2,357 $1,739
</TABLE>
(N) The National Health Transaction was financed by Genesis with borrowings
under its bank credit facilities aggregating approximately $51,800,000.
Genesis repaid approximately $36,200,000 of indebtedness assumed upon
consummation of the transaction. The Company also assumed mortgage
obligations of approximately $7,900,000 which were not repaid. Interest
rate assumptions are 6.8% for the Company's borrowing under its bank
credit facilities.
Prior to the closing of the stock acquisitions, an affiliate of a
financial institution purchased nine of the National Health eldercare
centers and subsequently leased the centers to a subsidiary of Genesis
under operating lease agreements.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Interest expense, net:
Interest expense-bank facility .................. $ 3,619 $ 2,714
Elimination of historical National Health
remaining expense ............................ (3,993) (2,995)
------------------ -----------------
$ (374) $ (281)
================== =================
Lease expense ................................... $ 4,949 $ 3,712
</TABLE>
F-28
<PAGE>
(O) Genesis has identified certain cost saving opportunities in connection
with the National Health Transaction. The Company has identified
duplicative positions and the costs associated with such positions, and
plans to eliminate these costs according to a transition plan within one
year of the acquisition.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Reduction in contract labor services .................... $(108) $ (81)
Personnel reduction in operating staff to eliminate
duplicative positions .................................. (252) (189)
------------------ -----------------
$(360) $(270)
================== =================
</TABLE>
(P) Genesis has identified certain revenue synergies relating to its
pharmacy, medical supply and group purchasing businesses. These services
are currently not provided by Genesis to National Health facilities nor
does National Health have the businesses to deliver these services.
<TABLE>
<CAPTION>
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
<S> <C> <C>
Revenues, net ........................................ $2,000 $1,500
Operating expenses other than depreciation,
amortization and lease expense ...................... 1,300 975
------------------ -----------------
Net impact ......................................... $ 700 $ 525
================== =================
</TABLE>
1996 EQUITY OFFERING ADJUSTMENT
(Q) Adjustment to reflect the application of the net proceeds of the 1996
Equity Offering to repay indebtedness under the Company's bank credit
facilities which currently bear interest at a weighted average annual
rate of approximately 6.8%.
Year Ended Nine Months Ended
September 30, 1995 June 30, 1996
------------------ -----------------
(In thousands)
Interest, net .......... $(13,720) $(8,831)
GMC TRANSACTION
(R) The historical financial statements of GMC include unusual, non-recurring
charges related to a provision to increase allowance for doubtful
accounts, the settlement of a matter relating to reimbursement for
nutritional services provided at a nursing facility previously managed by
a GMC subsidiary and an amount recorded relating to a class action suit.
The historical financial statements also include non-recurring charges
related to additional interest incurred under GMC's credit facility and a
discount on a note receivable.
<TABLE>
<CAPTION>
Year Ended
September 30, Nine Months Ended
1995 June 30, 1996
----------------- -----------------
(In thousands)
<S> <C> <C>
Operating expenses other than depreciation,
amortization and lease expense ....................... -- $(2,300)
Interest, net ......................................... -- (1,121)
</TABLE>
F-29
<PAGE>
(S) The historical financial results include a provision for costs on the
sale of accounts receivable, which is included in the interest expense
line item. The following pro forma adjustment represents the
reclassification of the portion of the provision that relates to
operating expenses:
<TABLE>
<CAPTION>
Year Ended
September 30, Nine Months Ended
1995 June 30, 1996
----------------- -----------------
(In thousands)
<S> <C> <C>
Operating expenses other than depreciation,
amortization and lease expense ....................... $ 1,383 $ 1,447
Interest expense, net ................................. (1,383) (1,447)
</TABLE>
(T) As a result of the GMC Transaction, certain corporate and administrative
overhead functions related to the prior ownership structure will be
merged. Genesis has identified duplicative physical locations which will
be merged into existing Genesis administrative locations.
<TABLE>
<CAPTION>
Nine Months
Annual Cost Cost
------------ ---------------
(In thousands)
<S> <C> <C>
Personnel reduction in operating staff to eliminate
duplicative position ................................... $(1,000) $ (750)
Other operating costs including legal and accounting
fees, advertising and office expense ................... (1,000) (750)
---------- --------
$(2,000) $(1,500)
========== ========
</TABLE>
The impact of the savings have been reflected in a pro forma adjustment
as follows:
<TABLE>
<CAPTION>
Year Ended
September 30, Nine Months Ended
1995 June 30, 1996
----------------- -----------------
(In thousands)
<S> <C> <C>
Operating expenses other than depreciation,
amortization and lease expense ....................... $(2,000) $(1,500)
</TABLE>
(U) A portion of the purchase price was financed with borrowings under the
Company's bank credit facility of approximately $91,000,000. Interest rate
assumptions are 6.8% for the Company's borrowings:
Year Ended
September 30, Nine Months Ended
1995 June 30, 1996
----------------- -----------------
(In thousands)
Interest expense -- bank
facilities ..................... $6,370 $4,778
OFFERING ADJUSTMENT
(V) Adjustment to reflect the application of the net proceeds of the Offering
to repay a portion of assumed GMC term indebtedness ($108,000,000 at a
weighted average rate of 12.25%) and other GMC indebtedness ($10,000,000
at a weighted average rate of 7%). The assumed rate of this Offering is
9.25%.
Year Ended Nine Months Ended
September 30,
1995 June 30, 1996
----------------- -----------------
(In thousands)
Interest expense, net:
Interest expense -- offering ... $ 11,562 $ 8,672
Eliminate historical interest
expense ...................... (13,930) (10,448)
---------- -----------
$ (2,368) $ (1,776)
=========== ===========
F-30
<PAGE>
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
(UNAUDITED)
The following unaudited pro forma condensed consolidated balance sheet
includes the historical consolidated condensed balance sheet of the Company
at June 30, 1996 and the pro forma adjustments to reflect the National Health
Transaction, the GMC Transaction, as adjusted to reflect the Offering and the
application of the estimated net proceeds as if they occurred on June 30,
1996. The pro forma adjustments should be read in conjunction with the
Company's historical consolidated financial statements, National Health's
historical combined financial statements and GMC's historical combined
financial statements.
<TABLE>
<CAPTION>
Pro Forma,
As Adjusted
Pro Forma Consolidated
National Pro Forma Genesis/
National Health GMC National
Genesis Health Adjustments GMC Adjustments Health/GMC
-------- --------- ------------ --- ------------ -------------
(In thousands)
<S> <C> <C> <C> <C> <C> <C>
Current assets................. $297,009 $23,401 $(9,108)(A) $75,834 $ -- $387,136
Property and equipment, net .. 313,388 58,608 7,346 (A)(D) 93,042 73,325(E) 545,709
Other assets ................. 267,951 13,795 (7,426)(A)(D) 22,808 44,000(E) 341,128
------- ------ ------ ------ ------ -------
Total assets ................. $878,348 $95,804 $(9,188) $191,684 $117,325 $1,273,973
======== ======= ======= ======== ======== ==========
Current liabilities .......... $ 69,410 $21,777 $(3,349)(A)(B)(C) $ 37,951 $ (5,820)(F)(G) $ 119,969
Long term debt, excluding
current maturities .......... 295,897 68,826 (1,158)(A)(B) 130,775 101,025 (G) 595,365
Other liabilities ............ 12,803 -- 520 (C) 4,078 41,000 (E) 58,401
Shareholders' equity ......... 500,238 5,201 (5,201)(A)(D) 18,880 (18,880)(E) 500,238
------- ------ ------ ------ ------ -------
Total liabilities and
shareholders' equity ........ $878,348 $95,804 $(9,188) $191,684 $117,325 $1,273,973
======== ======= ======= ======== ======== ==========
</TABLE>
Pro forma adjustments are as follows:
NATIONAL HEALTH TRANSACTION
(A) The assets and liabilities of National Health not acquired or assumed by
Genesis in the National Health Transaction are eliminated in a pro forma
adjustment as follows:
(In thousands)
Current assets ...................................... $(9,108)
Property and equipment ............................. (9,686)
Other assets ....................................... (11,141)
-------
Total assets ....................................... $(29,935)
========
Current liabilities ................................ $ (5,249)
Long term debt, excluding current
maturities ....................................... (16,758)
Other liabilities ................................. --
Shareholders' equity .............................. (7,928)
-------
Total liabilities and shareholders' equity $(29,935)
========
(B) The National Health Transaction was financed by Genesis with borrowings
under its bank credit facilities of approximately $51,800,000 which
includes the repayment of approximately $36,200,000. Additionally,
Genesis assumed existing indebtedness of approximately $7,900,000 which
was not repaid immediately. The impact of the borrowings under the bank
credit facilities is reflected in the following pro forma adjustment:
(In thousands)
Current liabilities ..................................... $ (100)
Long term debt, excluding current maturities ........... 15,600
F-31
<PAGE>
(C) Transaction costs which include professional fees, duplicative salary
costs and severance, taxes and title costs and certain other costs
incurred or to be incurred in order to consummate the transaction will be
accrued, net of tax benefits, in the amount of $2,520,000. The following
pro forma adjustment represents the accrual for these costs:
(In thousands)
Current liabilities ......................................... $2,000
Other liabilities .......................................... 520
(D) Purchase accounting adjustments include the following allocations:
(In thousands)
Property and equipment, net .................................. $17,032
Other assets ................................................ 3,715
Shareholders' equity ........................................ 2,727
GMC TRANSACTION
(E) Purchase accounting adjustments include the following allocations:
(In thousands)
Property and equipment, net .............................. $72,345
Other assets ............................................ 44,000
Other liabilities ....................................... 41,000
Shareholders' equity .................................... (18,880)
(F) Transaction costs which include professional fees, duplicative salary
costs and severance, taxes and title costs and certain other costs
incurred or to be incurred in order to consummate the transaction will be
accrued in the amount of $8,000,000. The following pro forma adjustment
represents the accrual for these costs:
(In thousands)
Current liabilities ....................................... $8,000
(G) The GMC Transaction was financed by the payment of $93,900,000
representing the equity purchase price, the repayment of approximately
$90,000,000 of existing indebtedness and the assumption of approximately
$47,900,000 of other indebtedness. The following pro forma adjustment
represents the incremental debt incurred in the transaction and reflects
the repayment of certain GMC indebtedness with the net proceeds of the
Offering:
(In thousands)
Current liabilities ..................................... $ (8,820)
Long-term debt .... .................................... 101,025
F-32
<PAGE>
No dealer, salesperson or other individual has been authorized to
give any information or make any representations other than those
contained or incorporated by reference in this Prospectus in
connection with the offer made by this Prospectus and, if given or
made, such information or representations must not be relied upon
as having been authorized by the Company. This Prospectus does not
constitute an offer to sell, or a solicitation of an offer to buy,
the Exchange Notes in any jurisdiction where, or to any person to
whom, it is unlawful to make such offer or solicitation. Neither
the delivery of this Prospectus nor any sale made hereunder shall,
under any circumstances, create any implication that there has not
been any change in the facts set forth in this Prospectus or in
the affairs of the Company since the date hereof.
----------------
TABLE OF CONTENTS
Page
Summary....................................................1
Cautionary Statement Regarding
Forward Looking Statements..............................13
Risk Factors..............................................13
Use of Proceeds...........................................17
Capitalization............................................18
Exchange Offer............................................19
Certain Federal Income Tax Consequences...................28
Selected Consolidated Financial Data .....................29
Management's Discussion and Analysis
of Financial Condition and Results
of Operations...........................................31
Business..................................................39
Management................................................50
Description of the Notes..................................54
Plan of Distribution......................................83
Legal Matters.............................................83
Experts...................................................84
Available Information.....................................84
Index to Financial Statements............................F-1
<PAGE>
$125,000,000
GENESIS HEALTH VENTURES, INC.
PROSPECTUS
Offer to Exchange its
9 1/4% Senior Subordinated Notes due 2006,
which have been registered under the
Securities Act of 1933, as amended, for any
and all of its outstanding 9 1/4% Senior
Subordinated Notes due 2006
December 11, 1996
